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ABSTRACT 
 
Seventeen novel osmium cymene complexes with O,O′- and P,P′-chelating ligands as well as 
N- and P-monodentate ligands are reported. The osmium cymene complexes were 
synthesised and characterised by spectroscopic techniques (NMR, IR and Raman), elemental 
analysis, thermal analysis, conductivity studies and X-ray crystallography.  The molecular 
structures of complexes 1(b), 2, 4, 6, 7(a)-(d) and 11 in this study are reported. The cymene 
rings of these complexes show different conformations due to loss of planarity influenced by 
the ancillary ligands as a result of ML back bonding. 
Osmium cymene complexes of the type [Os(η6-p-cymene)BrL2]+ (where L2 = chelating P,P′ 
ligand) and binuclear [{Os(η6-p-cymene)Br2}2 L2] (where L2 = bridging P,P′ ligand) were 
evaluated for anticancer activity against renal, melanoma, breast and HeLa cancer cells. The 
chelated-diphosphine osmium cymene complexes exhibited significant anticancer activities 
relative to the bridged-diphosphine osmium analogues. A series of O,O′-chelated osmium 
complexes exhibited moderate and poor anticancer activities.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 The role of metals in medicine 
 
Currently, transition metals regardless of their general toxicity play an important role in the 
mammalian biological systems as well as treatment of certain diseases.1,2 There are 
transitional metals that are approved for clinical use as supplements such as chromium, 
manganese, iron, cobalt, nickel, copper and molybdenum.3 These metals are known to 
perform unique functions in the body such as catalysis in biological reactions. Copper and 
zinc are found to play a role in the healing processes of wounds and burns.4,5 Copper is 
known to play an essential role in the cellular uptake of iron. Mercury complexes utilized in 
ancient Greece for treatment of scabies and lice.6 Gold cyanide was used to treat 
tuberculosis.7 Bismuth complexes were applied for treatment of syphilis, gastrointestinal 
disorder and exhibit anti-microbial, anti-cancer, anti-leishmanial properties.8 The iron 
complex, ferroquine is undergoing clinical trials against chloroquine resistant malaria 
parasite.6 Also, the ruthenium complex [RuCl2(chloroquine)]2 relative to chloroquine exhibits 
2-5 times greater potency against chloroquine resistant malaria parasite.9 
Vanadium complexes are found to be potent with less toxicity against human cancer cells 10 
The deficiency of vanadium is responsible for malfunctioning of thyroid, glucose and lipid 
metabolism.11 Titanium metal complexes with mixed ligand system are found to enhance 
solubility in aqueous media as well as exhibit increased anticancer activities relative to 
titanocene dichloride complex.12 Also the titanium complex dichlorobis(1-phenylbutane-1,3-
dionato)titanium(IV) entered clinical trials for its potency against colon cancer.13 
Molybdenum and tungsten complexes also were found to be cytotoxic against the HeLa, 
MCF-7 and N1E-115 cell lines in vitro screening.14  
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1.2 Brief background of metal arene complexes 
 
Arenes are purely organic hydrocarbons with π-electrons delocalised around the ring of 
carbon atoms. The CC bonds with delocalised electrons are shorter than the CC single 
bonds.  The arenes are part of a family of π-ligand systems which donate π-electrons to the 
metal with hapticity ranging from one to six (η1˗ η6) (chart 1.1).  The simplest of these arenes 
is the benzene ring, which usually donates six electrons to the metal centre during 
complexation. In this study, only the cymene ligand was used, which donates electrons in the 
range η1˗ η6 to the metal centre. 
                               
M M
M
M


M

M

 
Chart 1.1: Bonding possibilities of the arene ligands. 
 
The bonding of metal arenes is based mostly on the orbital interactions between the metal and 
the arene ligands (see figure 1.1). Here, the central metal acts as a Lewis acid and the arene 
ligand acts as the Lewis base. The interaction occurs by donation of π-electrons from the 
arene ligand to the σ d-orbitals of the metal atom (π→dσ).  Back bonding of the electrons 
from the metal atom to the arene ligand is possible resulting in shortened M−C bonds due to 
metal-arene bond reinforcement. The reinforcement arises when the metal centre has more 
electrons and the arene ligand is electron deficient;15 therefore, back donation (dπ→π*) 
reduces electron density on the metal centre.  
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M MCp2 2 Cp
4p
a2u,e1u
4s
a1g
3d
a1g, e1g, e2g
a1g, a2u
e1g, e1u
e2g,e2u
e1u

a1g

e2g

a2u

e2u
e1u
a1g
e2g
e1u
e1g
a2u
a1g  
Figure 1.1: The MCp2 molecular orbital diagram showing arene orbitals involved in 
bonding.16 
  
Back bonding is an important phenomenon in organometallic chemistry. The free arene 
ligand has electrons delocalised around the C−C atoms of the arene ligand. However, when 
the arene ligand is bonded to a metal centre, electrons are localised between the adjacent 
carbons of the bound carbon on the arene, with the consequence of C−C bonds longer than 
those of the free arene. This would suggest that alternating C=C and C−C bonds would be 
observed in the coordinated arene ring. The interaction changes the shape as well as the 
reactivity of the arene ligand. The shape of the η6-arene ligand may change from planar to 
pseudo boat and to pseudo chair conformation. The metal-arene bond that reduces the 
electron density on the arene ligand causing the arene ligand to have a slight positive charge 
and the central metal to have slight negative charge causes the change in reactivity of the 
arene ligand. 
Substituents on the arene ligand play an important role in metal complex stability because of 
electronic and steric effects17. The substituents also influence the reactivity of the arene 
ligand on coordination to the metal centre. Electron donating groups on the arene ligand such 
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as alkyls can assist in stabilizing the bound arene when electron poor metals deplete electron 
density. On the other hand, electron withdrawing groups such as fluorides on the arene 
further destabilizes the arene promoting nucleophilic attack on the arene ligand (see figure 
1.2).15 Furthermore, ancillary ligands on the metal complex play a role in the reactivity of the 
arene ligand. Strong π-acceptor ligands at positions trans to carbons on the arene weaken the 
metal-carbon bonds of the arene. The phenomenon may be observed through different 
M˗Carene bond lengths found in the molecular structures of the complexes. 
 
                            
F3C
M
nucleophilic attack
H
H H
H
H
enhanced acidity
steric hindrance
electron withdrawing group
CO
OC
CO  
Figure 1.2: Illustration of influence of substituents on the arene ligand.18 
 
Metal arene complexes were developed by the pioneering work of Pauson and Kealy19 in 
1951 when the two accidentally discovered ferrocene in an attempt to synthesize fulvalene 
(C10H8). Metal arene chemistry was further explored by Fischer and Hafner in 1955 on their 
work of developing metal arenes complexes with η6-ligands, such as 
bis(benzene)chromium(0). Jellinek20 reported the crystal structure of bis(benzene) 
chromium(0) at room temperature relative to the data reported by Weiss and Fischer. In 1979 
Muetterties and co-workers21 studied the arene exchange stability of transition metal 
complexes with η2, η4 and η6 ligands. The group discovered that metal arene complexes with 
η6 coordination required higher temperatures to replace the arene compared to η4- and η2-
metal arene complexes, which required less energy to break bonds. The chemistry of metal 
arene complexes play an important role in the field of catalysis.22 The arene ligands stabilize 
metal centres with high oxidation states and contribute to selectivity depending on the 
substituents and the ancillary ligands. 
Arenes play an important role in bioinorganic chemistry as agents that effect cellular uptake 
of metal complexes.23 The presence of arenes on the metal complex provides the 
hydrophobicity which is important for the passage of the metal complex across cell 
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membranes.24 The study of cellular uptake of osmium arene (arene = p-cymene, biphenyl) 
complexes revealed that the p-cymene complexes are taken up by the cell 2-3 times more 
than the biphenyl complexes and cisplatin. In addition, complexes with biphenyl as an arene 
ligand were found to have a non-covalent interaction with the DNA.25  Therefore, the arenes 
assist in increasing the cytotoxicity of the metal complex by intercalating the DNA structure 
causing distortions.26,27  
Habtemariam and co-workers28 investigated the effect of arene ligands on the anticancer 
activity of some ruthenium complexes (see chart 1.2). The group discovered that the 
cytotoxicity of arene complexes was depended on the size of the arene ligand. The more 
fused rings in the arene ligand the greater the potency, with the order: cyclophane  tetralin 
 indan, dibenzosuberane  dihydroanthracene, fluorene  5,6-dihydrophenanthrene  
tetrahydroanthracene. This trend is consistent with the study reported in 2002 by Aird and co-
workers27 where they observed that tetrahydroanthracene complexes are more cytotoxic than 
the dihydroanthracene complexes > biphenyl complexes > p-cymene complexes > benzene 
complexes.  
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9,10-dihydroanthracene
2,3-dihydro-1H-indene
9H-fluorene
5,8,9,10-tetrahydroanthracene
5,6-dihydrophenanthrene
1,2,3,4-tetrahydronaphthalene
cyclophane dibenzosuberane
p-cymene biphenyl
 
Chart 1.2: Structures of arene ligands investigated for their influences on the cytotoxicity in 
cancer cell lines.27,28 
 
1.3 Ruthenium arene complexes 
 
The chemistry of ruthenium arene complexes has been extensively studied in 
bioorganometallic chemistry and catalysis. There are a number of reports of ruthenium 
complexes with different arene ligands as well as different modes of arene coordination. In 
1972 Zelonka and Baird22 reported the synthesis of the first ruthenium arene complexes. 
Bennett and Smith29 in 1974 isolated the ruthenium arene dimer with μ2-chlorido ligands by 
dehydrogenation of cyclohexa-1,3-diene/cyclohexa-1,4-diene with ruthenium(III) trichloride 
in ethanol solution. Robertson and Stephenson30 reported stable η5-cyclohexadienyl 
complexes of ruthenium in 1977. Two groups of researchers reported neutral ruthenium η6-
arene complexes [Ru(C6H6)Cl2L] (L = C5H5N, Me2SO, PR3), negatively charged 
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Cs[Ru(C6H6)Cl3] and the cationic complex with μ3-chlorido ligands [Ru2(C6H6)2(μ3-Cl3)]PF6 
in 1978.29,31 In 1979 Bennett and Matheson32 reported the preparation of bis-arene ruthenium 
cationic complexes with varied arenes. Suravajjala and co-workers33 in 1993 reported the 
synthesis of the dicationic bis(η6-p-cymene) complex [Ru(η6-p-cymene)2](BF4)2 from 
refluxing the μ2-chlorido ruthenium dimer [Ru(η6-p-cymene)Cl2]2 with AgBF4 in acetone and 
then further refluxing the intermediate in trifluoroacetic acid and excess p-isopropyltoluene.  
The success of Cisplatin and second-generation platinum complexes as well as subsequent 
limitations led to the investigation of ruthenium complexes as future pharmaceutical agents. 
In 2001 Morris and co-workers34 reported ruthenium arene complexes which inhibit the in 
vitro growth of human ovarian cancer cells. In 2008 Bugarcic and co-workers24 reported 
ruthenium complexes with terphenyl arenes which showed different cytotoxicity, cell uptake 
and DNA binding properties depending on the ortho-, meta- and para- substituents of the two 
phenyl groups. The para-terphenyl complex was reported to have a “piano-stool geometry”, 
determined from X-ray crystallography, and the potency of this complex was reported to be 
similar to that of Cisplatin. 
   
1.4 Osmium arene complexes 
 
In contrast, osmium arene chemistry has received less attention compared to the ruthenium 
analogue. This may be a consequence of the inertness of osmium complexes because of its 
low spin 5dn configuration. Furthermore, the toxicity of osmium tetroxide as a starting 
material in the past has contributed to the difficulty in preparation of osmium complexes.35 In 
1984 Bandy and co-workers36 reported the preparation of bis(benzene) osmium complexes 
from co-condensation of osmium atoms with benzene. In 1990, Kiel and co-workers37 
reported the first hexamethylbenzene osmium complex when they investigated intermolecular 
C−H activations. In 1994 Gross and co-workers38 reported a new synthetic route for 
[Os(C5Me5)2Br4] as a starting material for the synthesis of osmium 
pentamethylcyclopentadienyl complexes with the aim of increasing interest in osmium 
chemistry. Field and co-workers39 reported the synthesis and characterisation of [Os(η5-
C5Ph5)(CO)2Br] from the reaction of osmium carbonyl cluster [Os3(CO)12] with 
pentaphenylcyclopentadienylbromide and 1-chlorobenzene. In 2012, Albertin and co-
workers40 reported the osmium cymene complexes with η2-alkene ligands. 
8 
 
Recently, osmium arene complexes with some anticancer activities have been reported. 
Kostrhunova and co-workers25 investigated DNA interactions of mononuclear osmium arene 
complexes. The group discovered that the osmium complex with a biphenyl arene ligand is 
more cytotoxic towards cancer cells relative to the analogous p-cymene osmium complex. In 
2010 van Rijt and co-workers41 reported the anticancer study of osmium complexes with four 
different η6-arene ligands (benzene, p-cymene, biphenyl and tetrahydroanthracene). In their 
study, the group revealed that biphenyl osmium complexes are easily taken up by cells. In 
addition, the biphenyl osmium complexes exhibit potency equivalent to the 
tetrahydroanthracene, however, better than the p-cymene complexes followed by the benzene 
complexes. In 2014 van Rijt and co-workers42 reported osmium arene complexes with higher 
anticancer activity compared to the ruthenium analogues. The osmium complexes were found 
to accumulate to higher concentrations in cell membranes resulting in disruption of the 
mitochondrial membranes as a result encourages cell death. Bergamo and co-workers43 
reported the anticancer activity of osmium biphenyl complex which is isostructural with the 
ruthenium analogue. The osmium biphenyl complex was found to be 6 times more potent 
than the ruthenium analogue. 
 
1.5 Osmium versus ruthenium complexes 
 
Ruthenium is a 4d transition metal whereas osmium is a heavier 5d congener. Ruthenium 
complexes are found to exhibit faster ligand exchange rates relative to the isostructrural 
osmium complexes.44 In addition, ruthenium arene complexes hydrolyse faster than the 
osmium arene analogues.45 Ruthenium complexes were found to be 40 times more reactive 
than the osmium analogues in anticancer studies.46 The inertness of osmium complexes is an 
advantage in anticancer activity, because the osmium complexes may reach the target with all 
ligands still coordinated to the osmium centre. Some osmium complexes were found to 
exhibit higher anticancer activities compared to the ruthenium analogue.43 Therefore, the 
hypothesis is that osmium complexes may offer greater anticancer activity based on enhanced 
stability and slow ligand exchange rates. 
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1.6 Chelating and monodentate ligands 
 
Chelating ligands are able to bond to the central metal through two or more donor atoms. 
These chelate ligands can be classified as bidentate, tridentate, tetradentate or more 
depending on the availability of electron-pair donor atoms on the chelate ligands. Chelate 
ligands are known to have very interesting properties once they are bounded to the metal 
centre; such properties include the chelate effect, which brings stability to the metal complex 
by forming metallacyclic rings. Chelate rings have different stability depending on the ring 
size. Three- to seven-membered chelate rings are well known and even larger chelate rings 
are known. The most common and stable chelate ring is the five-membered ring because of 
less sterically hindered bond angles, which are favourable for metal ions with larger radii 
resulting in no ring strains.47 The six-membered chelate rings are found to be reasonably 
stable if their formation results in electron delocalization.48  
The delocalization of electrons in the chelate ring is possible, and can contribute to the 
stability of the complex. Strong π-acceptor ligands can accept π-electrons from the electron 
rich metal atom to stabilize the whole metal complex depending on the type of substituents 
on the ligand system. Three-, four-, seven-membered and larger chelate rings are less 
common because of the resulting distortions of bond angles and unfavourable steric 
interactions.  
Chelate ligands also have the ability to bridge two metal centres which may give stable 
binuclear complex depending on the type of ligand systems. Diphosphine ligands may also 
bridge two metal centres, resulting in a flexible binuclear complex as a consequence of 
elongated alkyl chain length.49 Oxalates are known to bridge two metal centres resulting in 
two five-membered chelate rings on the binuclear complexes.   
Generally, chelate ligands have played important roles in the chemistry of catalysis, removal 
of toxic metals from the environment as well as human/animal biological systems and 
continue to play a key role in the development of metallopharmaceutical agents. Chelated 
diphosphine complexes of Ag(I) have shown some antitumour activity in in vitro studies as 
well as animal trials.50 In 1990 Berners-Price and co-workers51 reported the cytotoxicity and 
antitumour activity of gold(I) chelated with diphosphine ligands. 
The titanium-based complex cis[(EtO)2(bzac)2Ti] (where bzac = 1-phenylbutane-1,3-
diketonate) is reported to undergo clinical trials against colon cancer in animal models.13 The 
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O,Oʹ-chelating ligands are found to bring stability to the metal complex as well as electron 
delocalization in the resulting chelate rings.48 The chelate effect of diketones can also be 
observed in the anticancer studies of Carboplatin and Oxaliplatin52 which are in clinical use 
against Cisplatin resistant tumours. In 2004 Thompson and co-workers53 reported the effect 
of bis(maltolato)oxovanadium(IV) on type 2 diabetes in both in vivo and in vitro testing. 
Habtemariam and co-workers28 reported a ruthenium arene complex with an O,Oʹ chelating 
ligand [Ru(η6-p-cymene)(PhCOCHCOPh)Cl] which was found to be highly potent with an 
IC50 value of 11 μM. Turel and co-workers54 studied the ruthenium cymene complex with 
ofloxacin (C18H20FN3O4). This ligand chelated the ruthenium metal through the oxygen 
atoms and the complex was found to interact with DNA in solution. 
Monodentate ligands also play an important role in coordination chemistry. The phosphine 
ligands (PR3) are known as good σ-donor as well as good π-accepter depending on the R 
substituents (where R = alkyl or aryl). The PPh3 ligand is one of the most studied among 
monodentate phosphine ligands with almost all transition metals.  In anticancer studies, the 
PPh3 ligand was found to bring stability on the ruthenium complex [Ru(η6-p-
cymene)Cl(PTA)(PPh3)]BF4 consequently enhancing the anticancer activity of the ruthenium 
complex.55 
 
1.7 Aims and Objectives of the study 
 
The aim of this study was to synthesize osmium-cymene complexes with chelating O,Oʹ- and 
P,Pʹ- ligands as well as monodentate N- and P-donor ligands. Characterize the complexes 
using spectroscopic techniques (NMR, IR and Raman), elemental analysis, 
thermogravimetric analysis (TGA), conductivity studies and single crystal X-ray diffraction. 
The structure-activity relationship of the complexes against a range of cancer cells was to be 
investigated. The main objectives of this study were: 
 To synthesize and characterize osmium-cymene complexes with O,O′ and P,P′ 
chelating ligands as well as monodentate N- and P-donor ligands. 
 To evaluate the synthesized osmium-cymene complexes on the in vitro anticancer 
activities. 
 To establish structure reactivity patterns on the anticancer activities of osmium-
cymene complexes. 
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CHAPTER 2 
 
SYNTHESIS AND CHARACTERIZATION OF O,Oʹ-CHELATED OSMIUM CYMENE 
COMPLEXES  
 
2.1 Background 
 
Diketones are well known in the field of medicine as active ingredients or substrates in 
pharmaceuticals as well as industrial polymerisation catalysts.1,2 These compounds have also 
been applied in environment remediation for the removal of heavy metals due to their 
chelating properties.3 Studies have indicated that diketones preferably form neutral 
complexes with metal ions.4,5 However, a number of mononuclear as well as the binuclear 
complexes bearing positive charges have been reported.6 Another interesting property of 
diketones is their ability to bridge two, three and four metal complexes. The chemical and 
physical properties of diketones have been investigated with a range of transition metals.6-14 
Verma and co-workers15 reported the synthesis of O,Oʹ-chelated complexes of various 
transition metals.  
There are many types of diketones and those that are common are; α-diketones and β-
diketones, which differ in positions of the carbonyl carbons on the carbon framework. The 
carbonyl carbons on the α-diketone are adjacent to each other whereas the carbonyl carbons 
of the β-diketone are at a 1,3 position to each other. The α-diketone forms a five-membered 
chelate ring with metal centres which are considered to be the most stable chelate ring size 
favoured by metal centres with larger ionic radii.16 In contrast, β-diketones form six-
membered chelate rings, which are considered more stable than four- and seven-membered 
chelate rings but less stable than five-membered chelate rings.  
The most common O,Oʹ-chelating ligand in the α-diketone family is the oxalate ligand. The 
oxalate ligand has shown the ability to bridge two metal centres forming a bis-chelate.6 This 
property has led to the oxalate ligand being incorporated to many transition metals such as 
copper,10 chromium,17 cobalt,17 iron,17 manganese,18 molybdenum,19 nickel,20 platinum,21 
palladium22 and ruthenium.6,23 The magnetic properties of oxalate complexes of several 
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transition metals such as copper dimers,24 chromium-manganese and iron-manganese 
binuclear species25,26 have been reported.  
The chelate effect of the oxalato ligand plays a vital role in the medicinal properties of 
Oxaliplatin.27 Carboplatin and Oxaliplatin were introduced in 1999 and 2003 respectively as 
metal complexes bearing O,Oʹ-bidentate ligands and are currently both in clinical use world-
wide.27 The chelate effect of the O,Oʹ ligands delay the hydrolysis of these platinum 
complexes relative to Cisplatin, consequently changing the overall biological reactivity of 
Carboplatin and Oxaliplatin towards cancer cells. 
Complexes of α-diketones attached to π-systems such as tropolone are known. Ligands of this 
type have interesting chemical and electronic properties because of their electron rich π-
systems. The tropolone has six π-electrons in the seven-membered carbon ring, which can act 
as an electron-donating group during complexation to form complexes with η7 hapticity. The 
tropolone ligand can chelate an additional metal centre through  the O atoms.28 Since the 
oxygen on the carbonyl carbon is more reactive towards the metal ions than the π-bonds on 
the tropolone ring, the chelated O,Oʹ complex can be isolated. Melchart and co-workers9 
reported the synthesis of [Ru(η6-p-cymene)(2-O,Oʹ-C7H5O2)Cl] which is isostructural with 
complex 3 reported in this study. This group also studied the interaction of the ruthenium 
tropolonate complex with DNA bases. Their findings show that the ruthenium complex 
interacts with N1 of the guanine as well as N1 and N7 of the adenine DNA nucleobases.  
In this chapter, the synthesis and characterization of osmium cymene complexes with oxalate 
and tropolone ligands will be discussed. 
 
2.2 Preparation of O,Oʹ-osmium cymene complexes 
 
Complex 1(a) was prepared by reacting the osmium dimer [Os(η6-p-cymene)Br2]2 with 
Ag2C2O4 in CH2Cl2/CH3OH at room temperature. Further reaction of 1(a) with PPh4Br in 
CH2Cl2 at room temperature for 30 minutes resulted in the formation of 1(b). Synthesis of 
complexes 2, 4 and the attempted synthesis of [{Os(η6-p-cymene)(PPh3)}2 μ–C2O4)](BF4)2 
were carried out by the method reported by Yan and co-workers6 with some modifications. 
Complex 2 was prepared by reaction of Ag[Os(η6-p-cymene)Br(C2O4)] 1(a) and PPh3 in 
CH2Cl2/CH3OH solution at 44 ºC. Complex 3 was prepared by reacting the osmium dimer 
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and sodium tropolonate (NaC7H5O2) in CH2Cl2/CH3OH at room temperature. Complex 4 was 
prepared by the reaction of the osmium dimer with ammonium oxalate in CH2Cl2/CH3OH. 
Complex 5 was prepared by the method reported by Clayton and co-workers29 with some 
modifications. The osmium dimer and PPh3 were stirred in CH2Cl2 at room temperature for 
an extended period. The attempted preparation of [{Os(η6-p-cymene)(PPh3)}2 μ–
C2O4)](BF4)2 by reacting 4 and PPh3 in CH2Cl2 at room temperature resulted in a mixture of 
two products (2 and 5). The two complexes in the mixture were identified by the NMR and 
IR data of the pure complexes 2 and 5 prepared separately. All the complexes reported in this 
chapter were synthesized under the conditions reported in scheme 2.1.  The oxalate ligand in 
1(a), 1(b) and 2 contribute two electrons using the neutral electron counting method while in 
4 it contributes three electrons because of the delocalised electrons on both five-membered 
chelate rings. 
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The reaction of the osmium dimer with excess (NH4)2C2O4∙H2O did not result in the 
formation of the mononuclear complex NH4[Os(η6-p-cymene)(C2O4)Br] (see scheme 2.2). 
However, the reaction with the Ag2C2O4 did give the expected product. The failure to obtain 
the mononuclear complex NH4[Os(η6-p-cymene)(C2O4)Br] may be rationalized using the 
hard-soft-acid-base (HSAB) principle.  The NH4
+ ion is a hard acid and the anion complex 
[Os(η6-p-cymene)(C2O4)Br] is a soft base, which may result in a poorly stable complex 
NH4[Os(η6-p-cymene)(C2O4)Br] which readily reverts to the formation of the neutral 
binuclear complex 4. In addition, the NH4
+ ion and the Ag+ ion have different ionic radii, 
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which may cause noticeable differences in electrostatic interactions. Furthermore, the NH4
+ 
ion depend entirely on the electrostatic forces whereas the Ag+ ion has empty s-orbitals, 
which may contribute to the reactivity of this metal ion. Size selectivity due to large 
electrostatic interactions combined with hard/soft character of the cations played a role in the 
unsuccessful preparation of NH4[Os(η6-p-cymene)(C2O4)Br] and successful preparation of 
Ag[Os(η6-p-cymene)(C2O4)Br].30 
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Scheme 2.2  
 
Below is a proposed mechanism for the reaction of 4 with PPh3. Two possible reaction 
pathways will be discussed (see scheme 2.3). 
The interchange associative (Ia) mechanism was proposed to proceed via the following 
pathway. The first step involves the addition of the PPh3 ligand to form an intermediate (I). 
The η6-cymene at one of the Os centres (OsA) undergoes ring-slippage to an η4-cymene to 
accommodate the PPh3.
31 In this arrangement, the cymene ligand occupies two coordination 
sites instead of three. Elimination of the labile Br ligand proceeds fast (SN2) which results in 
formation of the positively charged intermediate (III) with PPh3 and Br ligands at the OsA 
and OsB centres respectively. 
In contrast, for an interchange dissociative (Id) mechanism the first step is proposed to 
involve the slow elimination of the Br ligand forming a five-coordinate complex on the OsA 
centre. The fast addition of the PPh3 ligand forming the positively charged (located on OsA 
centre) asymmetrically substituted binuclear osmium complex with PPh3 and Br ligands at 
different osmium centres.  
The second step for both the interchange associative and dissociative mechanism is assumed 
the same (see scheme 2.3). Addition of the second PPh3 ligand at OsB cleaves the OsB˗O bond 
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forming intermediate (IV). This happens because steric factors may not allow two PPh3 bulky 
ligands on the OsA centre while the OsB centre is less sterically crowded. The steric effect of 
the PPh3 ligand on OsA exerted on the C2O4 ligand and the bulkiness of the entering PPh3 
ligand favours the elimination of the OsB-O bond before the entering of the PPh3 ligand. 
Intermediate (IV) undergoes a second OsB˗O bond cleavage to form the neutral complex 2. 
The Br ligand in the solution occupies the vacant site completing the coordination geometry 
of the osmium centre by forming the neutral complex 5.  
Since 4 is a low-spin octahedral complex, it is expected that the interchange dissociative 
mechanism will be favoured. Under similar reaction conditions, the ruthenium analogue 
[{Ru(η6-p-cymene)Cl}2 (μ–C2O4)] is reported to afford the [{Ru(η6-p-cymene)(PPh3)}2 μ–
C2O4)](CF3SO3)2 complex,6 formed by substitution of the chloride ligands by PPh3. The 
reason for the differences in reactivity of 4 compared to the ruthenium analogue may be due 
to the change in metalligand orbital overlap provided by the 5d metal orbitals.32 The Br is a 
stronger ligand than chloride and the 5d osmium metal form the more stable complexes 
compared to the 4d ruthenium metal. In addition, the osmium complexes are found to react 
slowly compared to their ruthenium analogues, that is, Os−Br complex is found to be less 
labile than the Ru−Cl analogue.33 Hence, the differences in electronic properties of 4 
compared to the ruthenium analogue as well as the difference in electronegativity between 
the chlorido and bromido ligands are factors which could account for the observed 
differences in reactivity. 
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2.3 Results and Discussion 
 
2.3.1 Nuclear Magnetic Resonance (NMR) Spectroscopy  
 
2.3.1.1 1H NMR data 
Ha
Hb Hc
Hd
He
HcHb
He
(i)
   
Hf
Hg
Hh
Hf
Hg
(ii)
OH
O
 
Figure 2.1: The 1H NMR of (i) cymene ligand and (ii) tropolone ligand will be discussed with 
these assignments. 
 The 1H NMR data for complexes 1(a), 1(b), 2, 3 and 4 are reported in Table 2.1. The proton 
signals of Hb and Hc for 1(a) showed peaks slightly shifted downfield compared to those of 
1(b). This observation may be attributed to solvent effects because 1(a) was only soluble in 
DMSO-d6 whereas 1(b) was soluble in CDCl3 solvent. The two mononuclear complexes 1(a) 
and 1(b) are isostructural but differ with the cations. In addition, the slight difference in 
chemical shifts may be attributed to the change from the Ag+ cation to the PPh4
+ cation. The 
cation-π interaction was reported to have an influence on the NMR chemical shifts of 
complexes.34,35 In this case, the Ag+ cation may interact with the π-electrons of the cymene 
ligand to a larger extent than the PPh4
+ cation, deshielding Hb and Hc protons as well as 
enhancing the acidity.  
Complex 2 displayed Hb and Hc signals upfield relative to those of 1(a) and 1(b).  The upfield 
shift of 2 was due to PPh3. The binuclear complex 4 displays similar Hb and Hc signals to that 
of 1(a) whereas complex 1(b) exhibits an upfield shift relative to 4. Complex 3 shows the 
signals due to Hb and Hc downfield relative to complex 1(b) and upfield relative to complexes 
1(a) and 4. The results  of complex 5 were found to be comparable to 1H NMR data in 
literature.29 
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Table 2.1: 1H NMR data of 1(a), 1(b), 2, 3, and 4. 
 
Assignment 1(a)* 1(b) 2 3 4 
 δ(ppm) J(Hz
) 
δ(ppm) J(Hz) δ(ppm) J(Hz) δ(ppm) J(Hz) δ(ppm) J(Hz) 
He (d) 1.24 6.9 1.27 6.8 1.16 6.9 1.29 6.9 1.32 6.8 
Ha (s) 2.17 - 2.23 - 2.01 - 2.38 - 2.28 - 
Hd (sept) 2.67 6.8 2.80 6.9 2.47 6.8 2.76 6.9 2.77 6.8 
Hb (d) 6.09 6.4 5.64 5.9 5.29 5.4 5.78 5.5 5.97 5.9 
Hc (d) 6.22 5.9 5.91 5.4 5.51 5.9 6.00 5.8 6.21 5.9 
Hh (t) - - - - - - 6.80-6.87 8.8 - - 
Hf  and Hg 
(m) 
- - - - - - 7.20-7.31  
- 
- - 
m, 15H, Ph - - - - 7.41-7.50 - - - - - 
m, 20H,Ph - - 7.57-
7.91 
- - - - - - - 
*Spectra were recorded in CDCl
3
 except for 1(a), which was recorded in DMSO-d
6
 
 
 
2.3.1.2 13C NMR data 
The 13C NMR data for complexes 1(a), 1(b), 2, 3 and 4 are reported in Table 2.2, which 
supports the 1H NMR data. The influence of the O,Oʹ- and P- ligand systems on the cymene 
ligand was  observed. Complex 1(b) showed the most downfield carbon shift with respect to 
the aromatic carbons of the cymene in comparison to 1(a). Regardless of the similarity with 
respect to the anionic osmium complex, the Ag+ ion and PPh4
+ ion have a unique electrostatic 
influence on the two complexes 1(a) and 1(b).  The cation-π interaction of the soft Ag+ ion 
with the π-electrons of the cymene ligand may have contributed to the upfield shift in the 13C 
signals of the cymene.  In contrast, the PPh4
+ ion of 1(b) has four π-systems, which may have 
stronger π-π interactions with the π-electrons of the cymene, deshielding the cymene aromatic 
carbons. 
Complex 2 displayed carbon signals due to η6-C6H4 of the cymene upfield relative to 1(b) and 
downfield relative to 1(a). This may be attributed to the influence of PPh3 as a strong -donor 
as well as strong π-acceptor ligand. The P atom in complex 2 competes with the C atoms of 
the cymene for back-bonding electrons. The binuclear complex 4 displayed four signals due 
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to η6-C6H4 carbons of the cymene ligand upfield relative to 1(a), 1(b) and 2. This shift was 
due to increased π-back bonding from Os to the η6-C6H4 carbon atoms. Complex 3 displayed 
signals due to aromatic cymene carbons upfield relative to 1(a), 1(b) and 2 but shifted 
downfield compared to 4. The positions of these signals in complex 3 were attributed to the 
contribution of π-electrons from the tropolone ring.  
The ancillary ligands of the osmium cymene complexes have an effect on the CO signals of 
the oxalate moeity. The CO signals were observed as singlets at 163.78 ppm for 1(a), 166.90 
ppm for 1(b), 164.22 ppm for 2, 185.85 ppm for 3 and 175.39 ppm for 4. The CO signal of 
complex 1(a) appears upfield relative to that of 1(b) and 2. The carbonyl shift of 1(b) may be 
influenced by PPh4
+ cation and the carbonyl shift of 2 may be influenced by the presence of 
PPh3 ligand (see table 2.2). The cation-π interaction of the PPh4+ cation with the cymene may 
influence carbonyl shift on the NMR. Also, the solvent effect may be one factor that 
influenced the CO signals of 1(a), 1(b) and 2. Complex 4 shows the most downfield carbonyl 
signal than the mononuclear complexes 1(a), 1(b) and 2. This downfield shift was attributed 
to the oxalate ligand donating electrons to both osmium centres. Hence, the oxygen atoms 
pull electrons from the carbon atoms by induction resulting in the carbonyl carbons being 
deshielded. Complex 3 displayed a CO signal downfield compared to complexes 1(a), 1(b), 
2, 3 and 4 due to the presence of the tropolone ligand which has π-bonds in the ring. The 
NMR data for the CO signals of the mononuclear complexes suggest that the tropolonate 
ligand is a stronger σ-donor ligand compared to the oxalato ligand.  
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Table 2.2: 13C NMR data of 1(a), 1(b), 2, 3 and 4. 
Assignment 1(a)*  1(b) 2 3 4  
CH3C6H4 17.25 18.91 18.04 19.56 19.51 
CH(CH3)2 22.34 23.01 22.70 23.00 22.94 
CH(CH3)2 30.65 31.66 31.00 32.02 32.07 
η6-C6H4 95.41, 90.77, 
78.80, 77.46 
117.82, 117.15, 
71.76, 68.86 
98.82, 88.39, 
79.35, 79.10 
91.00, 87.26, 
71.76, 69.63 
90.68, 86.64, 
71.97, 69.75 
trop-3C - -  127.42, 127.23 - 
trop-C - -  138.07 - 
CAromatic - 130.79-135.75 128.91-
134.40 
- - 
CO 163.78 166.90 164.22 185.85 175.39 
*Spectra were recorded in CDCl
3
except for 1(a) which was recorded in DMSO-d
6 
trop = tropolonate ligand 
 
2.3.1.3 Heteronuclear Single Quantum Correlation (HSQC) NMR 
The Heteronuclear Single Quantum Correlation (HSQC) is a 2D NMR study of the 
correlation of 1H with other nuclei such as 13C, 15N, 31P, 29Si NMR that are observed as cross-
peaks on a two-dimensional spectrum. The correlation of quaternary carbons is not possible 
due to the absence of CH bonds. In this thesis, the experiments carried out involved proton-
carbon (1H13C) correlations and the magnetisation transfer between these nuclei allowed for 
the identification of protons bonded to different nuclei (13C), assisting with assignment of 1H 
and 13C resonances.   
Complex 3 has been characterised by 2D HSQC NMR. Data from this study suggests that the 
tropolone ligand becomes symmetrical upon coordination to the osmium centre. The free 
tropolone ligand is asymmetrical (see figure 2.1(i)). The singlet due to Ha correlates with the 
carbon signal at 19.56 ppm (CH3C6H4). The doublet due to He correlates with the carbon 
signal at 23.00 ppm (CH(CH3)2) (see figure 2.2). The septet due to Hd correlates with the 
carbon signal at 32.02 ppm (CH(CH3)2). The Hb protons on the cymene group were assigned 
as protons at ortho position to the methyl group while the Hc protons were assigned at meta 
position to the methyl group on the cymene ligand. The two sets of doublets due to Hb and Hc 
correlates with the carbon signals at 69.63 and 71.76 ppm respectively. For the tropolonate 
ligand, the triplet due to Hh correlates with the carbon signal at 127.42 ppm. The Hg protons 
correlate with the carbon signal at 127.23 ppm. The Hf protons correlate with the carbon 
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signal at 138.07 ppm (see figure 2.2). The HSQC spectrum allows for the unambiguous 
assignment of the aromatic cymene protons Hb and Hc.  
Os
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Hg
Hg
Hg
Hh
Hh
Hc Hc
Hf
He
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Hd
Hd
He
Ha
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Hb
Hb
Hb
Hc
 
Figure 2.2: The 2D HSQC spectra of 3 showing CH correlation. 
 
2.3.1.4 31P NMR data of 1(b) and 2 
The 31P NMR data for complexes 1(b) and 2 are reported below. The single P signal for 
complex 1(b) due to the PPh4 cation was observed at 24.06 ppm with two satellite peaks at 
24.43 and 23.69 ppm. The P signal of the PPh4
+ cation in 1(b) is deshielded compared to the 
P signal of PPh4Br (23.09 ppm). The P chemical shift for complex 1(b) was attributed to 
change in electrostatic interaction from the small Br anion to the larger osmium complex 
anion. The 31P spectrum of 2 showed a single signal at 1.78 ppm and satellite peaks at 1.90 
and 1.64 ppm which may be due to spinning side bands with 1J= 53 Hz which is less than 
1J(187Os˗31P) = 77 Hz observed for octahedral pentaosmium phosphinidene clusters.36 A 
second set of satellite peaks at 2.54 and 1.02 ppm was assigned to 187Os coupling with 
1J(187Os˗31P) = 309 Hz (see figure 2.3).   
26 
 
The two sets of satellites were attributed to the NMR active isotope of osmium which is 187Os 
(I = 1/2) with higher J-coupling constant and side spinning bands with lower J-coupling 
constant.37 In solution, only satellite signals are expected for the less abundant isotope 187Os, 
as the more abundant 189Os isotope has extremely efficient quadrupolar relaxation in solution. 
However, in solid-state 31P NMR, satellite peaks for 189Os isotope are also observed because 
of longer relaxation times.38,39  
 
 
Figure 2.3:  31P NMR spectrum of 2 showing two sets of satellite peaks. 
 
2.3.2 Infra-Red (IR) Spectroscopy  
 
Studies of carboxylate groups have shown that symmetric and asymmetric stretching bands of 
oxalate are found in the ranges 1400-1500 cm-1 and 1500-1700 cm-1 respectively.40 The infra-
red spectrum of 1(a) showed two very strong stretching bands with shoulder peaks at 
1688vs/1671sh/1640sh cm-1 and at 1595vs/1574sh cm-1 which were attributed to νasym(OCO) 
J = 53 Hz
J = 309 Hz
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bands (see figure 2.4).41 A very weak band at 1457 cm-1 and a medium band at 1422 cm-1 
were assigned to νsym(OCO) + ν(CC).  At 1265 cm-1 another medium stretching band was 
assigned to νsym(OCO). The very weak and weak stretching bands at 911 cm-1 and 876 cm-1 
respectively were assigned to ν(CC). The strong stretching band at 794 cm-1 was assigned to 
ν(CC) + δ(OCO).42 Surprisingly, complex 1(b) showed three strong stretching bands at 1695 cm-
1, 1674 cm-1 and 1653 cm-1 attributed to νasym(OCO). The two stretching bands at 1483 cm-1 
weak and 1436 cm-1 medium were assigned to νsym(OCO) + ν(CC). At 1378 cm-1 and 1371 cm-1 a 
strong peak and weak peak were observed respectively, and were assigned to νsym(OCO). The 
two very weak stretching bands at 910 cm-1 and 886 cm-1 were assigned to ν(CC). A strong 
band at 787 cm-1 was assigned to ν(CC) + δ(OCO).42 The mononuclear complex 2 also displayed 
three stretching bands at 1706 cm-1, 1693 cm-1 and 1669 cm-1 attributed to νasym(OCO). A very 
weak band and a weak band were observed at 1482 cm-1 and 1433 cm-1 respectively 
attributed to νsym(OCO) + ν(CC). A very strong broad stretching band with three splitting was 
observed at 1371/1363/1356 cm-1 was assigned to νsym(OCO). A very weak band at 904 cm-1 
and a weak band at 875 cm-1 was assigned to ν(CC). The strong stretching band at 786 cm-1 
was assigned to ν(CC) + δ(OCO).42   
 
 
Figure 2.4: Infra-red spectrum of complex 1(a). 
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Complex 3 showed a single strong stretching band at 1588 cm-1 attributed to ν(CC) (see figure 
2.5). The second strong peak at 1512 cm-1 was attributed to ν(CO) + ν(CC). The strong peak with 
a shoulder was attributed to ν(CC) at 1424 cm-1 and δ(C-H) at 1407 cm-1. The broad peak was 
attributed to ν(CO) at 1353/1341 cm-1.43 Complex 4 showed the characteristics bands of a 
bridging oxalate ligand νasym(OCO) at 1611 cm-1 which is a very strong band, νsym(OCO) + ν(CC) at 
1468 cm-1 which is a weak band and νsym(OCO) at 1387/1341 cm-1 which is also a very strong 
band.  A weak band at 881 cm-1 with a shoulder at 891 cm-1 were attributed to ν(CC) and 
another weak band  assigned as ν(CC) + δ(OCO) at 803/796 cm-1.19,24,41,42,44 The delocalised 
electrons in the chelate rings of the binuclear osmium complex results in a weakened CO 
bond and consequently lower stretching frequency compared to the C=O band. The stretching 
band of 4 was similar to that of the ruthenium analogue reported to be 1614 cm-1 by Yan and 
co-workers.6 Complex 1(b) displayed higher stretching bands for M−O−C bonds relative to 
1(a) and 4. Terminal CO bonds have higher stretching frequencies while the bridging 
alkoxy exhibits lower stretching frequencies. Complex 3 exhibits lower stretching 
frequencies because of the electrons delocalised in the 5-membered chelate ring.  
 
 
Figure 2.5: Infra-red spectrum of complex 3. 
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2.3.3 Raman Spectroscopy 
 
The Raman spectroscopy of 1(a), 1(b), 2 and 4 support the NMR and IR data, however, the 
Raman data of complex 3 was not obtained due to the dark colour of the sample. Complex 
1(a) displayed two stretching bands at 1695/1688 cm-1 weak and 1609/1575 cm-1 very weak 
attributed to νasym(OCO) (see figure 2.6). The stretching bands due to νsym(OCO) + ν(CC) were 
observed at 1457 cm-1 a shoulder and at 1426 cm-1 which is a very strong band. A medium 
band at 1269 cm-1 was assigned to νsym(OCO). A weak stretching band at 912 cm-1 and a very 
weak band at 893 cm-1 were assigned to ν(CC).41,42 Additional weak band due to ν(Os-Br) was 
observed at 182 cm-1. Complex 1(b) shows three medium stretching bands at 1697/1680/1654 
cm-1 attributed to νasym(OCO). The very weak stretching bands at 1483/1460/1440 cm-1 were 
assigned to νsym(OCO) + ν(CC). A medium stretching band at 1384 cm-1 and a very weak band at 
1317 cm-1 were attributed to νsym(OCO). A very weak stretching band at 907 cm-1 was assigned 
to ν(CC). Also a medium stretching band due to ν(Os-Br) was observed at 197 cm-1. The OsBr 
bands for 1(a) and 1(b) appeared at different wavelengths attributed to the difference in 
cations, which exhibit different electrostatic interactions towards the osmium complex anion.  
 
 
Figure 2.6: Raman spectrum of complex 1(a). 
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Complex 2 showed two weak stretching bands at 1697 cm-1 and 1669 cm-1 due to νasym(OCO). 
The very weak bands due to νsym(OCO) + ν(CC) were observed at 1483 cm-1,1455 cm-1 and 1440 
cm-1. A very weak stretching band at 1388 cm-1 and a medium stretching band at 1364 cm-1 
were attributed to νsym(OCO). The two very weak bands were observed at 906 cm-1 and 889 cm-1 
due to ν(CC). Complex 4 displayed a weak single stretching band at 1655 cm-1 due to 
νasym(OCO). A very strong stretching band at 1480 cm-1 and a strong stretching band at 1445 
cm-1 were assigned to νsym(OCO) + ν(CC). The very weak stretching bands at 1380/1361 cm-1 and 
1319/1301 cm-1 were assigned to νsym(OCO).  A very weak stretching band at 921/904 cm-1 
were assigned to ν(CC). In addition, a medium peak due to ν(Os-Br) was observed at 200 cm-1. 
Because of the symmetry of the binuclear complex 4, a single Os−Br peak was observed. The 
OsBr bands in this study were assigned according to literature data.45 
 
2.3.4 Thermogravimetric analysis (TGA) 
 
Thermal stability studies on all complexes reported in this chapter were carried out using 
TGA. Complex 1(a) displayed remarkable thermal stability with three distinct degradation 
steps. The first step around 50 – 97.6 ºC was attributed the residual CH2Cl2 solvent. The 
second step showed the onset of decomposition at 160.1 to 322.8 ºC accounting for 44.3% 
mass loss attributed to the loss of the cymene, C2O4. The third step showed mass loss at 648.3 
ºC attributed to the loss of Br ligand which was followed by oxidation of Ag(I) to AgO and 
Os(II) to OsO2 and/or OsO4 with 29% residue of silver and osmium beyond 800 ºC (see 
figure 2.7).46  
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Figure 2.7: TGA thermograms of 1(a) with DTG curve. 
 
Complex 1(b) shows four distinct degradation steps. The loss of the CH2Cl2 solvent was 
observed at 123.8 to 199.8 ºC. The first degradation step due to the onset decomposition of 
22.1% mass loss at 245.2 ºC attributed to the loss of the cymene and C2O4 ligands. The 
second degradation step of 8.2% mass loss corresponds to the loss of one phenyl group of the 
PPh4
+ counter ion at 298.2 to 345.6 ºC. The third step of degradation at 345.6 to 400.5 ºC 
corresponds to the loss of second phenyl group with 10.8% mass loss. The third step of 
degradation at 400.5 to 469.1 ºC corresponds to the loss of two phenyl groups with about 
16.0% mass loss. The fourth step was incomplete below 800 ºC with about 27% remaining 
fragment attributed to [OsPBr]. Complexes 1(a) and 1(b) degrade in different pathways 
because of the different electrostatic forces between the cations and the complex anion (see 
figure 2.8). The PPh4
+ cation has a positive influence on the thermal stability of 1(b). In 1(b), 
there is a systematic loss of four phenyl groups from PPh4
+ at 295.1 to 469.1 ºC which results 
in the possible OsP bond formation. The boiling point of P at 280.5 ºC supports our theory 
of a chemical vapour deposition reaction to yield [OsBrP]. 
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Figure 2.8: The proposed decomposition pathways of 1(a) and 1(b). 
 
Complex 2 shows three degradation steps, the onset decomposition of 33.6% mass at 168.1 to 
331.0 ºC was attributed to the loss of cymene and the C2O4. The second degradation of 11.6% 
mass loss at 314.3 to 424.2 ºC was attributed to the loss of one phenyl group. The third 
degradation step of 19.7% mass loss was attributed to the loss of the two-phenyl groups at 
424.2 to 627.0 ºC. The remaining 37% was attributed to [OsPBr] fragment. In contrast, 
complex 3 was observed to decompose in three distinct steps. For this complex the first step 
corresponds to the loss of the cymene ligand at 236.1 to 304.2 ºC accounting for 26.9% mass 
loss (see figure 2.9). The second step corresponds to the loss of the tropolonate ligand at 
304.2 to 446.4 ºC accounting for 24.2% mass loss. The last step was attributed to the 
breaking of Os−Br bond and probably the loss of OsO2 and OsO4 resulting in the 14% 
residue remaining attributed to Os metal.46   
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Figure 2.9: TGA thermogram of 3 with DTG curve. 
 
Complex 4 decomposes in two distinct steps. The first degradation step corresponds to the 
loss of two cymene groups and the oxalate ligand at 248.8 to 316.3 ºC account for 41.2% 
mass loss. The second degradation step shows 14.4% mass loss which corresponds to two 
bromide ligands at 368.0 to 483.5 ºC (see figure 2.10). The osmium metal undergo oxidation 
to OsO2 and/or OsO4 followed by reduction to Os metal accounting for 41.4% mass loss at 
temperatures between 483.5 to 731.6 ºC.  
  
34 
 
 
Figure 2.10: TGA thermogram of 4 with DTG curve. 
 
 
2.3.5 Conductivity studies 
 
The conductivity of ionic complexes 1(a) and 1(b) were measured at a concentration of 10-3 
M in nitrobenzene solvent. From literature reports, 1:1 complexes are expected to give 
conductivities within the range 20-30 Scm2mol-1.47 The results for complex 1(a) at a 
concentration of 1.5 × 10-3 M was not observed because the conductance of the complex was 
below the detection limit. The non-conductivity behaviour of this complex was attributed to 
low mobility of the ions involved and the interference of the solvent. Complex 1(b) gave a 
molar conductivity value of 15.43 Scm2.mol-1 at a concentration of 1.2 × 10-3 M. The molar 
conductivity of 1(b) appeared to be below the range. This was attributed to the low mobility 
of ions involved as well as the bulkiness of the PPh4 cation.  
The results for complex 1(b) were calculated using the following equations. 
 = G × K   . . . . . . [1]  
Where  = conductivity (S/cm), G = conductance (S), K = cell constant (cm-1)  
 
Converting the conductivity to the molar conductivity the following equation was used: 
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ɅM =  / CM  . . . . . . [2] 
Where ɅM is the molar conductivity and CM is the molar concentration of complex 1(b) = 1.2 
× 10-3 M 
Then by substituting values obtained from equations [1] and [2], we obtained the following, 
 ɅM = 15.43 S cm2/mol 
 
NB: The conductance of the samples were obtained after subtracting the value of the blank; Nitrobenzene 
= 3.45 μS from the measured values. 
 
 
2.3.6 Crystallography  
 
Single crystal X-ray crystallography confirmed the molecular structures of 1(b), 2 and 4. 
Table 2.3 contains the crystal data and structural refinement parameters of 1(b), 2 and 4. The 
general assignments of atoms in the three molecular structures are as indicated below (see 
figure 2.11). 
 
C1
C2
C3
C4
C5
C6
C7
C8
C10C9
Os1
O1
O2
C11
C12
O3
O4
L
L = Br or PPh3  
Figure 2.11: General assignment of atoms in the molecular structures of 1(b), 2 and 4 
discussed in this chapter. 
 
2.3.6.1 Molecular structure of 1(b). 
Crystals of 1(b) suitable for X-ray diffraction were obtained by slow diffusion of diethyl 
ether into a dichloromethane solution at room temperature. Complex 1(b) measured the Os-
centroidcymene distance as 1.642 Å. Loss of aromaticity was observed in the cymene ligand 
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through short and long C−C bonds which shows the localization of the C=C bonds in three 
sets of bonds C(1)−C(2), C(2)−C(3), C(3)−C(4) (see table 2.4). The Os−C bond lengths were 
observed to be slightly longer for Os(1)−C(1), Os(1)−C(3) and Os(1)−C(5) bonds. The loss of 
planarity in the cymene ring was observed in the deviation of the ring carbons from the mean 
plane defined by C(1), C(2), C(4) and C(5). The C(3) deviated by 0.083 Å below the mean 
plane and C(6) deviated by 0.049 Å also below the mean plane, which resulted in the cymene 
ligand adopting an inverted boat conformation. The oxalate bite angle O(1)−Os(1)−O(2) was 
measured at 77.05º.  
The torsion angle C(3)−C(4)−C(5)−C(6) was found to be slightly higher than zero which 
indicates the distortion of the cymene ligand (see table 2.4). Complex 1(b) showed 
intermolecular hydrogen bond between O(2) and a H atom on one of the phenyl rings of the 
PPh4
+ ion. A C−H…O contact distance measured as 2.479 Å at an angle 149.22º. Also, found 
was a C−H…O intramolecular hydrogen bond between the hydrogen of C(10) and O(2) which 
measured 2.673 Å at 149.01º. Further intermolecular hydrogen bonding was observed 
between O(4) atom and a H atom of the phenyl ring of PPh4
+ ion. A C−H…O hydrogen bond 
was measured as 2.582 Å at an angle 145.22º (see figure 2.12). A C−H…Br intermolecular 
hydrogen bonding was also observed between the hydrogen on the phenyl ring with Br(1) 
which measured 2.996 Å at 150.08º (see figure 2.12). The two C−H…O and one C−H…Br 
hydrogen bonds play a significant role in holding the two oppositely charged ions.  
The effects of coordination of the oxalato ligand in 1(b) are discussed below in comparison 
with the molecular structure of the uncoordinated oxalate ligand. The molecular structure of 
the uncoordinated oxalate ion (AMOXAL02†1) has been reported to have O(1)−C−C and 
O(2)−C−C bond angles of 117.79º and 117.00º respectfully as well as an O(1)−C−O(2) bond 
angle of 125.21º.48 Also the free oxalate ligand bond lengths C−O(1), C−O(2) and C−C have 
been reported as 1.255 Å, 1.258 Å, and 1.548 Å respectively. In comparison, the coordinated 
oxalate ligand of complex 1(b) has the following bond angles O(1)−C(11)−C(12), 
O(2)−C(12)−C(11), O(3)−C(11)−C(12), O(4)−C(12)−C(11), O(1)−C(11)−O(3) and 
O(2)−C(12)−O(4) which were measured at 114.29º, 114.63º, 121.10º, 120.33º, 124.48º and 
124.96º respectively. The oxalate ligand in 1(b) was affected upon coordination to the 
osmium centre, which can be observed through slight changes to the bond angles. The bond 
lengths of the coordinated oxalate ligand were measured as 1.300 Å for O(1)−C(11), 1.291 Å 
                                                          
†1 The CIF file used for comparison was obtained from the CCDC database. 
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for O(2)−C(12), 1.214 Å for O(3)−C(11), 1.221 Å for O(4)−C(12) and 1.543 Å for 
C(11)−C(12). The C(11)O(3) and C(12)O(4) of 1(b) were shorter than those of the free 
ligand which may be attributed to introduction of electron density from Os into the chelate 
ring.  
Similarly, the effects of electrostatic interactions on the PPh4
+ ion in 1(b) relative to the PPh4
+ 
ion in PPh4Br (DEMYEZ03
†2) were compared. The PPh4
+ ion in complex 1(b) measured 
similar C−P bond lengths and C−P−C bond angles relative to the PPh4Br.49 Hence, the 
electrostatic interaction between PPh4
+ and the osmium complex has a negligible effect on 
the PPh4
+ ion. 
 
                  
                 
Figure 2.12: Molecular structure of 1(b) at 50% probability thermal ellipsoids.    
 
 
                                                          
†2 The CIF file used for comparison was obtained from the CCDC database. 
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2.3.6.2 Molecular structure of 2. 
Crystals of 2 were obtained from slow diffusion of diethyl ether into a dichloromethane 
solution at room temperature. The complex has a monoclinic crystal system with P21 space 
group. The neutral complex 2 has both oxalate and PPh3 ligands attached to the same osmium 
centre. Evidence of loss of aromaticity was observed with alternating shorter and longer CC 
bonds around the cymene ligand. The three sets of carbons; C(1)−C(2), C(3)−C(4) and 
C(5)−C(6) have shorter distances than C(2)−C(3), C(4)−C(5) and C(6)−C(1) (see table 2.3). 
The trans influence of the PPh3 ligand was observed on C(1) and C(2) with longer Os−C 
bond lengths than the four carbon atoms; C(3), C(4), C(5), and C(6) around the cymene. This 
was caused by competing of back bonding electrons from the osmium centre between 
aromatic carbon atoms and phosphorus atom. The Os−C bond lengths due to C(3), C(4), C(5) 
and C(6) were shorter because oxygen atoms trans to the four  carbon atoms exert a weaker 
trans influence than C(sp2) atoms (see table 2.4).50 
The distance from the centroid of the cymene ring to the osmium centre was measured as 
1.700 Å whereas the ruthenium analogue (RUJHOT†3) was found to be 1.704 Å.6 The 
difference in M−centroid distance was attributed to the stronger interaction of the osmium to 
the cymene in this study relative to the ruthenium analogue. The O(1)−Os(1)−O(2) bite angle 
was measured at 77.77º. The Os(1)−P(1) bond length at 2.350 Å was slightly shorter than that 
reported for the analogous Ru complex (2.367 Å).6 The bond lengths C(11)O(1) and 
C(12)O(2) measured as 1.283 and 1.295 Å respectively were slightly longer than that of the 
C(11)O(3) and C(12)O(4) measured as 1.209 Å and 1.225 Å respectively.  
The presence of weak intramolecular hydrogen bonding between O(1) and a H atom on the 
phenyl ring of PPh3 was observed. The C−H…O contact distance was measured as 2.741 Å at 
an angle of 115.11º (see figure 2.13). A second interaction of the bridging oxygen atom 
(O(2)) with one of the H atoms of the isopropyl group of the cymene ligand was observed. 
Here, the C−H…O bond distance measured 2.545 Å at an angle of 133.46º (see figure 2.13). 
This contact is classified as a weak hydrogen bonding in literature.51 Loss of planarity was 
observed in the cymene ring with deviation from planarity of C(3) measured as 0.047 Å 
                                                          
†3 The CIF file used for comparison was obtained from the CCDC database. 
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above the mean plane. The C(6) was deviated by 0.053 Å below the mean plane, which 
resulted in the cymene ligand adopting a pseudo-chair conformation.  
The free oxalate and the coordinated oxalato ligands were compared in order to deduce the 
effects of coordination on the oxalato ligand in 2. The free oxalate ligand shows O−C−C 
bond angles which are measured at 117.79º and 117.00º as well as the O−C−O bond angle at 
125.21º.48 The free oxalate ligand reported bond lengths due to C−O and C−C, which are 
1.255 Å and 1.258 Å as well as 1.548 Å respectively. In this study, the parameters for 2 have 
been determined for O(1)−C(11)−O(3) and O(2)−C(12)−O(4) bond angles which were 
measured at 125.50º and 124.40º respectively. The torsion angle O(1)−C(11)−C(12)−O(2) 
was measured at 3.66º which indicated that the chelate ring was slightly distorted from the 
planar (see table 2.4).    
The bond angles due to O(1)−C(11)−C(12) and O(2)−C(12)−C(11) were at 114.8º and 114.1º 
respectively. There was a slight difference in bond angles of the coordinated and the free 
oxalate ligand.  The bond lengths of the coordinated oxalate ligand due to O(1)−C(11), 
O(2)−C(12) and C(11)−C(12) were measured as 1.283 Å, 1.296 Å and 1.548 Å respectively. 
The bond lengths of the carbonyl groups, C(11)−O(3) and C(12)−O(4) were measured as 
1.226 Å and 1.209 Å respectively. This observation may be attributed to possible hydrogen 
bonding of O(1) and O(2) because the C−H…O bond length seems to be slightly longer for 
C(11)O(3) bond but shorter for C(12)O(4). The bond lengths [C(11)O(3) and 
C(12)O(4)] were slightly different from that of the free oxalate ligand, as expected.  
The free PPh3 and the coordinated PPh3 ligands were also compared to determine the effects 
of coordination on the bond lengths and angles of PPh3 in 2. The free PPh3 ligand 
(PTRPHE03†4) has the C−P−C bond angles which were measured at 103.08º, 103.44º and 
101.66º.52 The P−C bond lengths of the free PPh3 ligand have been reported as 1.827 Å, 
1.831 Å and 1.832 Å.52 The C−P−C bond angles of the coordinated PPh3 ligand in 2 were 
measured at 102.23º, 105.27º and 104.62º. The coordinated PPh3 ligand P−C bond lengths 
were found be 1.819 Å, 1.820 Å and 1.834 Å. The deviation of two C−P−C bond angles for 2 
from that of the free ligand was attributed to the combination of steric demand and OsPC 
back-bonding. The bond lengths were slightly less than that of the free ligands, which may be 
due to back bonding. 
                                                          
†4 The CIF file used for comparison was obtained from the CCDC database. 
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Figure 2.13: Molecular structure of 2 at 50% probability thermal ellipsoids. 
 
2.3.6.3 Molecular structure of 4. 
Crystals of 4 suitable for X-ray diffraction were obtained by slow diffusion of diethyl ether 
into dichloromethane solution at room temperature. Complex 4 was found to crystalize in 
orthorhombic system with space group Pbca. The complex has a centre of symmetry hence 
the two nuclear fragmentations have equal bond distances as well as bond angles. Complex 4 
gives a molecular structure with bis-chelated five-membered rings on both osmium centres. 
There was a difference in bond distances observed from the aromatic carbons to the osmium 
centre. The distance from the aromatic carbon atoms C(1), C(3) and C(6) on the cymene to 
Os(1) were longer than the other three aromatic carbon atoms C(2), C(4) and C(5) (see table 
2.4). An indication of weaker interaction due to OsCcymene long bond lengths may be 
attributed to the trans influence caused by the oxygen atoms adjacent to the three atoms. The 
shortest distance was observed for the Os(1)C(2) bond  which indicates a stronger 
interaction between the Os(1) and C(2) atoms.  
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The carbons in the cymene ligand showed different CC bond distances, which indicated a 
loss of aromaticity of the cymene ligand once bounded to the osmium metal (see table 2.4). 
The distance from the osmium centre to the cymene centroid was found to be 1.636 Å. In 
contrast, the ruthenium analogues have Rucentroidcymene distance of 1.644 Å (RUJHIN†5) 
and 1.650 Å (RUJHEJ†6) which were slightly longer compared to the Oscentroidcymene 
distance.6 The observation may be attributed to the characteristics of the 5d transition metals 
to favour formation of more stable complexes relative to the 4d analogues. A weak C−H…Br 
intramolecular hydrogen bond was observed between the hydrogen of C(8) and Br atoms (see 
figure 2.14). The C−H…Br contact measures a distance of 3.081 Å at an angle 133.01º. 
The bite angle O(1)−Os(1)−O(2) was measured at 77.10º which is significantly less than the 
ideal octahedral complex of 90º (see figure 2.14). The distortion of the bond angle 
O(1)−Os(1)−O(2) was caused by the oxalato ligand since the oxalato ligand has shorter 
carbon chain length. The interatomic distance between the two donor oxygen atoms [O(1) 
and O(2)] was measured as 2.664 Å. The torsion angle O(1)C(11)C(12)O(2) measured at 
0.63º indicates that the oxalate ligand was slightly distorted. The minor distortion was 
observed because of the trans influence due to aromatic carbons on the cymene equally affect 
the bridged-oxalato ligand from both osmium centres. The loss of planarity was observed in 
the cymene via the mean plane defined by C(1), C(2), C(4) and C(5). The deviation of C(3) 
was observed to be 0.003 Å below the mean plane and C(6) was measured as 0.030 Å also 
below the mean plane. The deviation of C(6) was found to be 10 times more than the 
deviation of C(3) because of the different substituents on these two carbon atoms. The 
cymene ligand adopted an inverted boat conformation. The torsion angle 
C(6)−C(1)−C(2)C(3) was found to be 2.80º which also indicates the loss of planarity of the 
cymene. The intramolecular distances between the two osmium centres was found to be 
5.540 Å.   
 
The effects of the bis-chelating mode of the oxalato ligand in 4 relative to the free oxalate 
ligand were compared. The bond angles O(1)−C(11)−C(12) and O(2)−C(12)−C(11) were 
measured at 117.31º and 116.74º respectively. The bond angles of the coordinated oxalato 
ligand were found to be slightly deviated from the bond angles of the free ligands (117.79º 
and 117.00º).48 The O(1)−C(11)−O(3)  bond angle was measured at 125.94º for 4 while in the 
                                                          
†5 The CIF file used for comparison was obtained from the CCDC database. 
†6 The CIF file used for comparison was obtained from the CCDC database. 
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free oxalate ligand it was measured at 125.21º. The slight difference may be attributed to the 
coordination of the oxalato ligand to two osmium centres. The O(1)−C(11), O(2)−C(12) and 
C(11)−C(12) bond lengths are measured to be 1.256 Å, 1.256 Å and 1.523 Å respectively. In 
free oxalate ligand these bond lengths are O−C (1.250 and 1.230 Å), and C−C (1.580 Å). 
Surprisingly, the bond lengths of the free oxalate ligand and the bridging oxalate ligand were 
similar.  
  
   
Figure 2.14: Molecular structure of 4 at 50% probability thermal ellipsoids.  
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Table 2.3: Crystal data and structure refinement of 1(b), 2, and 4. 
 1(b) 2 4 
Chemical formula C36H34BrO4OsP C30H29O4OsP C22H28Br2O4Os2 
Molecular mass 831.71 674.70 896.66 
Crystal system Monoclinic Monoclinic Orthorhombic 
Space group P21 P21 Pbca 
Crystal colour and shape Yellow sheets Yellow-brownish cubes Yellow needle 
a(Å) 7.5565(8) 9.745(5) 10.8433(5) 
b(Å) 10.7431(12) 11.825(5) 11.8395(5) 
c(Å) 19.144(2) 11.403(5) 18.7871(8) 
α(°) 90.00 90.000(5) 90.00 
β(°) 100.154(4) 99.261(5) 90.00 
γ(°) 90.00 90.000(5) 90.00 
V(Å3) 1529.8(3) 1296.9(10) 2411.87(18) 
Z 2 2 4 
T(K) 173(2) 173(2) 173(2) 
Dcalc (mg/m3) 1.806 1.728 2.469 
Absorption coefficient 5.566 mm-1 5.012 mm-1 13.865 mm-1 
Reflections collected 70605 59101 34419 
Independent reflections 7361 [R(int) = 0.0939] 6222 [R(int) = 0.0398] 2911 [R(int) = 0.0903] 
Data / restraints / 
parameters 
7361 / 1 / 391 6222 / 1 / 308 2911 / 0 / 139 
F(000) 816 664 1656 
Final R indices [I>2(I)] R1 = 0.0240,  
wR2 = 0.0623 
R1 = 0.0206,  
wR2 = 0.0529 
R1 = 0.0511,  
wR2 = 0.1041 
R indices (all data) R1 = 0.0245,  
wR2 = 0.0636 
R1 = 0.0210,  
wR2 = 0.0532 
R1 = 0.0555, 
wR2 = 0.1061 
Goodness-of-fit on F2 0.421 0.945 1.3811 
Largest diff. peak and 
hole 
0.727 and −2.154 e.Å-3 0.815 and −2.134 e.Å-3 2.308 and −2.853 e.Å-3 
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Table 2.4: Selected bond lengths (Å), Os-centroidcymene (Å), bond and torsion angles (º) of 
1(b), 2 and 4. 
Atom type label 1(b) 2 4 
Os(1)C(1) 2.175(6) 2.234(4) 2.179(10) 
Os(1)C(2) 2.165(5) 2.245(4) 2.138(11) 
Os(1)C(3) 2.184(6) 2.208(3) 2.176(11) 
Os(1)C(4) 2.150(6) 2.194(3) 2.161(9) 
Os(1)C(5) 2.182(6) 2.210(3) 2.162(9) 
Os(1)C(6) 2.163(6) 2.201(4) 2.177(9) 
C(1)C(2) 1.414(12) 1.387(5) 1.420(2) 
C(2)C(3) 1.414(11) 1.436(5) 1.420(2) 
C(3)C(4) 1.415(10) 1.418(5) 1.431(16) 
C(4)C(5) 1.438(10) 1.430(5) 1.397(15) 
C(5)C(6) 1.417(9) 1.407(5) 1.404(14) 
C(6)C(1) 1.416(9) 1.446(6) 1.441(17) 
Os(1)O(1) 2.099(4) 2.078(3) 2.136(7) 
Os(1)O(2) 2.100(4) 2.093(3) 2.137(6) 
Os(1)Br(1) 2.5324(7) − 2.5168(11) 
Os(1)P(1) − 2.3503(11) − 
Oscentroidcymene 1.642 1.700 1.636 
Bond angles  
O(1)Os(1)O(2) 77.05(16) 77.77(10) 77.1(2) 
Torsion angles  
C(6)C(1)C(2)C(3) 0.54 −0.5(6) 0.4(15) 
C(3)C(4)C(5)C(6) −4.14 −1.1(5) 2.8(16) 
O(1)C(11)C(12)O(2) −1.04 3.7(5) −0.63 
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2.4 Conclusions 
 
Five novel O,Oʹ-chelated osmium cymene complexes have been synthesized and 
characterized. The synthesis of the mononuclear complex NH4[Os(η6-p-cymene)(C2O4)Br] 
was not achieved instead a novel binuclear complex 4 was isolated. In addition, attempts to 
synthesize [{Os(η6-p-cymene)(PPh3)}2 μ-C2O4](BF4)2 were unsuccessful, instead a mixture 
of two neutral complexes 2 and 5 were obtained. The reaction of 4 with PPh3 cleaved the 
Os−O bonds of the five membered O,Oʹ-chelate ring at one osmium centre to afford a 
mixture of two neutral mononuclear complexes 2 and 5. The spectroscopic techniques (NMR, 
IR and Raman) have played an important role in the identification of the two complexes. The 
binuclear osmium complex 4 exhibited unique reactivity compared to that reported for the 
ruthenium analogue.  
The presence of PPh4
+ as a counter ion improves the solubility, electrolytic properties and 
have a significant impact on vibrational modes of the carboxylate group of 1(b). Thermal 
studies showed that 1(a) and 2 were less thermally stable with lower decomposition 
temperatures ca. 210 ºC relative to 1(b), 3 and 4. The Os−O thermal stability was observed to 
follow the trend: 3 ˃ 4 ˃ 1(b) ˃ 1(a) ˃ 2.   
Single crystal X-ray diffraction confirmed the molecular structures of 1(b), 2 and 4. The 
bridged-oxalato in 4 showed less distortion compared to the oxalato ligand in mononuclear 
complexes 1(b) and 2. The strong trans influence due to the PPh3 ligand in 2 elongates the 
Os−C bonds trans to the PPh3 ligand. In addition, 2 has the longest Oscentroidcymene distance 
than 1(b) and 4, attributed to the trans influence by PPh3 ligand. The Os−O bond lengths 
increases in the following trend: 4 ˃ 1(b) ˃ 2 which suggest that the stability of the bond may 
depend on other factors other than the length. The coordination of the cymene ligand to the 
osmium metal and the trans influence have shown to affect the aromaticity and planarity of 
the cymene ligand. The loss of aromaticity and planarity were found to be dependent on the 
ligand system around the osmium centre. The in vitro anticancer activity results of complexes 
1(b), 3 and 4 will be discussed in Chapter 5. 
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CHAPTER 3 
 
SYNTHESIS OF MONODENTATE PHOSPHINE AND P,Pʹ-CHELATED OSMIUM 
CYMENE COMPLEXES 
 
3.1 Background 
 
Phosphine ligands are ubiquitous in organometallic chemistry. The electronic and steric 
properties of phosphine ligands brought more interest in the study of phosphines from 
catalysis to medicinal applications.1 In 1993 Polam and Porter2 reported the molecular 
structure of the ruthenium arene complex [Ru(η6-C6H5CH3)(PPh3)2Cl]BF4 obtained by 
refluxing [Ru(PPh3)3Cl2] and AgBF4 in toluene. Their findings show that the toluene moiety 
was coordinated to ruthenium centre upon the cleavage of one PPh3 and chloride ligand. 
Lalrempuia and co-workers3 in 2003 reported the molecular structure of the ruthenium 
complex with a cymene ligand [Ru(η6-p-cymene)(PPh3)2Cl]BF4.  These two complexes are 
similar to complex 6 reported in this chapter but differ in the binding of the arene, halide and 
most importantly differs with respect to the metal centre.  
The chemistry of diphosphine ligands has been known in coordination chemistry because of 
their wide range of applications in the fields of catalysis and metallopharmaceuticals. The 
diphosphine ligands are good π-acceptor ligands bringing stability to the whole complex by 
reducing electron density on the metal centre through π-back donation to the empty P 3d-
orbitals. Hence, these ligands have been incorporated to a wide range of transition metals 
such as copper,4 gold,4 silver,4 osmium,5 ruthenium,6,7 palladium,8 chromium,9 molybdenum,9 
tungsten,9 rhodium.10 Diphosphine ligands are capable of coordinating as monodentate as 
well as bidentate ligands. As bidentate, these species form chelate rings with metals resulting 
in stable complex formation compared to monodentate coordination. Furthermore, these 
ligands can also bridge two metals centres acting as a monodentate ligand at each metal 
centre.5  
As bridging ligands, the diphosphines with shorter carbon chain length such as 
[R2P(CH2)nPR2 (where n = 1 or 2)] are capable of locking the two metal centres into close 
proximity. The diphosphine with longer carbon chain length such as R2P(CH2)nPR2 (where n 
= 3, 4 and higher) are more flexible with the two metal centres further apart. The electronic 
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communication of the two metal centres with bridging ligands is observed to be stronger 
depending on the ancillary ligands and the nature of the bridging ligand.11 In the bridging 
diphosphine ligands, the electronic communication was reported to be stronger with shorter 
carbon chain length [R2P(CH2)nPR2 (where n = 1 or 2)] and the presence of non π-acceptor 
ancillary ligands.12 
Chaplin and co-workers7 reported a series of chelated diphosphine ruthenium cymene 
complexes [Ru(η6-p-cymene)Cl(P−P)]PF6 (where P−P = diphenylphospinomethane (dppm), 
diphenylphosphinovinyl (dppv), diphenylphosphinoethane (dppe), 
diphenylphosphinopropane (dppp) and diphenylphosphinoferrocene (dppf). The group 
investigated chelation kinetics of the diphosphine ruthenium cymene complexes in 
CH2ClCH2Cl upon heating which resulted in the loss of PPh3 ligand that activated the ring 
closing process. Their findings show that the Ru−dppm complex chelates at the same rate (t1/2 
= 30 minutes) as the Ru−dppv complex. The Ru−dppp complex undergoes the chelation 
process slightly faster (t1/2 = 22 minutes) than the Ru−dppe complex (t1/2 = 28 minutes). The 
Ru−dppf undergoes ring closing process in t1/2 = 1 minute. In another mechanistic study, 
ruthenium cymene complexes [Ru(η6-p-cymene)(η1-(P−P)Cl2] (where P−P = dppm and dppv) 
were investigated for their rate of chelation in different solvents to afford [Ru(η6-p-
cymene)(P−P)Cl]Cl. The Ru−dppm was found to chelate 4 times more slowly in different 
mixed ratios of CH3OH/CH2ClCH2Cl (solvent (v/v); 2:1, 1:1, 1:2) than the Ru-dppv complex. 
Jensen and co-workers6 reported the synthesis of the diphosphine complexes from the 
bis(acetonitrile) ruthenium cymene complex [Ru(η6-p-cymene)(CH3CN)2Cl]+. The group 
reported the ring contributions to 31P NMR coordination shifts calculated relative to suitable 
monodentate analogues of the bidentate complexes. Therefore, the ring contributions to 31P 
NMR coordination shifts of complexes of this type [Ru(η6-p-cymene)(P−P)Cl]PF6 (where 
P−P = dppm, dppe and dppp) complexes were calculated relative to 
methyldiphenylphosphine (PCH3Ph2) monodentate analogue. The Ru−dppm complex was 
found to have an upfield ring contribution compared to the Ru−dppe and Ru−dppp 
complexes. The Ru−dppe complex was found to have a downfield ring contribution 
compared to the Ru−dppp complex.  
The synthesis methods reported by Chaplin and co-workers as well as Jensen and co-workers 
were used in this study to achieve the synthesis of osmium cymene complexes with chelating- 
and bridging-diphosphines (see scheme 3.1).  
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3.2 Preparation of P,Pʹ-osmium cymene complexes 
 
The preparation of the monodentate and chelated complexes 6 and 7(a)-(d) were carried out 
by the method reported by Jensen and co-workers.6 Complex 6 was prepared by reacting 
[Os(η6-p-cymene)(CH3CN)2Br]BF4 and PPh3 in CH2Cl2 at room temperature. The PPh3 
ligands slowly substitute the more labile CH3CN ligands. Complexes 7(a)-(d) were prepared 
by reacting [Os(η6-p-cymene)(CH3CN)2Br]BF4 and the corresponding diphosphine ligand 
[PPh2−(CH2)n−PPh2 (where n = 1 – 4)] in CH2Cl2 at room temperature. The substitution of 
the more labile CH3CN ligands gave the chelated diphosphine complexes as positively 
charged complexes.  Complexes 8(a)-(d) were prepared by drop-wise addition of the solution 
of the corresponding diphosphine ligand [PPh2−(CH2)n−PPh2 (where n = 1 – 4)] in CH2Cl2 to 
a stirred solution of the osmium dimer [Os(η6-p-cymene)Br2]2. Under these conditions the 
diphosphine ligand coordinate to two osmium centers in a bridging mode, affording a neutral 
binuclear complex (see scheme 3.1). 
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3.3 Results and Discussion 
 
 
3.3.1 Nuclear Magnetic Resonance (NMR) Spectroscopy  
 
3.3.1.1 1H NMR data 
 
                                                
Ha
Hb Hc
Hd
He
HcHb
He
   
Figure 3.1: 1H NMR data of the cymene ligand will be discussed with these assignments. 
 
The 1H NMR data for complexes 6 and 7(a)-(d) are reported in Table 3.1. The 1H NMR 
signals indicated differences in shifts of the cymene aromatic protons as the carbon chain 
length of the diphosphine was increased. The cymene protons Hb and Hc of 7(a) appear to be 
deshielded than that of the four complexes (see figure 3.2). The downfield shift of the protons 
Hb and Hc were observed because of the trans influence exerted by the phosphorus atoms. 
Less electron density on the carbons results in deshielding the nuclei of the protons Hb and 
Hc, consequently increasing the acidity of these protons.  Complex 7(b) showed Hb and Hc 
signals that are deshielded relative to the Hb and Hc signals of complexes 6 and 7(d) (see 
figure 3.2) which suggested strong interaction between the osmium centre and the 
phosphorus atoms of complex 7(b). The coupling constants for Hb and Hc protons are 
dependent on the dihedral angle between these protons. Different coupling constants are 
obtained because of the non-planarity of the cymene-ring protons as determined by 
crystallography measurements.  
Complex 7(c) showed Hb and Hc signals that are slightly deshielded relative to complexes 6 
and 7(d).  The cymene aromatic protons of 6 and 7(d) were observed to be shielded (see 
figure 3.2). The shift may be due to the trans influence of the phosphorus atoms. The 1H 
NMR data for complexes 6 and 7(d) suggest that the Os−P bonds are slightly longer than 
those of complexes 7(a)-(c), which results in carbons trans to the phosphorus atoms 
competing for electrons during back-bonding and thus shielding the nucleus of the Hb and Hc 
protons. Hence, deshielded cymene aromatic protons Hb and Hc suggested that the 
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phosphorus trans to carbons on the cymene has a stronger interaction with the osmium 
centre, and as a result may lead to shortened Os−P bond lengths. 
 
Figure 3.2: The cymene protons Hb and Hc of 6 and 7(a)-(d) with traces of CH2Cl2 (*). 
 
The proton Hd also exhibits differences in signal shifts which were the opposite to that 
observed for protons Hb and Hc (see table 3.1). The signal due to Hd for complex 6 was 
observed to be deshielded relative to complexes 7(a)-(d).  Complex 7(d) also shows a 
deshielded septet signal due to Hd relative to complexes 7(a)-(c). Complex 7(c) was 
deshielded compared to 7(b) and 7(a). Complex 7(b) was deshielded compared to 7(a). These 
results suggest that as the carbon chain length of the diphosphine ligand increases more 
electron density is shifted away from the cymene carbon bonded to the proton Hd. 
 
 
 
6
7(a)
7(b)
7(c)
7(d) *
*
*
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Table 3.1: 1H NMR data of 6 and 7(a)-(b). 
Assignment 6 7(a)* 7(b) 7(c) 7(d) 
 δ(ppm) J(Hz) δ(ppm) J(Hz) δ(ppm) J(Hz) δ(ppm) J(Hz) δ(ppm) J(Hz) 
He (d) 1.20 6.9 0.91 6.9 0.89 7.0 0.75 6.8 0.97 6.9 
Ha (s) 2.15 - 1.45 - 1.26 - 1.37 - 1.17 - 
4H,PCH2CH2CH2CH2 (br) - - - - - - - - 1.58-2.27 - 
2H, PCH2CH2CH2P (m) - - - - - - 1.77-2.54 - - - 
Hd (sept) 2.75 7.0 2.20 6.8 2.38 6.7 2.46 6.8 2.65 7.1 
2H,PCH2- (m) - - - - 2.65, 2.99 - 3.21 - 3.90 - 
2H, P-CH2-P (dd) - - 4.73 5.4 - - - - - - 
Hb (d) 5.23 5.9 6.31 5.9 5.87 4.1 5.58 5.9 5.05 5.9 
Hc (d) 5.80 # 6.45 5.9 6.01 6.4 5.97 5.4 5.80 5.4 
20H, Ph (m) - - 7.26-7.67 - 7.21-7.70 - 7.25-7.55 - 7.31-7.58 - 
30H, Ph (m) 7.23-7.37 - - - - - - - - - 
*Spectra were recorded in CDCl
3
 except for 7(a) which was recorded in DMSO-d
6; 
# Poorly resolved doublet. 
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The 1H NMR data for 8(a)-(d) are found in Table 3.2. A virtual triplet was observed for the 
bridging-methylene in 8(a) at 4.88 ppm because the phosphorus-phosphorus coupling 
becomes larger resulting in the 1H NMR of the CH2− being affected. In addition, complex 
8(a) is less sterically hindered (anti conformer), which has no mirror plane consequently the 
CH2− protons are not equivalent, hence, a distorted triplet was observed rather than a 
doublet. Also, the aromatic protons Hc for 8(a) were displayed upfield relative to Hc for 8(b)-
(d) (see figure 3.3). The 1H NMR signals of 8(b) and 8(c) were similar despite the additional 
CH2− in 8(c). However, the aromatic protons Hc of 8(c) appeared downfield relative to Hc 
of 8(b). Complex 8(d) displayed Hb and Hc downfield relative to 8(a)-(c). The observation 
may be attributed to the competition of π-back bonding electrons between the P atoms and 
the aromatic cymene carbons.  
Table 3.2: 1H NMR data of 8(a)-(d). 
Assignments 8(a) 8(b) 8(c) 8(d) 
 δ(ppm) J(Hz) δ(ppm) J(Hz) δ(ppm) J(Hz) δ(ppm) J(Hz) 
He (d) 0.94 6.4 0.79 6.9 0.82 7.0 0.75 7.0 
4H, PCH2CH2 (br) − − 0.95 − 0.99 − 0.91 − 
2H,PCH2 (br) 1.90 − − − − − − − 
Ha (s) 2.09 − 1.95 − 1.97 − 1.98 − 
Hd (sept) 2.52 6.9 2.48 6.9 2.51 6.9 2.49 7.0 
4H,PCH2- (br) − − 2.64 − 2.66 − 2.51 − 
2H, PCH2 (m) 3.49-3.71 − − − − − − − 
Virtual triplet, 1H,CH2  4.88 7.3 - − − − − − 
Hb (d) 5.07 4.7 5.15 5.9 5.17 5.9 5.20 5.9 
Hc (d) 5.31 5.9 5.29 5.9 5.31 5.3 5.36 5.3 
20H, Ph (m) 7.04-7.59 − 7.24-7.52 − 7.24 – 7.56 − 7.27-7.68 − 
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Figure 3.3: 1H NMR spectra of 8(a)-8(d) showing the Hb and Hc protons. 
 
3.3.1.2 13C NMR data 
 
The 13C NMR data supports the 1H NMR data and Table 3.3 contains the 13C data for 6 and 
7(a)-(d). Complex 6 shows shielded aromatic cymene carbons relative to 7(a), 7(b) and 7(d). 
Complex 7(a) showed a deshielded 13C signal due to the dppm methylene carbon relative to 
the free ligand (28.07 ppm). This is because of the two phosphorus atoms withdrawing 
electrons from the carbon atom during σ-bonding to the metal. The two complexes 7(b) and 
7(c) exhibit virtual triplets at 27.80 ppm with J = 24 Hz and  23.79 ppm with J = 20 Hz 
respectfully which are due to P−C coupling (see table 3.3).6 This was observed because the 
ortho carbons on the phenyl group coupled to the P atom appear as virtual triplet and the ipso 
carbons as a second order multiplet under the influence of strong coupling of the two 
phosphorus atoms.13  
8(a)
8(b)
8(c)
8(d)
58 
 
Complex 7(d) shows the cymene aromatic carbons downfield relative to 6 and 7(a)-(c). These 
observations indicate that the cymene ligand in 7(d) is a stronger σ-donor relative to 6 and 
7(a)-(c).  
 
Table 3.3: 13C NMR data of 6 and 7(a)-(d). 
Assignment 6 δ(ppm)  7(a) δ(ppm) 7(b) δ(ppm)  7(c) δ(ppm)  7(d) δ(ppm) 
CH3C6H4 15.30 16.37 15.52 15.60 14.99 
CH(CH3)2 21.79 21.64 21.44 21.12 21.57 
PCH2CH2 - - 29.72 21.47 22.66 
PCH2 - - 27.80  
(J(P-C) = 24Hz), 
23.79  
(J(P-C) = 20Hz) 
28.83 
CH(CH3)2 31.63 29.86 30.50 30.54 30.70 
PCH2 - 43.69 - - - 
η6-C6H4 96.42, 89.37, 
81.30, 73.13 
112.98, 95.79, 
84.37, 81.07 
117.56, 95.40, 
85.96 (J = 3Hz), 
83.41(J = 8 Hz) 
94.00, 86.32, 
85.15, 70.60 
126.25, 92.45, 
87.53, 83.32 
CAromatic 128.31-134.71 128.44-131.70 128.49-135.03 128.73-136.02 128.88-133.35 
 
The 13C NMR data of complexes 8(a)-(d) are reported in Table 3.4. The 13C data also 
supported the 1H NMR data. The 13C signal due to PCH2P for 8(a) appeared at δ = 53.65 
ppm. This was attributed to the withdrawing of electron density by the two electronegative P 
atoms from CH2− resulting in the carbon becoming electron deficient, thus exposing the 
nucleus of that carbon. Complex 8(b) showed a virtual triplet for the PCH2 at δ = 26.72 ppm 
with J(31P−13C) = 23 Hz. This was observed because of the strong phosphorus–phosphorus 
coupling which result in each phosphorus atom coupling both two carbons on the dppe chain 
length. The triplet arises when both doublets are very close to one another because of the 
phosphorus-phosphorus coupling, which result in combination of the similar inner signals. 
Hence, a triplet was observed which is caused by a second order effects.  
Complex 8(c) showed a doublet of doublets at δ = 26.52 ppm with J(31P−13C) = 15 Hz. This 
observation was attributed to the strong phosphorus-phosphorus coupling which results in 
each phosphorus atom coupling with both the two carbon atoms in an alkyl chain length 
PCH2CH2CH2P. Complex 8(d) showed only two signals due to the bridged-dppb at δ = 22.65 
and 29.69 ppm because of the symmetry of the binuclear complex.   
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The signals due to aromatic cymene carbons appear similar for the four diphosphine-bridged 
complexes (see table 3.4). This observation may be due to similar interactions of the 
diphosphine ligands to the osmium centre.  
Table 3.4: 13C NMR data of 8(a)-(d). 
Assignment 8(a) δ (ppm) 8(b) δ (ppm) 8(c) δ (ppm) 8(d) δ (ppm) 
CH3C6H4 18.71 17.80 17.61 17.49 
PCH2CH2 − 19.30 19.14 22.65 
CH(CH3)2 22.49 21.87 21.69 21.48 
PCH2 − 26.72(J=23Hz) 26.52(J=15Hz) 29.69 
CH(CH3)2 30.45 30.22 30.04 30.03 
PCH2P 53.65 − − − 
η6-C6H4 101.66, 87.52, 
82.95, 78.28 
100.59, 86.19, 
82.72(J=3Hz), 
78.09(J=6Hz) 
100.43, 85.98, 
82.50, 
77.90(J=6Hz) 
99.86, 85.45, 
82.81, 77.92 
CAromatic 127.04-134.54 128.05-133.48 127.85-133.33 128.11-133.39 
   
 
3.3.1.3 19F NMR data of 6 and 7(a)-(d) 
 
The 19F NMR confirmed the presence of the BF4 counter ion in complexes 6 and 7(a)-(d). 
Two 19F signals were observed; the low intensity signal was attributed to 10B-F coupling 
because of 19.58% of 10BF4 (
10B, I = 3) (see figure 3.4). The high intensity signal was 
attributed to 11B-F coupling because of the 80.42% of 11BF4 (
11B, I = 3/2).14,15 The two 
signals appear separated due to the isotope shift since the two boron isotopes exhibit different 
electronic properties in bonding.  
The 19F NMR signals for [Os(η6-p-cymene)(NCCH3)2Br]BF4 was observed as two singlets at 
151.84 and 151.89 ppm. Complex 6 shows the fluorine chemical shifts at −157.67 and 
−157.72 ppm. Complex 7(a) shows two singlet fluorine peaks at −143.46 and −143.52 ppm, 
complex 7(b) at −152.86 and −152.92 ppm, complex 7(c) at −152.51 and −152.56 ppm, 
complex 7(d) at −152.85 and −152.91 ppm (see figure 3.4).  
Complex 6 displayed 19F signals upfield relative to the signals for [Os(η6-p-
cymene)(NCCH3)2Br]BF4. This observation may be attributed to weaker interaction between 
the complex ion and the BF4 ion caused by the bulkiness on the cation complex. Complex 
7(a) shows deshielded fluorine peaks due to the solvent effect. This observation may be due 
to interaction between the S atom of the DMSO solvent and the F atom of BF4 counter ion. 
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Hence, electron density on the fluorine atoms would be reduced consequently deshielding the 
fluorine nucleus. Complex 7(b) and 7(d) displayed similar 19F signals; this may be attributed 
to similar electrostatic interactions of the complex ions with the counter ion. Complex 7(c) 
showed 19F signals slightly downfield relative to 7(b) and 7(d) because of the difference in 
electrostatic interactions. 
 
 
 
 
Figure 3.4: 19F NMR spectra of 6 and 7(a)-(d) showing fluorine peaks. 
 
 
 
 
 
6
7(a)
7(b)
7(c)
7(d)
61 
 
3.3.1.4 31P NMR data 
 
The 31P NMR data for complexes 6 and 7(a)-(d) are discussed below. Complex 6 showed a 
single 31P peak at −28.94 ppm with two sets of satellite peaks. The first set of satellite peaks 
at −28.85 and −29.03 ppm with J(187Os−31P) = 271 Hz. The second set of satellite peaks was 
observed at −28.27 and −29.61 ppm attributed to the spinning side bands with 1J = 36 Hz (see 
figure 3.5). The presence of two sets of satellite peaks in complex 6 may be due to the NMR 
active isotope of osmium which is 187Os and the spinning side bands.16 In literature, 31P NMR 
studies in solution reported satellites peaks due to the less abundant 187Os isotope.17 The 
satellites peaks due to 189Os isotope are reported to be observed only in solid-state 31P NMR 
studies because of the extremely efficient quadrupolar relaxation in solution.18 As explained 
in Chapter 2, the two sets of satellite peaks were assigned to spinning side bands (high 
intensity peaks with J = 36 Hz) and 187Os (low intensity peaks with J = 271 Hz). 
 
 
Figure 3.5: 31P NMR spectrum of 6 with two sets of satellite peaks. 
J = 36 Hz
J = 271 Hz
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A single 31P peak for complex 7(a) appeared at −43.52 ppm, more shielded than the free 
dppm ligand (−22.51ppm). The satellite peaks appeared at −42.98 and −44.06 ppm with 
J(187Os−31P) = 218 Hz (see figure 3.6). Complex 7(b) showed a single phosphorus peak at 
30.33 ppm, more deshielded than the free dppe ligand (−12.64 ppm). The two satellite peaks 
appear at 29.88 and 32.01 ppm with J(187Os−31P) = 259 Hz. Complex 7(c) showed a 
phosphorus peak at −25.00 ppm, which is more deshielded than the free ligand (−17.52ppm). 
The satellite peaks appeared at −24.39 and −25.62 ppm with J(187Os−31P) = 249 Hz (see 
figure 3.6). Complex 7(d) showed the P peak at −17.10 ppm, which was slightly shielded 
than the free dppb ligand (−16.19 ppm). The two satellite peaks appeared with J = 260 Hz 
due to 187Os −31P coupling. The J(Os-P) values of the chelated diphosphine complexes were 
found to follow the decreasing trend: 7(d) ˃ 7(b) ˃ 7(c) ˃ 7(a). 
 
 
Figure 3.6: 31P NMR spectra of 7(a) and 7(c) showing satellite peaks. 
 
J = 249 Hz
J = 218 Hz
7(c)
7(a)
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The 31P NMR chemical shifts are dependent of the electronic environment on the phosphorus 
atom, the bond angle as well as the shielding cones of unsaturated systems.16 The alkyl 
groups bonded to phosphorus atoms are electron donating groups hence more electron density 
will be observed on the phosphorus atom as well as π-back bonding with the central metal. 
The P donor atoms in 7(a) were more shielded and that suggests that the dppm is a good π-
acceptor ligand and the C−P−C bond angles may have deviated towards tetrahedral geometry 
(109.5º). This would result in increased C−P−C bond angles consequently shifting the 31P 
chemical shift upfield relative to the free dppm ligand. Complex 7(b) showed a P signal, 
which was the most deshielded, compared to 7(a), 7(c) and 7(c). This may be attributed to the 
change in geometry of the dppe in the chelated metal complex. 
The P signal of 7(c) appeared upfield relative to the free ligand, which suggests a change in 
the dppp ligand geometry upon coordination and π-back bonding. Complex 7(d) appeared 
more deshielded compared to 7(a)-(c); which suggests that the dppb ligand is a less effective 
π-acceptor compared to the dppm, dppe and dppp ligands. Furthermore, the increased ring 
size is expected to have a negligible effect on the C−P−C bond angle upon coordination to 
osmium; hence, only a slight shift in signal was observed relative to the free dppb ligand. The 
above observations suggest that the ability of the diphosphine ligand to chelate decreases as 
the carbon chain length increases. 
The ring contribution (Δr) to 31P NMR for the chelating diphosphine osmium complexes was 
calculated with respect to the monodentate bis(phosphine) osmium complex 6. Table 3.5 
contains the ring contribution factors for complexes 7(a)-(d).  
The four membered ring complex 7(a) was found to be the most shielded with a ring 
contribution of 2.40 ppm while 7(b) showed the most downfield ring contribution (see table 
3.5).6,19 Complexes 7(c) and 7(d) also showed some downfield ring contribution compared to 
7(a). The ring contribution of the chelate moiety increases with an increase in ring size with 
respect to monodentate bis(PPh3) complex. The four membered chelate ring complex 7(a) 
and the six membered chelate ring complex 7(c) gave a ring contribution which appears 
upfield whereas the five membered chelate ring complex 7(b) and the seven membered 
chelate ring complex 7(d) gave a ring contribution which appeared downfield. The chelating 
osmium complexes showed similar pattern to that reported by Garrou19 for platinum 
complexes and also reported later by Jensen and co-workers6 with ruthenium complexes. The 
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observation may have an implication with respect to the OsP bond lengths and the OsP 
bond stability which will be discussed later in the thermal studies and crystallography.     
Table 3.5: Ring contribution to 31P NMR coordination shifts of [Os(η6-p-cymene)(L2)Br]+ 
complexes relative to the monodentate PPh3. 
L2 δ (31P) Complex δ (31P) Free 
ligand 
Coordination 
shift (Δ δ)* 
Ring contribution 
(Δr)# 
Ring size 
2PPh3 −28.94 −5.53 −23.41 − − 
dppm −43.52 −22.51 −21.01 2.40 4 
dppe 30.13 −12.64 42.77 66.18 5 
dppp −25.00 −17.52 −7.48 15.93 6 
dppb −17.10 −16.19 −0.91 22.50 7 
Δδ* = δ (31P) complex – δ (31P) free ligand 
Δr# = Δδ (chelate) – Δδ (monodentate) 
 
The 31P NMR data for the bridging-diphosphine osmium complexes 8(a)-(d) are discussed 
below. Complex 8(a) exhibited a single 31P peak at −28.73 ppm with two satellite peaks 
giving 1J(187Os−31P) = 274 Hz. Complex 8(b) showed a single 31P peak at −25.22 with two 
satellite peaks attributed to 187Os with coupling constant as 1J(187Os−31P) = 273 Hz. The 31P 
signal of 8(c) appeared as a single peak at −25.44 ppm with satellite peaks giving coupling 
constants 1J(187Os−31P) = 274 Hz. Complex 8(d) showed a single peak due to P at −23.77 
ppm. The non-chelate ring complexes also exhibited negative phosphorus chemical shifts. 
The environments of phosphorus atoms for the bridging compounds are expected to be less 
sterically crowded. The bond angles on the phosphorus atoms are expected to be less strained 
and consequently show downfield chemical shifts.  
 
3.3.2 Infra-Red (IR) Spectroscopy  
 
The stretching frequency of the B−F bonds was also observed in the infra-red spectra 
supporting the 19F NMR data for complexes 6 and 7(a)-(d). The stretching frequency due to 
ν(B-F) was observed as a single peak for complex 6 at 1052 cm-1 and 1046 cm-1 for 7(a). The 
three complexes 7(b), 7(c) and 7(d) show the presence of a B−F band at 1061 cm-1. The 
observed difference in the B−F stretching frequency may be attributed to the stronger 
electrostatic interaction between the BF4 and the complex cation of 7(a). The cation complex 
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comes closer to the counter ion resulting in possible hydrogen bonding between the fluorine 
atoms and the hydrogens on the arenes. 
 
3.3.3 Raman Spectroscopy 
 
The presence of the metal-halide bonds was confirmed by Raman spectroscopy for all nine 
complexes in this chapter. Complexes 6 and 7(a)-(d) showed a single medium intensity 
vibrational peak due to the presence of a single Os−Br bond.  Complex 6 displayed the 
Os−Br medium peak at 201 cm-1 and a weak peak at 1056 cm-1 attributed to ν(B-F). Complex 
7(a) displayed the Os−Br medium peak at 205 cm-1 and a weak peak due to at 1059 cm-1. 
Complex 7(b) displayed the Os−Br peak at 202 cm-1 and a weak peak at 1056 cm-1 due to ν(B-
F). Complex 7(c) displayed a medium peak due to ν(Os-Br) at 205 cm-1 and a weak peak due to 
ν(B-F) at 1060 cm-1. Complex 7(d) displayed a medium peak due to ν(Os-Br) at 199 cm-1 and a 
weak peak due to ν(B-F) at 1057 cm-1.  
The four-bridged complexes 8(a)-(d) displayed two peaks due to the two pairs of bromido 
ligands on each osmium centre. The two vibrational peaks were observed as an indication 
that the bromido ligands are bonded in a cis mode hence two bromide atoms exhibit 
symmetrical (intense peak) and anti-symmetrical (low intense peak) stretching vibrations. 
Complex 8(a) exhibits two vibrational medium peaks at 208 and 183 cm-1 (see figure 3.7), 
8(b) at 203 and 182 cm-1, 8(c) at 203 and 182 cm-1, 8(d) at 205 and 186 cm-1. The OsBr 
bands were assigned according to the literature data.20  
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Figure 3.7: Raman spectra of 8(a)-(d) showing two Os−Br signals. 
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3.3.4 Thermogravimetric analysis (TGA) 
 
The thermal stability of the complexes was studied and the results show some similarity in 
degradation for complexes 6 and 7(a)-(d). Complex 6 shows four separate degradation steps 
(see figure 3.8). The first step corresponds to the loss of cymene at 227.6 to 267.9 ºC 
accounting for 12.5% mass loss. The second degradation step of 17.5% at 267.9 to 333.3 ºC 
was attributed to BF4 counter ion and Ph fragment. The third degradation at 333.3 to 607.3 ºC 
accounting for 19.1% was attributed to the loss of PPh2 fragment. The fourth degradation step 
at 607.3 to 774.8 ºC accounting for 7.9% was attributed to the loss of the Br ligand. The 
remaining 43% was attributed to [Os(PPh3)] fragment.  
 
Figure 3.8: TGA thermogram of 6 with DTG curve. 
 
In contrast, the chelated complexes 7(a)-(d) degrade differently compared to the monodentate 
complex 6. Complex 7(a) shows 5.2% mass loss at 110.6 ºC attributed to the CH2Cl2 solvent. 
The onset decomposition of 7(a) was observed at 287.1 to 380.9 ºC accounting for 30.5% 
mass loss attributed to cymene, Br and BF4 counter ion. The second degradation was 
observed at 585.6 to 794.6 ºC accounting for 8.4% mass loss attributed to one phenyl group. 
The remaining 43% was attributed to the [Os{Ph2P(CH2)PPh}] fragment. Complex 7(b) 
shows the mass loss at 108.1 ºC attributed to the CH2Cl2 solvent as observed in 
1H NMR data 
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accounting for 1.3%. The onset decomposition of 7(b) was observed at 279.0 to 371.29 ºC 
accounting for 31.4% attributed to cymene, BF4 and Br (see figure 3.9). The second 
degradation step at 476.7 to 586.9 ºC accounting for 8.9% mass loss was attributed to the loss 
of one phenyl group. The third degradation step was observed at 631.0 to 798.9 ºC 
accounting for 8.9% mass loss attributed to the second phenyl group. The remaining 38% of 
the mass was attributed to the [Os{PhP(CH2)2PPh}] fragment.  
 
Figure 3.9: TGA thermogram of 7(b) with DTG curve. 
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Complex 7(c) shows the onset decomposition at 240.2 to 365.2 ºC accounting for 32.0% 
mass loss due to the cymene, BF4
 and Br. The second degradation was observed at 365.2 to 
466.1 ºC accounting for 9.6% mass loss attributed to one phenyl group. The third degradation 
was observed at 537.6 to 722.5 ºC accounting for 8.9% attributed to the loss of the second 
phenyl group. The remaining 44% was attributed to [Os{PhP(CH2)2PPh}] fragment. 
Complex 7(d) shows the onset decomposition at 217.99 to 353.6 ºC accounting for 32.1% 
mass loss attributed to cymene, BF4 and Br. The second degradation step was observed at 
355.0 to 516.0 ºC accounting for 14.4% mass loss attributed to the loss of one phenyl group 
and –CH2CH2CH2CH2– group. The remaining 53% fragment was attributed to 
[Os(PPh2)(PPh)] fragment (see figure 3.10). The chelated-diphosphine complexes shows a 
decrease in thermal stability as the alkyl chain length of the diphosphine ligand is increased 
to be: 7(a) ˃7(b) ˃ 7(c) ˃ 7(d).  
 
 
Figure 3.10: TGA thermogram of 7(d) with DTG curve. 
 
The bridging diphosphine osmium complexes 8(a)-(d) were also tested for thermal stability. 
A two-step decomposition process followed by continuous degradation was observed for all 
four complexes. Complex 8(a) degrades in several steps. The first step at 113.6 to 154.4 ºC 
was attributed to the loss of CH2Cl2 solvent. The onset decomposition was observed at 223.3 
to 253.4 ºC accounting for 8.7% mass loss attributed to one cymene group. At 253.4 to 265.8 
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ºC the mass loss attributed to CH3CHCH3 group accounting for 2.9%. The next degradation 
was observed at 265.8 to 328.2 ºC accounting for 12.6% mass loss which was attributed to 
toluene and a phenyl group. At 328.2 to 385.2 ºC a mass loss of 7.3% was attributed to the 
phenyl group and the CH2 fragments. At 385.2 to 554.1 ºC a mass loss of 28.4% was 
attributed to the loss of two bromide ligands and P2Ph2 fragment. At 662.8 to 799.9 ºC a mass 
loss of 19% was attributed to the loss of two bromide ligands and the reduction of the 
oxidised osmium compounds (OsO2/OsO4) to the Os metal which account for 12% residue.
21 
Complex 8(b) shows three degradation steps. The onset decomposition of 8(b) was observed 
at 240.2 to 340.9 ºC accounting for 31.4% mass loss attributed to two cymene ligands and 
two bromide ligands (see figure 3.11). The second degradation was observed at 340.9 to 
532.0 ºC accounting for 17.9% mass loss attributed to three phenyl groups. The third 
degradation was observed at 532.0 to 570.6 ºC accounting for 4.1% mass loss attributed to 
PCH2CH2 fragment. The remaining [BrOs−(PhP)OsBr] fragment account for 48% 
residue.  
 
 
Figure 3.11: TGA thermogram of 8(b) with DTG curve. 
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Complex 8(c) shows the first degradation step at 235.4 to 355.9 ºC accounting for 31.2% 
mass loss, which was attributed to two cymene ligands and two Br ligands. The second step 
of degradation was observed at 355.9 to 509.4 ºC accounting for 13.2% mass loss attributed 
to two phenyl groups and CH2CH2CH2 fragment. At 509.4 to 591.3 ºC, there was a mass 
loss of 6.1% attributed to one phenyl group. The last degradation step of 9.3% was observed 
at 591.3 to 770.1 ºC attributed to the loss of PPh fragment. The remaining 38.4% was 
attributed to [BrOs(P)OsBr] fragment. Surprisingly, complex 8(d) degrade in a similar 
manner as 8(c). The onset decomposition of 8(d) was observed at 270.4 to 347.1 ºC 
accounting for 31.9% mass loss attributed to two cymene ligands and two Br ligands. The 
second degradation step was observed at 353.1 to 520.7 ºC accounting for 14.5% mass loss 
attributed to two phenyl groups and CH2CH2CH2CH2 fragment. The third degradation step 
was observed at 534.8 to 783.3 ºC accounting for 13.4% mass loss attributed to PPh2 
fragment. The remaining 38.4% residue was attributed to [BrOs(P)OsBr] fragment. The 
three complexes 8(b)-(d) shows similar pattern of fragment loss with 8(d) being the most 
thermally stable followed by 8(b) whereas 8(c) was the least thermally stable complex. In 
general, the thermal stability trend of the bridged-diphosphine complexes was found to be: 
8(d) ˃ 8(b) ˃ 8(c) ˃ 8(a). 
 
 
72 
 
 
Figure 3.12: TGA thermogram of 8(d) with DTG curve. 
 
 
3.3.5 Conductivity studies 
 
The five complexes 6 and 7(a)-(d) were tested for conductivity because of their salt-like 
structures. Table 3.6 contains the molar conductivity data of complexes 6 and 7(a)-(d). The 
literature values for molar conductivities of 1:1 electrolytes in nitrobenzene at 10-3 M are 
found within the given range 20 − 30 S cm2/mol.22 Complex 6 recorded a value within the 
expected range (see table 3.6). These results may be attributed to the high mobility of the 
involved ions. Complexes 7(b) and 7(d) gave the molar conductivity values, which are within 
the expected range for complexes in nitrobenzene (see table 3.6). However, complexes 7(a) 
and 7(c) gave values that are lower than the expected range. The reason for these lower molar 
conductivities for complexes 7(a) and 7(c) may be attributed to their chemical structures, 
which contribute to their poor mobility in nitrobenzene. 
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Table 3.6: The molar conductivity values of 6 and 7(a)-(d) in nitrobenzene solvent. 
Complex  c × 10-3M Conductance (c × μS)* ɅM (S cm2/mol) 
6 1.4 41.55 22.56 
7(a) 1.1 27.45 18.97 
7(b) 1.0 30.25 22.99 
7(c) 1.2 25.45 16.12 
7(d) 1.1 31.55 21.80 
* The conductance of the samples were obtained after subtracting the value of the blank; Nitrobenzene = 
3.45 μS from the measured values. 
 
The molar conductivities of the complexes were obtained by the following calculations. 
For complex 6 
 = G × K   . . . . . . [1]   
Where  = conductivity (S/cm), G = conductance (S), K = cell constant (cm-1)  
Converting the conductivity to the molar conductivity the following equation was used: 
ɅM =  / CM  . . . . . . [2] 
Where ɅM is the molar conductivity and CM is the molar concentration of 6 = 1.4 × 10-3 M 
Then substituting the values into equation [2] we obtain 
           ɅM = 22.56 S cm2/mol 
 
 
3.3.6 Crystallography 
 
The molecular structures of complexes 6 and 7(a)-(d) were confirmed by the single crystal X-
ray diffraction. Table 3.7 contains the crystal data and structure refinements of complexes 6 
and 7(a)-(d). Table 3.8 contains selected bond, interatomic and Oscentroid distances while 
Table 3.9 contains bond and torsion angles of complexes 6 and 7(a)-(d). 
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Figure 3.13: The assignment pattern of molecular structures of complexes 6 and 7(a)-(d) in 
this chapter. 
                                   
3.3.6.1 Molecular structure of 6.      
Crystals of 6 suitable for X-ray diffraction were obtained by slow diffusion of diethyl ether 
into dichloromethane solution at room temperature. Complex 6 was found to crystallise in a 
monoclinic crystal system with space group P21/n. Figure 3.11 shows the molecular structure 
of 6 with the fluorine atoms ellipsoids bigger than expected. Vibrations of the fluorine atoms 
within the crystal pockets may cause this ellipsoids to be bigger. The results of 6 showed 
alternating short and long C−C bonds around the cymene ligand which indicated loss of 
aromaticity. The sets of carbons, C(1)−C(2), C(3)−C(4) and C(5)−C(6) were observed to be 
longer than C(2)−C(3), C(4)−C(5) and C(6)−C(1). The torsion angle C(3)−C(2)−C(1)−C(6) 
supports the loss of aromaticity of the cymene ligand.   
The cymene aromatic carbons bonded directly to the osmium centre display different bond 
distances. Carbon atoms C(2), C(3), C(4) and C(6) have longer bond distances to the osmium 
centre than C(1) and C(5). This was an indication of the trans influence of the strong π-
acceptor phosphorus atoms. The distance from the osmium centre to the centroid of the 
cymene was found to be 1.784 Å. In contrast, the ruthenium analogue (ESOLUT†7) measured 
1.793 Å which was slightly longer than the osmium analogue.3 The observation was 
attributed to stronger interaction of the osmium and the cymene ligand. The loss of planarity 
was measured along the mean plane of C(1), C(2) and C(4), C(5). The C(3) showed some 
deviation by 0.067 Å above the mean plane and C(6) was 0.037 Å below the mean plane, 
                                                          
†7 The CIF file used for comparison was obtained from the CCDC database.  
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which result in the cymene ligand adopting a chair conformation. The deviation from the 
mean plane was attributed to the presence of strong π-acceptor ability of the PPh3 group. 
The bond distances of the two phosphorus atoms bonded to the osmium centre were slightly 
different to each other. The Os(1)−P(1) bond distance was found to be longer relative to 
Os(1)−P(2) which indicated less interaction. In contrast, the Os(1)−P(2) bond distance was 
found to be shorter with the difference of 0.0339 Å compared to Os(1)−P(1). The interatomic 
distance of the two phosphorus atoms was measured as 3.600 Å at 98.00º influenced by steric 
crowding at the metal centre due to the bulky phenyl groups. This was supported by the 
chelate bite angle P(1)−Os(1)−P(2) which was above 90º an indication of distortion from the 
known octahedral geometry. The difference in M−P bond lengths, P(1)…P(2) interatomic 
distance and the P(1)−M−P(2) bite angles between the osmium and ruthenium analogues is 
negligible. In complex 6, the longest bond was found to be the Os(1)−Br(1) which indicated 
weak interaction between the Os−Br bond.  
Complex 6 shows four intramolecular and two intermolecular hydrogen bonding. The four 
intramolecular hydrogen bonding were all due to C−H…Br interaction. The intramolecular 
hydrogen bond C−H…Br due to hydrogen on C(10) measured 3.051 Å at 128.04º which 
indicated a weaker interaction. The other two intramolecular hydrogen bonds C−H…Br due to 
hydrogens on two phenyl groups on the same PPh3 measures 3.017 Å at 146.91º and 2.782 Å 
at 128.43º (see figure 3.14). The last intramolecular hydrogen bond CH…Br due to the 
hydrogen on the phenyl of the other PPh3 measures 2.937 at 125.13º. The two intermolecular 
hydrogen bonds were on one fluorine atom bonding to two hydrogens of neighbouring 
carbons on the phenyl ring of one PPh3 ligand (see figure 3.14). The two C−H…F hydrogen 
bonds measures 2.899 Å at 127.63º and 2.937 Å at 126.24º which was a weak interaction.23  
The effect of coordination of two PPh3 ligands at one metal centre is discussed here relative 
to the free PPh3 ligand. The molecular structure of the free PPh3 ligand (PTRPHE03
†8) 
reported the C−P−C bond angles at 103.08º, 103.44º and 101.66º.24 The coordinated PPh3 in 
this study has C−P(1)−C bond angles measured at 97.12º, 100.23º and 106.88º. The second 
PPh3 shows C−P(2)−C bond angles that were at 97.02º, 102.58º and 105.51º. The reduced 
C−P−C bond angle of the coordinated ligand indicates steric effects on the coordinated PPh3 
whereas the increased C−P−C bond angles may result from π-π repulsion between the phenyl 
groups. Therefore, the deviation of the C−P−C bond angles from the free ligand geometry 
                                                          
†8 The CIF file used for comparison was obtained from the CCDC database. 
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towards the tetrahedral geometry (109.5º) may also have an impact on the upfield shift of 31P 
NMR in solution. In addition, the free PPh3 ligand has C−P bond lengths of 1.827 Å, 1.831 Å 
and 1.832 Å. However, in this study the C−P bond lengths were measured as 1.829 Å, 1.842 
Å and 1.845 Å on P(1) atom while 1.836 Å, 1.837 Å and 1.842 Å were measured on P(2) 
atom. 
       
Figure 3.14: Molecular structure of 6 at 50% probability thermal ellipsoids. 
 
3.3.6.2 The molecular structure of 7(a). 
Crystals of 7(a) suitable for single crystal X-ray diffraction were obtained by slow diffusion 
of diethyl ether into a dichloromethane solution. Complex 7(a) was found to crystallise an 
orthorhombic system with space group P212121. Figure 3.12 shows complex 7(a) as a four 
membered chelate ring with one phenyl ring disordered at the P(2) atom. The carbon atoms 
on the phenyl groups show some disorientation resulting in larger ellipsoids than observed for 
aromatic carbons around the cymene. Loss of aromaticity was observed on the cymene ligand 
because of alternating long and short C−C bonds. C(2)−C(3), C(4)−C(5) and C(5)−C(6) were 
longer than C(1)−C(2), C(3)−C(4) and C(6)−C(1). In addition, the different Os−C bonds 
lengths were observed because of the trans influence of the P-donor ligands. In this case the 
both C atoms of the cymene and P atoms trans to each other share the s and d-orbitals, hence, 
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additional participation of s and d orbitals in the Os−P bond because of π-bonding capacity of 
P-donor ligands will result in a weaker Os−C bond. The ligands or C atoms cis to the P-donor 
ligand uses an independent s and d orbitals, therefore, would be less affected. The three 
carbon atoms on the cymene; C(3), C(4) and C(6) bonded to Os(1) atom exhibited longer 
bond lengths because of the phosphorus atoms trans to this three carbons. The distance from 
the osmium centre to the cymene centroid was observed to be 1.756 Å. In comparison, the 
ruthenium analogue (RAZLES†9) measured the Rucentroid distance as 1.760 Å which is 
slightly longer than the Oscentroid distance in this study.25 
Complex 7(a) displayed steric strain with one phenyl group on P(2) showing some disorder. 
The disorder may be due to the steric effect caused by shorter chain length on the 
diphosphine. In addition, the steric effect hypothesis was also supported by the shortness of 
the Os−P bonds. The shorter carbon chain length of the diphosphine ligand also affects the 
bond angle which was observed to be smaller than in the free dppm ligand (73º).26 
Consequently, these factors bring more steric influence on the central metal and change the 
geometry at the metal centre. The two P-donor atoms exhibited a difference in MP bond 
lengths of 0.0137 Å. Taking into account the two phenyl groups on each P atoms, limited 
space is available to accommodate the four phenyl groups on the four-membered chelate ring. 
This resulted in one phenyl group being forced to deviate from the natural dppm structure. 
The π-π stacking caused by the attractions or repulsions of π-systems may also be the reason 
one phenyl group on P(2) was disordered. The Os(1)−Br(1) bond was the longest bond which 
indicated weaker interaction of bromide ligand and the osmium centre.  
Intermolecular hydrogen bonding between one fluorine atom and the H atoms on C(1), C(2) 
and one phenyl group were observed. The C−H…F hydrogen bond with the shortest distance 
was found on C(1) measuring 2.263 Å at 141.31º which indicated strong hydrogen bonding.23 
The fluorine involved in hydrogen bonding was found to have a shorter B−F bond (1.317 Å) 
than the other three B−F bonds.  The hydrogen on C(2) showed two possible C−H…F 
hydrogen bonds with different fluorine atoms. The C−H…F hydrogen bonds on C(2) 
measures 2.782 Å at 144.05º and 2.660 Å at 130.01º (see figure 3.15).  A further C−H…F 
hydrogen bond with an H atom on the phenyl group measures 2.666 Å at 128.02º. The loss of 
planarity on the cymene ligand was measured along the mean plane defined by C(1), C(2), 
C(4) and C(5). The deviation from planarity of C(3) was measured as 0.038 Å above the 
                                                          
†9 The CIF file used for comparison was obtained from the CCDC database. 
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mean plane and for C(6) was measured as 0.071 Å above the mean plane. In this case, the 
cymene ligand adopts the boat conformation.  
Coordination of the dppm ligand results in significant changes in bond lengths and angles, 
which are discussed below. The molecular structure of the free dppm ligand (GEHGAB02†10) 
measured the bond angle due to P−C−P at 107.63º and the coordinated dppm in this study 
measured at 93.50º.27 This was attributed to the steric effects of the phenyl rings and the 
cymene ligand. The bond angles for the free dppm ligand due to C−P−C are reported at 
103.12º and 101.53º for C(sp3)−P−(sp2) as well as 101.98º for C(sp2)−P−C(sp2). The second 
P atom of the free dppm ligand measured C(sp3)PC(sp2) at 99.94º and 103.17º while the 
C(sp2)−P−C(sp2) was measured at 101.22º.27  In this study the C−P−C bond angles were 
measured at 106.58º for C(sp3)−P(1)−C(sp2), 110.20º for C(sp3)−P(1)−C(sp2) and 100.00º for 
C(sp2)P(1)C(sp2). The two C(sp3)P(1)C(sp2) bond angles at P(1) approach the 
tetrahedral value (109.5º) while the C(sp2)P(1)C(sp2) value remains similar to the values of 
the free dppm ligand.  
On the P(2) atom with disorder the CPC bond angles were measured at 107.00º for 
C(sp3)P(2)C(sp2), 108.60º for C(sp2)P(2)C(sp2) and 102.50º for another 
C(sp3)P(2)C(sp2). The other set of bond angles are 92.50º for C(sp2)P(2)C(sp2), 114.60º 
for C(sp3)P(2)C(sp2) and 17.40º for another C(sp2)P(2)C(sp2). The C(sp3)P(2)C(sp2) 
and the C(sp2)P(2)C(sp2) values approaches that of the tetrahedral value while the other 
C(sp3)P(2)C(sp2) value remains within the values of the free dppm ligand. The dppm 
ligand has been strongly affected by electronic and steric effects upon coordination to the 
metal centre. The significant changes of the CPC bond angles towards tetrahedral 
geometry (109.5º) may also be an additional reason 7(a) gave the most upfield shift in 31P 
NMR solution.  
The C(sp3)−P bond lengths of the coordinated dppm ligand measured  1.846 Å for P(1) and 
1.841 Å for P(2) while the free dppm measured C(sp3)−P as 1.847 Å and 1.855 Å. However, 
C(sp2)−P bond lengths of the free dppm ligands were measured as 1.827 Å and 1.837 Å on 
one P atom and the second P atom measured 1.830 Å and 1.841 Å. The coordinated dppm 
measured 1.803 Å and 1.821 Å on P(1) and 1.801 Å and 1.895 Å (disordered) on P(2) atom. 
 
                                                          
†10 The CIF file used for comparison was obtained from the CCDC database.  
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Figure 3.15: Molecular structure of 7(a) at 50% probability thermal ellipsoids.  
 
3.3.6.3 Molecular structure of 7(b). 
Crystals of 7(b) suitable for X-ray diffraction were obtained by slow diffusion of diethyl 
ether into a dichloromethane solution at room temperature. Complex 7(b) crystallises in the 
orthorhombic system with a space group P212121. Figure 3.16 shows the molecular structure 
of 7(b) with short contacts due to hydrogen bonding. Loss of aromaticity in the cymene 
ligand was observed with alternating short and long CC bonds. The sets of carbons with 
longer CC bonds were C(2)C(3) and C(4)C(5), the shorter sets of carbons were 
C(1)C(2) and C(3)C(4) whereas C(5)C(6) and C(6)C(1) measured bond lengths which 
are intermediate. Complex 7(b) measured different bond lengths from the Os centre to the 
carbons of the cymene. The Os(1)C(3) and Os(1)C(4) were found to measure longer bond 
lengths, whereas Os(1)C(1), Os(1)C(2) and Os(1)C(5) were found to measure shorter 
bond lengths. The longer OsC bonds indicated the effect of back bonding by the π-acceptor 
P atoms. The distance from the centroid to the metal centre was measured as 1.771 Å. In 
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contrast, the ruthenium analogue (RAHLIW†11) measured 1.786 Å for Rucentroidcymene 
which is slightly longer than that of Oscentroidcymene distance.25 This is an indication of 
stronger Oscymene interaction compared to the Rucymene interaction.  
 The loss of planarity of the cymene ligand also supported the differences in Os−C bond 
lengths. The mean plane was defined by C(1), C(2), C(4) and C(5). C(3) measured 0.043 Å 
above the mean plane  and C(6) measured 0.078 Å also above the mean plane. The steric 
effect and π-back bonding may be responsible for the deviation of C(3) and C(4) from the 
mean plane. The two carbon atoms, C(1) and C(4) measures 0.032 Å above the mean plane 
whereas C(2) and C(5) measures 0.033 Å and 0.032 Å below the mean plane respectively.  
The bite angle P(1)Os(1)P(2) of 7(b) measures 82.85º which is more acute than the ideal 
90º expected in an octahedral arrangement. This observation may be attributed to the shorter 
carbon chain length of the dppe ligand. The interatomic distance of the two P atoms measured 
3.087 Å at 180º. Two intermolecular hydrogen bonding were observed in the molecular 
structure of 7(b). The first CH…F intermolecular hydrogen bond due to an H atom on one of 
the phenyl groups of P(2) measures 2.503 Å at 145.35º. The second CH…F intermolecular 
hydrogen bond due to an H of the carbon on the alkyl backbone of the dppe measured 2.657 
Å at 125.62º.  
Similarly, the bond lengths and angles of the coordinated dppe and the free ddpe ligands were 
compared. The molecular structure of the free dppe ligand (DPPETH02†12) reported the 
following CPC bond angles. The bond angles were measured at 101.05º for 
C(sp2)PC(sp2), 100.22º and 102.37º for C(sp2)PC(sp3).28 The CPC bond angles of 
7(b) were measured at 104.53º for C(sp2)P(1)C(sp2) and 98.66º for C(sp2)P(2)C(sp2). 
The other bond angles were measured at 103.58º and 104.34º for C(sp2)P(1)C(sp3) while 
bond angles on P(2) atom were measured at 104.52º and 105.33º. The small 
C(sp2)P(2)C(sp2)  bond angle was caused by steric hindrance. The coordinated dppe 
measured the C(sp3)−P bond lengths as 1.831 Å in both P(1) and P(2) atoms but the 
uncoordinated dppe ligand measured C(sp3)−P bond length as 1.844 Å. The short C(sp3)−P 
bonds were caused by Os−P−C back-bonding. 
 
 
                                                          
†11 The CIF file used for comparison was obtained from the CCDC database. 
†12 The CIF file used for comparison was obtained from the CCDC database. 
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Figure 3.16: Molecular structure of 7(b) at 50% probability thermal ellipsoid. 
 
3.3.6.4 Molecular structure of 7(c). 
Crystals of 7(c) suitable for single crystal X-ray diffraction were obtained by slow diffusion 
of diethyl ether into dichloromethane solution at room temperature. The complex crystallises 
in a monoclinic crystal system with a space group P21/n. Figure 3.14 shows the molecular 
structure of 7(c) as a six-membered chelate ring with short hydrogen contacts. The observed 
alternating short and long CC bonds indicated loss of aromaticity of the cymene ligand. The 
three sets of carbons, C(2)C(3), C(4)C(5) and C(6)C(1) measured longer bonds than 
C(1)C(2), C(3)C(4) and C(5)C(6). The distance from the osmium to the centroid of the 
cymene was found to be 1.762 Å.  The three carbon atoms C(3), C(4) and C(6) are observed 
to have longer bond distances to the osmium centre than three carbon atoms C(1), C(2) and 
C(5) on the cymene. An indication of how the π-back bonding affect the carbons on the 
cymene trans to the phosphorus atoms. The OsP bond distances showed to be similar 
indicating a slight difference of 0.0025 Å.  
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The P(1)Os(1)P(2) bite angle measured greater than 90° to accommodate the long carbon 
chain length and four phenyl groups. The Os(1)Br(1) bond was found to be longer than all 
bonds in the complex with 2.5545 Å because of weaker interaction due to the poor π-acceptor 
ability of the bromido ligand. One intramolecular and three intermolecular hydrogen bonds 
were observed. The weaker intramolecular hydrogen bond was due to CH…Br, which 
measured 3.233 Å at 121.27º (see figure 3.17). The three intermolecular hydrogen bonds due 
to CH…F measured 2.694 Å at 160.79º and 2.596 Å at 140.26º with the same F atom while 
the weak CH…F hydrogen bond measured 2.993 Å at 128.56º with the second F atom (see 
figure 3.17).  Loss of planarity of the cymene ligand as measured along the C(1), C(2), C(4) 
and C(5) mean plane was observed. The deviation of C(3) was measured as 0.006 Å above 
the mean plane and for C(6) was 0.035 Å above the mean plane. The cymene ligand adopted 
a boat conformation. The molecular structure of the free dppp ligand was reported with 
disorder; hence, the chelated-dppp in this study was not compared to the free dppp ligand. 
 
           
Figure 3.17: Molecular structure of 7(c) at 50% probability thermal ellipsoids. 
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3.3.6.5 Molecular structure of 7(d). 
Crystals of 7(d) suitable for X-ray diffraction were obtained by slow diffusion of diethyl 
ether into a dichloromethane solution at room temperature. Complex 7(d) crystallises in a 
monoclinic crystal system with P21/n space group.  Figure 3.15 shows the molecular structure 
of 7(d), which has a seven-membered chelate ring. The fluorine atoms of the BF4 counter ion 
show disorder with large ellipsoids. This may result from vibrations or electronic effects 
during interactions with the complex ion.  The loss of aromaticity was observed in the 
cymene ligand with alternating short and long CC bond lengths. The three sets of carbons 
which measured shorter bond lengths were C(1)C(2), C(3)C(4) and C(5)C(6) compared 
to C(2)C(3), C(4)C5) and C(6)C(1) which measured longer CC distances. The Os−C 
bond lengths showed evidence of the trans influence of the P atoms because of different 
Os−C bond lengths. The four carbons C(1), C(2), C(5) and C(6) have shorter distances  to the 
Os centre compared to C(3) and C(4).  
The distance from the Os centre to the centroid of the cymene was measured at 1.770 Å. The 
bite angle P(1)Os(1)P(2) was measured at 94.45º. The POsP bite angle increases with an 
increase in carbon chain length. Hence, the coordinated dppb exhibits slight differences in 31P 
NMR data compared to the free ligand. The Os(1)Br(1) bond distance was observed to be 
the longest bond length compared to all bonds in the complex because electronegative atoms 
keeps their electrons towards themselves  resulting in weaker interactions.  
There were two intramolecular and two intermolecular hydrogen bonding interactions 
observed. The weak intramolecular interaction of CH…Br measured 2.899 Å at 123.81º due 
to an H atom of the alkyl carbon on the dppb (see figure 3.18). A weak intramolecular bond 
CH…Br measured 3.107 Å at 126.45º due to interaction of an H atom on C(10) (see figure 
3.18). The two intermolecular hydrogen bonds were due to two hydrogens of neighbouring 
carbon atoms on the phenyl ring and the two fluorine atoms of BF4 anion (see figure 3.18). 
The intermolecular CH…F hydrogen bond measured 2.676 Å at 145.69º. The second 
intermolecular CH…F hydrogen bond measured 2.649 Å  at 129.95º (see figure 3.18).The 
loss of planarity was measured along the mean plane defined by C(1), C(2), C(4) and C(5). 
The deviation of C(3) from the mean plane was found to be 0.025 Å above the mean plane 
and C(6) deviated by 0.037 Å above the mean plane, which suggest that the cymene ligand 
adopted a boat conformation. The torsion angle of C(3) to C(6) along C(1) and C(2) was 
measured at 3.90º also supports the claim of loss of planarity. This may be attributed to the 
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steric crowding around the osmium centre by the phenyl rings resulting in the bending of the 
methyl and propyl substituents of the cymene above the mean plane. The trans influence of 
the P-donor atoms also contributed to the loss of planarity of the cymene ligand.  
The effects of coordination of the dppb ligand relative to the free dppb ligand were compared. 
The molecular structure of the free dppb ligand (GASVUR01†13) measured the bond angles 
due to C(sp2)PC(sp2) at 100.63º, C(sp2)PC(sp3) at 100.83º and 102.24º.29 In this study, 
the CPC angles were measured at 101.52º for C(sp2)P(1)C(sp2), 99.82º and 103.52º for 
C(sp2)P(1)C(sp3). On the second P atom, the bond angles were measured at 103.78º for 
C(sp2)P(2)C(sp2), 101.85º for C(sp2)P(2)C(sp3) and another C(sp2)P(1)C(sp3) at 
98.96º. There was a slight difference between the C(sp3)−P(1) (1.828 Å) and C(sp3)−P(2) 
(1.838 Å) bond lengths of the coordinated dppb, which are slightly shorter than the C(sp3)−P 
(1.847 Å) of the free dppb ligand. The differences were attributed to the Os−P−C back 
bonding. There was a negligible effect on the bond angles of the coordinated dppb relative to 
the free dppb ligand. 
 
       
Figure 3.18: Molecular structure of 7(d) at 50% probability thermal ellipsoids.  
                                                          
†13 The CIF file used for comparison was obtained from the CCDC database. 
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Table 3.7: Crystal data and structure refinement of 6 and 7(a)-(d). 
 6 7(a) 7(b) 7(c) 7(d) 
Chemical formula C46H44BBrF4OsP2  C35H36BBrF4OsP2  C36H38BBrF4OsP2 C37H40BBrF4OsP2  C38H42BBrF4OsP2 
Chemical formula weighed 1015.67 874.99 889.52 903.55 917.58 
Crystal system Monoclinic Orthorhombic Orthorhombic Monoclinic Monoclinic 
Space group P21/n P212121 P212121 P21/n P21/n 
Crystal colour and shape Reddish cubes Yellow cubes Yellow cubes Yellow cubes Yellow rectangles 
a(Å) 11.0792(7) 11.7760(5)  12.4702(13) 11.1986(5) 11.2054(9) 
b(Å) 30.180(2) 15.3492(6)   15.2982(15) 24.2160(12) 24.899(2) 
c(Å) 12.4379(9) 18.4176(6) 17.2694(17) 12.7674(6) 12.6930(9) 
α(º) 90.00 90.00 90.00 90.00 90.00 
β(º) 103.606(3) 90.00 90.00 98.859(2) 97.223(2) 
γ(º) 90.00 90.00 90.00 90.00 90.00 
V(Å3) 4042.2(5) 3329.0(2) 3294.5(6) 3421.0(3) 3513.3(5) 
Z 4 4 4 4 4 
T(K) 243(2) 173(2) 173(2) 173(2) 173(2) 
Dcalc (mg/m3) 1.669 1.746 1.793 1.754 1.735 
Reflections collected 49781 124299 71858 105074 100808 
Independent reflections 9770 [R(int) = 0.0667] 8049 [R(int) = 0.0583]  7950 [R(int) = 0.0815] 8249 [R(int) = 0.0594] 8458 [R(int) = 0.1271] 
F(000) 2008 1710 1744 1776 1808 
Final R indices [I>2σ(I)] R1 = 0.0241,  
wR2 = 0.0484 
R1 = 0.0249,  
wR2 = 0.0527 
R1 = 0.0238 
wR2 = 0.0530 
R1 = 0.0258,  
wR2 = 0.0536 
R1 = 0.0323,  
wR2 = 0.0756 
R indices (all data) R1 = 0.0351,  
wR2 = 0.0503 
R1 = 0.0256, 
wR2 = 0.0531 
R1 = 0.0258 
wR2 = 0.0544 
R1 = 0.0326, 
wR2 = 0.0566 
R1 = 0.0403, 
wR2 = 0.0802 
Goodness-of-fit on F2 0.965 1.114 1.077 0.884 1.111 
Largest diff. peak and hole 0.814 and −1.144 e.Å-3 0.709 and −0.760 e.Å-3 0.625 and −1.107 e.Å-3 1.341 and −0.938 e.Å-3 1.423 and −1.501 e.Å-3 
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Table 3.8: Selected bond lengths (Å), Oscentroidcymene distance (Å) and interatomic 
distances (Å) of 6 and 7(a)-(d).  
Atom type label 6 7(a) 7(b) 7(c) 7(d) 
Os(1)C(1) 2.217(2) 2.220(4) 2.243(4) 2.242(3) 2.249(3) 
Os(1)C(2) 2.286(2) 2.243(4) 2.243(4) 2.244(3) 2.252(3) 
Os(1)C(3) 2.346(2) 2.323(4) 2.347(4) 2.307(3) 2.327(3) 
Os(1)C(4) 2.260(2) 2.283(4) 2.288(4) 2.283(3) 2.291(4) 
Os(1)C(5) 2.233(3) 2.192(4) 2.189(3) 2.211(3) 2.201(4) 
Os(1)C(6) 2.291(2) 2.269(4) 2.278(4) 2.266(3) 2.258(4) 
C(1)C(2) 1.416(3) 1.402(7) 1.397(6) 1.404(5) 1.396(5) 
C(2)C(3) 1.402(3) 1.427(7) 1.436(6) 1.426(5) 1.427(5) 
C(3)C(4) 1.411(3) 1.104(6) 1.388(6) 1.400(5) 1.402(6) 
C(4)C(5) 1.402(3) 1.432(6) 1.427(6) 1.428(5) 1.418(6) 
C(5)C(6) 1.418(3) 1.420(6) 1.415(6) 1.403(5) 1.409(6) 
C(6)C(1) 1.404(4) 1.411(7) 1.417(6) 1.420(5) 1.411(6) 
Os(1)P(1) 2.4019(6) 2.3138(11) 2.3386(10) 2.3379(8) 2.3507(9) 
Os(1)P(2) 2.3680(7) 2.3275(11) 2.3265(10) 2.3354(8) 2.3605(9) 
P(1)…P(2) 3.600 2.6862(18) 3.087 3.368 3.458 
Os(1)Br(1) 2.5345(3) 2.5302(4) 2.5401(4) 2.5545(3) 2.5483(4) 
Os(1)centroidcymene 1.784 1.756 1.771 1.762 1.770 
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Table 3.9: Selected bond and torsion angles (º) of 6 and 7(a)-(d). 
Bond angles 6 7(a) 7(b) 7(c) 7(d) 
P(1)Os(1)P(2) 98.00(2) 70.73(5) 82.85(3) 92.23(3) 94.45(3) 
P(1)Os(1)Br(1) 90.200(17) 85.28(3) 81.41(3) 81.99(2) 87.96(2) 
P(2)Os(1)Br(1) 88.266(17) 84.04(3) 89.71(3) 84.84(2) 84.75(2) 
Torsion angles  
C(3)C(2)C(1)C(6) 3.0(4) 1.2(7) 4.6(6) 1.9(5) 3.9(5) 
C(3)C(4)C(5)C(6) 0.2(4) 4.2(6) 7.7(5) 4.7(5) 5.0(5) 
 
 
3.4 Conclusions 
 
In this chapter, nine novel osmium cymene complexes with phosphine ligands are reported. 
The spectroscopic techniques (NMR, IR and Raman) played an important role in 
characterisation of the nine osmium cymene complexes in this chapter. The cationic 
complexes have shown interesting electrostatic interaction with BF4 anion in 
19F NMR 
studies. The 31P NMR studies revealed additional osmium satellite peaks with small coupling 
constant, which were postulated to be caused by the most abundant 189Os isotope. 
Single crystal X-ray diffraction confirmed the molecular structures of 6 and 7(a)-(d). The 
ability of the diphosphine ligands to form strong chelates increase with a decrease in carbon 
chain length on the diphosphine backbone, observed from their MP bond lengths. The bite 
angles of the complexes 7(a)-(d) increases with an increase in carbon chain length. Complex 
6 and 7(d) shows longer OsP bond lengths than the complexes 7(a)-(c) which supports the 
1H NMR data. Hence, the downfield shift of the aromatic cymene protons Hb and Hc suggest 
shorter OsP bond lengths and upfield aromatic cymene Hb and Hc suggest longer OsP bond 
lengths. The trans influence of the P-donor atoms has affected the same aromatic carbons of 
the cymene ligand, which indicated that the chelating diphosphines are coordinated in a 
similar manner. Also the electronic effects of the diphosphine ligands with regards to the 
deviation from the mean plane seem to decreases with an increase in carbon chain length.   
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The Os-centroidcymene distance was observed to be larger for 7(b) and 7(d), however, 7(a) and 
7(c) have shorter Os-centroidcymene distances. The BF bonds for all the complexes in this 
study were found to fall within the range 1.317  1.395 Å which were comparable to the 
values in literature.30 Complexes 6, 7(c) and 7(d) have at least one intramolecular hydrogen 
bonding interaction with the bromine ligand. All the cation complexes have at least one 
intermolecular hydrogen bonding interaction with the BF4 counter ion.  The in vitro 
anticancer activity results of the nine complexes reported here will be discussed in Chapter 5.  
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CHAPTER 4 
 
SYNTHESIS OF OSMIUM CYMENE COMPLEXES WITH N- AND/OR P-DONOR 
LIGANDS 
 
4.1 Background 
 
The chemistry of monodentate N-donor ligands has been studied extensively.1,2 The widely 
used polar aprotic solvent acetonitrile (CH3CN) is commonly incorporated as a labile ligand 
in transition metal complexes. The preparation method of ruthenium arene complex [Ru(η5-
C5H5)(CH3CN)3]
+ with acetonitrile ligands were reported by Moriaty and co-workers.3 The 
ruthenium complex with two different arene ligands [Ru(η5-C5H5)(η6-C6H6)]PF6 irradiated in 
CH3CN solution yielded the trisacetonitrile cyclopentadienyl ruthenium species [Ru(η5-
C5H5)(CH3CN)3]PF6 which can be used as a starting material for the synthesis of a variety of 
ruthenium arene complexes. Thorburn and co-workers4 reported the synthesis of ruthenium 
complexes [{Ru(dppb)(CH3CN)}2μ-Cl3]PF6 and fac-[RuCl(dppb)(CH3CN)3]PF6 from 
Ru2Cl5(dppb)2. The fac-tris(acetonitrile) ruthenium complex has shown some catalytic 
properties for homogenous hydrogenation of terminal olefins and imines. 
Complexes with PPh3 and CH3CN ligands on the same metal centres are also known. Copper 
complexes with PPh3 and CH3CN with distorted tetrahedral geometry have been reported.
5 
The ruthenium complex [Ru(η6-p-cymene)Cl(CH3CN)(PPh3)]+ with both N-donor and P-
donor ligands was reported by Chaplin and co-workers.6 Transition metal complexes with 
ligands that contain borderline donor N- and hard donor O-ligating sites have been reported.7 
These types of complexes exhibit various electronic and steric properties as well as various 
coordination modes. The 2-aminobenzamide ligand has been coordinated to 3d transition 
metals such as Cu(II), Ni(II) and Zn(II) which chelates through the N-amino and O-amido 
functional groups to form stable six-membered chelate ring complexes.7 
 
In medicine, ruthenium arene complexes with labile ligands such as CH3CN were found to be 
inactive against ovarian because of the poor stability of the complex.8 Ruthenium arene 
complexes with a PPh3 ligand however, were found to exhibit enhanced anticancer activities 
attributed to the presence of the PPh3 ligand.
9 The organic benzamide derivatives are known 
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to exhibit biological activities such as anticancer, antimicrobial, antimalarial, analgesic and 
anti-inflammatory properties.10 Hence, when coordinated to transition metals such as Co(II), 
Cu(II) and Ni(II), these benzamide derivatives exhibit antimicrobial and anticancer 
activities.10 In this chapter, osmium cymene complexes with monodentate N- and P-donor 
ligands are reported. 
 
4.2 Preparation of monodentate N- and P-donor osmium cymene complexes  
 
The use of metal arene dimers bridged with halides presented an opportunity to synthesise 
bisacetonitrile complexes at room temperature.11 The halides bridge the two metal centres by 
forming a dative bond and a coordinate bond to the metal centres. This results in the halide 
having reduced electron density; hence, an electron pair donor solvent easily cleaves the 
metal-halide dative bond resulting in a vacant coordinate site. This allows a -donor ligand 
such as CH3CN to coordinate to the metal centre. The preparation of 9 was adopted with 
modifications from the method reported by Jensen and co-workers.11  The bromide bridged 
osmium dimer was stirred at room temperature in excess acetonitrile in the presence of 
NH4BF4 salt. Complex 10 was prepared with the method adopted from Chaplin and co-
workers6 with some modifications. Complex 9 was then further reacted with PPh3 (see 
scheme 4.1).  
Complex 11 was prepared from the osmium dimer [Os(η6-p-cymene)Br2]2 and 2-
aminobenzamide in the presence of NH4BF4 in CH2Cl2 at room temperature. The expected 
[Os(η6-p-cymene)(2-N,Nʹ-C7H8N2O)Br]BF4 product was not obtained instead 11 was 
isolated where the 2-aminobenzamide coordinates as a monodentate ligand. Complex 11 was 
isolated because the N atom of the amine group offers more electrons towards -bonding 
than the N atom of the amido group. On the amido group, electrons are being pulled towards 
the electronegative O atom, consequently reducing the electron density on the N atom.  
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4.3 Results and Discussion 
 
 
4.3.1 Nuclear Magnetic Resonance (NMR) Spectroscopy  
 
4.3.1.1 1H NMR data 
                    
Ha
Hb Hc
Hd
He
HcHb
He
(i)
                            Hi
Hj
Hl
Hk
HmHn
(ii)
H2N
H2N
O
 
Figure 4.1: 1H NMR for the (i) cymene and (ii) 2-aminobenzamide will be discussed 
according to this assignment and standard IUPAC naming for carbons will be used for 2-
aminobenzamide. 
The 1H NMR data were collected for complexes 9, 10 and 11. Complexes 9 and 10 are 
similar in structure except for replacement of one of the CH3CN ligands in 9 by the PPh3 
ligand in 10, hence, different electronic properties were observed. A singlet due to six protons 
of the two CH3CN ligands on 9 was observed at 2.74 ppm downfield relative to the free 
CH3CN ligand (2.10 ppm). A singlet due to three protons of the CH3CN in 10 was observed 
at 2.18 ppm slightly downfield relative to the free CH3CN ligand. The observation may be 
attributed to the -donor ability of the CH3CN ligand. Upon coordination, the N atom of the 
CH3CN ligand becomes electron deficient, resulting in electrons being pulled from the CH3 
by inductive effect deshielding the CH3 protons. Complex 11 displayed a minor downfield 
shift on protons Hi, Hj, Hk, Hl and Hm relative to the free 2-aminobenzamide ligand (see 
figure 4.1(ii)).  
The Hb and Hc protons of 9 appeared upfield at 5.86 and 6.05 ppm respectively, relative to 
the Hb (6.02 ppm) and Hc (6.15 ppm)
12 protons of the starting material. This observation may 
be attributed to the CH3CN ligand as a good -donor but a poor π-acceptor, consequently 
back bonding electrons are donated to the carbons of the cymene ligand. Complex 10 
displayed four sets of Hb and Hc protons because of the R and S isomers that co-exist in 
CDCl3 solution. Complex 11 displayed two sets of doublets due to Hb (6.03 ppm) and Hc 
(6.09 ppm). The protons Hc were slightly upfield relative to the Hc protons of the starting 
material [Os(η6-p-cymene)Br2]2. This observation was attributed to the competition of back-
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bonding electrons by aromatic cymene carbons and the N atom coordinated to the osmium 
centre. 
  
4.3.1.2 13C NMR data 
The 13C NMR data for complexes 9, 10, 11 support the 1H NMR data. A peak for the CH3 
group of CH3CN ligand for complexes 10 was observed upfield relative 9 (see table 4.1). The 
upfield shift of this signal in 10 was attributed to the presence of the PPh3. The C≡N carbon 
of CH3CN in 9 appears upfield while for 10 this signal appears downfield (see table 4.1). The 
observation may be attributed to the effect of PPh3 by participating in competing for back-
bonding electrons as compared to 9 where the cymene, Br and CH3CN ligands were present.   
The aromatic carbons of the cymene appeared downfield for 10 relative to the upfield shift of 
the aromatic carbons of the cymene in 9. This observation may be attributed to the poor π-
acceptor CH3CN ligands in 9. However, the strong π-acceptor PPh3 ligand in 10 offers 
competition of back-bonding electrons deshielding the aromatic carbons. Complex 11 
displayed carbon signals similar to the free 2-aminobenzamide ligand. 
 
Table 4.1: 13C NMR data of 9 and 10. 
Assignments 9 δ(ppm) 10 δ(ppm) 
CH3CN 4.19 3.32 
CH3C6H4 18.97 18.36 
CH(CH3)2 22.63 20.92 
CH(CH3)2 31.40 31.06 
η6-C6H4 97.67, 94.41, 78.69, 75.74 121.92, 109.88 (J=7 Hz), 96.99, 89.14 
(J=6 Hz), 83.43, 80.61 
C≡N 122.09 130.05 
CAromatic - 128.72-135.07 
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4.3.1.3 Heteronuclear Single Quantum Correlation (HSQC) NMR 
Complex 11 was characterised by a 2D HSQC NMR experiment to confirm the assignments. 
The Ha protons (2.22 ppm) appear as a singlet peak correlating to the carbon signal at 18.45 
ppm (see figure 4.2). The He protons (1.20 ppm) appear as a doublet correlating to a carbon 
signal at 21.74 ppm. The Hd proton (2.83 ppm) appears as a septet correlating to a carbon 
signal at 30.16 ppm. The Hb (6.03 ppm) and Hc (6.09 ppm) protons appear as two pairs of 
doublets correlating to carbon signals at 78.21 and 78.75 ppm respectively (see figure 4.2). 
The 2-aminobenzamide ligand protons were assigned below. The triplet of doublets due to 
proton Hl (6.48 ppm) correlates to the carbon signal (C5) at 114.83 ppm. This triplet of 
doublets is observed because of Hl coupling with Hm and Hk to give two signals of doublets; 
in addition, the third doublet occurs because of a long-range 4J-coupling of Hl with Hj. The 
doublet of doublets due to proton Hj (6.69 ppm) correlate to the carbon signal (C3) at 116.84 
ppm. The set of triplet of doublets due to proton Hk (7.12 ppm) correlate to the carbon signal 
(C4) at 132.31 ppm. The doublet of doublets due to proton Hm (7.52 ppm) correlates to the 
carbon signal (C6) at 129.17 ppm.   
 
Figure 4.2: The 2D HSQC NMR spectrum of 11 showing C−H correlations. 
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4.3.1.4 19F NMR data of 9 and 10 
A 19F NMR study was carried out to confirm the presence of the BF4 counter ion in 9 and 10. 
Complex 9 shows two F signals at 151.84 and 151.89 ppm found to be upfield relative to 
NH4BF4 (−148.88 and −148.94 ppm) which was used as a reagent (see figure 4.3). Complex 
10 displayed two F signals at 152.31 and 152.37 ppm slightly upfield relative to 9 which 
was used as a starting material for the synthesis of 10. The 19F signals also appear shifted 
from NH4BF4 to 9 then to 10 because of the significant changes in cationic complex 
structures. In addition, two 19F signal were observed due to the co-existence of the two boron 
isotopes (10B and 11B) in solution.13,14  
 
Figure 4.3: 19F NMR spectra for 9 and 10 showing the shift in fluorine signals. 
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4.3.1.5 31P NMR data of 10 
Complex 10 displayed a P signal at 2.69 ppm with two sets of satellites peaks at 2.56 and 
2.84 ppm with 1J = 56 Hz attributed to the spinning side bands.15 Another pair of satellite 
peaks was observed at 2.02 and 3.36 ppm with 1J(187Os31P) = 271 Hz due to the NMR 
active isotope of osmium (see figure 4.4). 15,16 In Chapter 2, the assignment of the two sets of 
satellite peaks was explained; hence, a similar assignment was used in this chapter. The P 
signal appeared to be deshielded relative to the free PPh3 ligand at 5.53 ppm. This 
deshielding may be attributed to the competition for the back-donated electrons influenced by 
other ligands around the osmium centre. In addition, the bond angle (CPC) on the 
coordinated ligand may be less strained with phenyl groups far away from each other because 
of the absence of the lone pair lobe.  
            
Figure 4.4: 31P NMR spectrum of 10 showing two sets of satellite peaks. 
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4.3.2 Infra-Red (IR) Spectroscopy  
 
The IR data shows that 9 exhibits two weak peaks at 2331 and 2303 cm-1 due to the reduced 
CN triple bond in the two acetonitrile groups in different environments. A strong peak 
assigned to the BF bond was observed at 1052 cm-1. However, as expected 10 exhibits a 
single medium peak due to CN triple bond of the acetonitrile at 2322 cm-1 and the B−F bond 
as a strong peak at 1054 cm-1. Complex 11 shows a stretching frequency due to ν(C=O) at 1660 
cm-1, as well as NH peaks at 3332, 3263, 3177 and 3112 cm-1.  
 
4.3.3 Raman Spectroscopy 
 
The IR results were supported by Raman spectroscopy data where additional evidence of the 
Os-Br bonds were obtained. Complex 9 exhibited a vibrational peak of medium intensity due 
to OsBr at 203 cm-1 which agrees with the Raman data by Bottger and co-workers.17 The 
two vibrational strong peaks due to ν(C≡N) at 2331 and 2303 cm-1 which support the IR data 
(see figure 4.6). Complex 10 shows a OsBr stretch at 202 cm-1, a weak peak due to ν(B-F) at 
1061 cm-1 and a medium peak at 2327 cm-1 attributed to ν(C≡N). Complex 11 shows two 
vibrational peaks due to Os−Br in different environments at 178 and 200 cm-1 as well as peak 
at 1669 cm-1 due to ν(C=O). 
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Figure 4.5: Raman spectrum of 9 showing Os−Br and two C≡N stretching bands. 
 
4.3.4 Thermogravimetric analysis (TGA) 
 
The thermal decomposition of the three complexes showed some similarity. Complex 9 
shows 2.1% mass loss between 80.8 to 135.3 ºC attributed to the acetonitrile solvent. The 
onset decomposition of 9 was observed at 163.9 to 287.3 ºC with 30.4% mass loss attributed 
to BF4 counter ion and two NCCH3 ligands. At 287.3 to 337.4 ºC a mass loss of 19.7% was 
attributed to the loss of the cymene. two CH3CN ligands and the BF4 counter ion. The loss of 
13.7% mass at 394.0 to 684.3 ºC was attributed to the Br ligand (see figure 4.6). At 684.3 ºC 
oxidation of Os metal to OsO2 and/or OsO4 takes place resulting in a residue of about 26% at 
800 ºC attributed to Os metal. 18  
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Figure 4.6:TGA thermogram of 9 with DTG curve. 
 
Complex 10 shows an initial 2.6% loss in mass at 80.1 to 174.3 ºC attributed to the loss of the 
acetonitrile solvent. The onset decomposition of 10 was observed at 176.1 to 327.9 ºC with 
34.5% mass loss attributed to the loss of the CH3CN and cymene ligands as well as the BF4 
counter ion. At 426.5 to 764.5 ºC a mass loss of 16.5% was observed, attributed to the loss of 
Br and one phenyl. The remaining 39% mass was attributed to Os–PPh2 fragment. Complex 
11 shows mass loss of 32.2% at 140.8 to 303.7 ºC attributed to the loss of the cymene and 
one Br ligands. The second degradation of 12.6% was attributed to the loss of the second Br 
ligand at temperatures from 267.9 to 347.1 ºC (see figure 4.7). The third degradation of 
50.2% fragment was attributed to the loss of 2-aminobenzamide group and the Os metal 
undergoing oxidation to OsO2/OsO4 followed by reduction to Os metal at temperatures 
between 416.2 ºC to 539.7 ºC.18 The presence of the PPh3 ligand has a significant impact on 
the thermal stability of 10 relative to 9. The thermal studies of 9 and 10 have shown that the 
CH3CN and cymene ligand decomposes first at temperatures around 170 ºC. The OsN 
bonds of the CH3CN ligand in 9 and 10 are thermally less stable relative to the OsN bond of 
the 2-aminobenzamide in 11. 
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Figure 4.7: TGA thermogram of 11 with DTG curve. 
 
 
4.3.5 Conductivity studies 
 
Conductivity studies were also carried out on complexes 9 and 10. For 1:1 complexes at 
ca.10-3 M in nitrobenzene solvent it is expected that the molar conductivity (ɅM) 
measurement be within the range 20–30 Scm2mol-1.19 Complex 9 gave a molar conductivity 
value found to be below the expected range (see table 4.2). This may be attributed to lability 
of the CH3CN ligand, which destabilizes the complex. Complex 10 gave a value that is within 
the range (see table 4.2). This may be attributed to the inertness of the complex after the 
coordination of the PPh3 ligand. This result supports the theory of lower molar conductivity 
than the expected range due to the lability of the CH3CN ligand. 
Table 4.2: The concentrations, conductance and molar conductivity values of 9 and 10. 
Complex  c × 10-3 M Conductance (c × μS)* ɅM (S cm2 mol-1) 
9 1.1 20.55 14.20 
10 1.1 29.35 20.28 
*The conductance of the samples were obtained after subtracting the value of the blank; Nitrobenzene = 
3.45 μS from the measured values. 
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The molar conductivities were calculated using the following equations: 
For complex 9. 
 = G × K   . . . . . . [1]   
Where  = conductivity (S/cm), G = conductance (S), K = cell constant (cm-1)  
Taking that G = 20.55 μS and K = 0.76 cm-1, then substituting the values in equation [1],  
Converting the conductivity to the molar conductivity the following equation was used: 
ɅM =  / CM  . . . . . . [2] 
                 = 14.20 S cm2/mol 
 
 
 
4.3.6 Crystallography 
    
Complex 11 co-crystallized with a disordered 2-aminobenzamide molecule. Table 4.3 
contains the crystal data and structure refinement and Table 4.4 contains selected bond 
lengths and bond angles of 11.  
Crystals of 11 suitable for X-ray diffraction was obtained by slow diffusion of the diethyl 
ether into a dichloromethane solution at room temperature. Figure 4.7 shows the molecular 
structure of 11, which crystallised in a triclinic crystal system with P-1 space group. The CC 
bond lengths measured different distances around the aromatic cymene, an indication of loss 
of aromaticity. The set of CC bonds which measured longer bond lengths are; C(2)C(3), 
C(3)C(4) and C(4)C(5). The C−C set which measured shorter bond lengths are; C(1)−C(2), 
C(5)−C(6), and C(6)−C(1). The OsC bond lengths also measured different distances, 
attributed to the loss of planarity. The Os(1)C(1) and Os(1)(6) measured shortest bond 
lengths compared to other carbons around the aromatic cymene, which indicated stronger 
interactions. The Os(1)C(3) and Os(1)C(4) measured the longest bond lengths, influenced 
by back-bonding from the N(2) atom on trans position, which is in agreement with 1H NMR 
data. The Oscentroidcymene distance was measured as 1.653 Å.  In addition, the loss of 
planarity was measured along the mean plane defined by C(2), C(3), C(5) and C(6). C(1) 
104 
 
measured 0.029 Å below the mean plane and C(3) measured 0.006 Å also below the mean 
plane. The coordinated 2-aminobenzamide ligand was observed to be out of plane with a 
torsion angle [centroidcymeneOs(1)N(2)C(12)] measured at 26.09º.  
Complex 11 co-crystallised with a molecule of 2-aminobenzamide. Complex 11 and co-
crystallised 2-aminobenzamide were found to be held together by C−H…N intermolecular 
hydrogen bonding (see figure 4.8). The short contact was measured as 2.602 Å at 148.91º due 
to one hydrogen of C(10) of the cymene with N(3) of the co-crystallised 2-aminobenzamide, 
which is classified as a strong hydrogen bond.20 The two intramolecular hydrogen bonds were 
observed as results of N−H…O and C−H…Br interactions (see figure 4.8). The N−H…O 
interaction was due to the hydrogen of N(2) with O(1) on the coordinated 2-aminobenzamide. 
This N−H…O intramolecular interaction was measured as 1.951 Å at 143.85º, which is 
classified as a strong hydrogen bonding.20 The C−H…Br intramolecular interaction was 
measured as 3.358 Å at 127.65º, which was due to the hydrogen on C(13) of the 2-
aminobenzamide and Br(1). The C−H…Br intramolecular hydrogen bond was observed to 
have an influence on the Os(1)Br(1) bond length. The two Br atoms measured different 
OsBr bond lengths, with Br(1) longer than Br(2).  
The Br(1)…Br(2) measured an interatomic distance of 3.469 Å at an angle subtended at the Os 
centre of 85.87º. The bond angles Br(1)−Os(1)−Br(2) were measured at 85.87º, 
Br(1)−Os(1)−N(2) measured at 81.87º and Br(2)−Os(1)−N(2) measured at 80.50º. The 
torsion angle C(1)C(6)C(5)C(4) was measured at 3.45º which support the loss of 
planarity of the cymene ligand. 
The effect of coordination of 2-aminobenzamide was observed relative to the co-crystallized 
2-aminobenzamide and the free 2-aminobenzamide ligand (JIXCIC†14). The crystal structure 
of the free 2-aminobanzamide was reported by Kashino and co-workers.21 The free 2-
aminobenzamide measured C(2)N(2) as 1.391 Å and the co-crystallized 2-aminobenzamide 
in this study measured C(24)N(3) as 1.377 Å whereas the coordinated ligand measured 
C(12)N(2) as  1.439 Å. This observation in coordinated 2-aminobenzamide was attributed to 
the strong -donor ability of N(2). Furthermore, in JIXCIC the C(7)N(1) measured 1.327 Å 
and the co-crystallised 2-aminobenzamide measured  C(24)N(3) as 1.398 Å  whereas the 
coordinated 2-aminobenzamide ligand measured C(17)N(1) as 1.332 Å. The C−H…N 
                                                          
†14 The CIF file used for comparison was obtained from the CCDC database. 
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hydrogen bonding have an effect on the CN bond of the co-crystallized 2-aminobenzamide 
ligand. The N−H…O hydrogen bonding has a significant effect on the CO bond of the 
coordinated 2-aminobenzamide.  
                     
 
Figure 4.8: Molecular structure of 11 at 50% probability thermal ellipsoids. 
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Table 4.3: Crystal data and structure refinement of 11∙2-aminobenzamide. 
 
  
Chemical formula C24 H25 Br2 N4 O2Os 
Molecular mass 687.45 
Crystal system Triclinic 
Space group P-1 
Crystal colour and shape Yellow-brownish cubes 
a(Å) 8.483(2) 
b(Å) 9.938(3 
c(Å) 14.914(4) 
α(°) 87.285(11) 
β(°) 74.264(11) 
γ(°) 67.131(11) 
V(Å3) 1112.7(5) 
Z 2 
T(K) 173(2) 
Dcalc (mg/m3) 2.052 
Absorption coefficient 9.339 mm-1 
Reflections collected 56810 
Independent reflections 5361 [R(int) = 0.4236] 
Data / restraints / parameters 5361 / 54 / 280 
F(000) 654 
Final R indices [I>2(I)] R1 = 0.0895, wR2 = 0.2259 
R indices (all data) R1 = 0.0972, wR2 = 0.2400 
Goodness-of-fit on F2 1.034 
Largest diff. peak and hole 7.043 and −8.175 e.Å-3 
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Table 4.4: Selected bond lengths (Å), bond angles (º) and torsion angles (º) of 11. 
Atom type label 11 
Os(1)C(1) 2.158(15) 
Os(1)C(2) 2.178(12) 
Os(1)C(3) 2.189(11) 
Os(1)C(4) 2.196(10) 
Os(1)C(5) 2.175(13) 
Os(1)C(6) 2.162(15) 
C(1)C(2) 1.400(2) 
C(2)C(3) 1.432(17) 
C(3)C(4) 1.440(17) 
C(4)C(5) 1.441(16) 
C(5)C(6) 1.399(18) 
C(6)C(1) 1.380(2) 
Os(1)N(2) 2.180(10) 
Os(1)Br(1) 2.5634(15) 
Os(1)Br(2) 2.5292(16) 
Br(1)…Br(2) 3.469 
Os(1)centroidcymene 1.653 
Bond angles  
Br(1)Os(1)Br(2) 85.87(7) 
Br(1)Os(1)N(2) 81.87(3) 
Br(2)Os(1)N(2) 80.50(3) 
Torsion angles  
C(1)C(6)C(5)C(4) 3.45 
C(1)C(2)C(3)C(4) −0.03 
 
4.4 Conclusions 
 
The novel osmium cymene complexes with monodentate N- and P-donor ligands were 
synthesised and fully characterised. The presence of a PPh3 ligand was found to play a 
significant role on the electronic and electrolytic properties of 10. Complex 10 was found to 
be thermally stable relative to 9 because of the substitution of the labile CH3CN ligand by the 
non-labile PPh3 ligand. In addition, the electrolytic properties of 10 were found to be good, 
with 10 exhibiting higher molar conductivity than the substrate complex 9 attributed to the 
PPh3 ligand. The 2-aminobenzamide in 11 coordinates to the osmium centre with the most 
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electron rich amino group. Steric hindrance has an influence on the choice of coordination of 
2-aminobenzamide with only monodentate N atom as opposed to chelation with N,O or N,Nʹ 
atoms.   
 The effects of coordination of 2-aminobenzamide with N atom of the amino group has 
significant effects on the cymene ligand according to NMR and crystallography data. 
Hydrogen bonding plays an important role in co-crystallization of 11 with 2-aminobenzamide 
ligand. The in vitro anticancer activity results of complexes 9 and 10 will be discussed in 
Chapter 5. 
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CHAPTER 5  
 
ANTICANCER STUDIES OF OSMIUM CYMENE COMPLEXES WITH CHELATED O,Oʹ 
AND P,Pʹ AS WELL AS MONODENTATE N- AND P-DONOR LIGANDS 
 
5.1 Background 
  
5.1.1 Platinum complexes as chemotherapeutic agents  
 
Platinum complexes have been found to be cytotoxic against a variety of cancer cell lines. 
Cisplatin has been used since 1978 for treatment of a number of tumours such as ovarian, 
non-small cell, small cell lung, neck, head, and testicular cancers.1 It is understood that 
Cisplatin is activated by hydrolysis of one or both chloride ligands. The resulting platinum 
aqua adduct then coordinates covalently with the DNA bases and subsequently induces 
programmed cell death, apoptosis (see scheme 5.1).2 The second generation of platinum 
complexes such as Carboplatin and Oxaliplatin were approved world-wide for treatment of 
Cisplatin resistant tumours in 1993 and 2003 respectively (see chart 5.1).3,4 The presence of 
O,Oʹ- and N,Nʹ-chelate rings on  Carboplatin and the O,Oʹ-chelate ring on Oxaliplatin brings 
inertness towards hydrolysis. These complexes exhibit a different mode of anticancer activity 
against Cisplatin resistant tumours such as colon carcinoma.5  
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Nedaplatin has been approved for clinical use in Japan against ovarian carcinomas, head and 
neck tumours as well as oesophageal and bladder cancer (See chart 5.1).6 Lobaplatin is a 
platinum complex with both O,Oʹ- and N,Nʹ-chelate rings which is approved in China for 
treatment of non-small-cell-lung cancer, breast tumours and certain forms of leukaemia.7 
Heptaplatin is a platinum complex with six-membered and seven-membered O,Oʹ-chelate 
rings on the platinum centre. This platinum based complex is currently in clinical use for 
gastric cancer, head and neck squamous cancers in South Korea.6 Satraplatin, Picoplatin and 
BBR3464 are currently in clinical trials in the United States for treatment of various tumours 
such as malignancies, lymphomas, colorectal, prostate, melanoma, pancreatic and lung 
cancers (see chart 5.1).8 However, platinum complexes as anticancer agents are still limited 
by challenges such as drug resistance9 and side effects.10 As a result, many platinum 
complexes have been abandoned in early phases of clinical trials.8 Hence, there is a need for 
non-platinum complexes to overcome the challenges observed with platinum complexes. 
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Chart 5.1: Platinum complexes with anticancer activity. 
 
5.1.2 Ruthenium complexes as promising cancer chemotherapy agents 
 
After the discovery of the limitations of the platinum complexes, ruthenium chemistry was 
developed rapidly to tackle challenges faced by platinum complexes in treatment of cancer. 
Ruthenium complexes have been found to have interesting properties in biological systems. 
Ruthenium complexes can undergo oxidation/reduction, exhibit lower toxicity relative to 
other platinum group metals, have lower rate of ligand exchange and can mimic the binding 
of iron to certain biological molecules.11 Ruthenium complexes have been found to exhibit 
anticancer, antimalarial and antibiotic activities.11 The two classical ruthenium coordination 
complexes NAMI-A12 and KP101913 have been undergoing clinical trials since 1999 and 
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2003 respectively for their potency against colorectal cancer. These complexes have been 
found to be soluble and selectively potent against solid  tumours.1,13 The ruthenium complex 
NAMI-A is currently undergoing phase II clinical trials.14 
The development of ruthenium arene complexes for anticancer screening contributed to the 
fast developing field of bio-organometallic chemistry. These half-sandwich ruthenium 
complexes with “piano-stool” geometry have been coordinated with a number of N,Nʹ-, O,Oʹ-
, N,O-15 and P,Pʹ-16,17 chelating ligands as well as N-, P- and O- monodentate ligands. In 
2001, Morris and co-workers18 reported ruthenium arene complexes bonded to 
ethylenediamine. These complexes were found to be potent against human ovarian (A2780) 
cancer cells. The synthesis of ruthenium arene PTA (PTA = 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane) complexes was first reported in 2005.19 The RAPTA 
complexes were found to be selective towards the TS/A mouse adenocarcinoma cancer cell 
line but non-active against the HBL-100 human mammary (non-tumour) cell line.19 
Introduction of the PPh3 ligand to the RAPTA complex to form [Ru(η6-p-
cymene)Cl(PTA)(PPh3)]BF4 was found to increase the cytotoxicity towards the TS/A 
adenocarcinoma and the non-tumourigenic HBL-100 cancer cells.20 The ruthenium arene 
moiety has been coordinated to biologically active molecules and the effect of ruthenium 
metal on biological activities of the molecule/adduct was investigated.11 
 
5.1.3 Osmium complexes as emerging cancer chemotherapy agents  
Osmium complexes have been recently studied as potential metallopharmaceuticals against 
cancerous cells. Osmium complexes were synthesised based on ruthenium analogues and the 
biological activities were investigated.21 The complexes of osmium were found to prefer 
higher oxidation states, exhibit stronger π-back donation at lower oxidation states and 
hydrolyse slower depending on the ligand system compared to the ruthenium analogues.22,23 
Kostrhunova and co-workers24 investigated the ability of osmium arene complexes to bind to 
DNA. Their results showed binding of osmium biphenyl complexes to the DNA guanine 
nucleotide. The contact was found to be a noncovalent interaction of the guanine and the 
arene ligands. Filak and co-workers25 in 2010 reported the synthesis of ruthenium cymene 
and osmium cymene complexes with indolo[3,2-c]quinolones and indolo[3,2-d]benzazepines. 
The complexes were tested for cytotoxicity against ovarian carcinoma (CH1), colon 
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adenocarcinoma (SW480) and non-small-cell lung carcinoma (A549) and were found to be 
potent against all the three cell lines.  
Fu and co-workers26 in 2011 reported the osmium cymene phenylazopyridine complex with a 
higher cytotoxicity than the isostructural ruthenium analogue.  More recently, van Rijt and 
co-workers27 in 2014 investigated the mechanism of action of the compound first reported by 
Fu and co-workers in 2011. The group found that [Os(η6-p-cymene)(NMe2-
phenylazopyridine)I]PF6 induces apoptosis which is linked to the involvement of 
mitochondrial pathways. Again in 2013 Fu and co-workers28 reported the anticancer activity 
of osmium cymene complexes with chiral centres which were found to have different 
selectivity patterns. The development of osmium complexes for medicinal application was 
further advanced by the work of Filak and co-workers29 when they reported chelated osmium 
cymene indolo[3,2,-c]-quinoline complexes which exhibited higher potency than the 
ruthenium analogues. 
These results suggest that osmium complexes exhibit different mechanisms of actions. In 
addition, osmium complexes can exhibit more potency towards cancer cells relative to their 
ruthenium analogues depending on the ligand system. Hence in this study, the osmium 
cymene complexes with various ligand systems were investigated against a range of cancer 
cell lines.   
5.1.4 The role of the arene ligands in anticancer complexes 
 
Arenes play an important role in the field of bioinorganic chemistry. The arene ligand which 
donates π-electrons to the oxidized metal ion brings stability to the whole metal complex. The 
arene ligands also increase the hydrophobicity of the complex, which increases the cellular 
uptake of the complexes. As a result, there is increased cytotoxicity of complexes towards 
cancer cells. The size of the arene ligand also plays a role because larger size arenes are more 
hydrophobic and are taken up by the cells to a greater degree than complexes with small size 
arene ligands.15 There are reports of some metal coordinated arene ligands having non-
covalent interactions with the DNA.24 
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5.1.5 The role of labile ligands in anticancer complexes 
 
The labile ligands play an important role in biological studies of metal complexes where 
interaction of complexes studied is covalent with the specific biomolecule. These labile 
groups are weak bases with high electronegativity. These species are known to hold onto 
their electrons as a result forming weaker bonds with metal ions. They also play a role in the 
rate of ligand substitution. Larger labile groups have a steric effect on the central metal hence 
leave easily resulting in SN1 process being faster for the entering group. Likewise, a smaller 
leaving group will favour an SN2 process depending on the nature of the entering group. The 
bonds between the labile group and the metal can easily be cleaved with the introduction of a 
stronger binding ligand. The labile group is influenced by the ancillary ligands as well as the 
metal ion charge. The M-X bond (where X is a labile group) can break easily influenced by 
the trans effect, back bonding as well as the bulkiness of the ancillary ligands.30  
In the fields of catalysis and bioinorganic chemistry, halides are preferred as labile groups 
because of their high electronegativity and readiness to depart. Romero-Canelon and co-
workers31 discovered that different halides bring different properties to the metal complex 
such as the chlorido complexes activating twice faster than the iodido complexes. In their 
study of ruthenium and osmium arene azo- and imido-pyridine complexes, they discovered 
that the iodido complex increases polarization of the positive charge on the chelated face of 
the pseudo-octahedral complexes than the chlorido complexes. These iodido complexes were 
found to be more potent and selective towards cancer cells than the analogous chlorido 
complexes.31  
van Rijt and co-workers27 reported osmium biphenyl complexes with iodido and chlorido 
ligands. The iodido complex was found to be more potent than the chlorido complex.  Karami 
and co-workers32 compared the influence of the bromide and chloride ligands on the 
palladium(II) binuclear complexes with a bridging diphosphine ligand. They discovered that 
the bromido complex exhibits higher cytotoxicity against the HeLa, HT-29 and K562 cell 
lines than the chlorido complex. The property of the iodide ligand to undergo slower 
hydrolyses than the chloride ligand offers a more suitable leaving group for 
metallopharmaceuticals. Dougan and co-workers33 observed that the iodide ligand can act as 
a two electron donor ligand forming stronger bonds with metal centres than the more 
electronegative chloride ligand. Furthermore, the iodide ligand hydrolyse slower than the 
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chloride ligand; however the iodide ligand is being considered a stronger ligand than the 
chloride ligand.33    
 
5.2 SRB vs. MTT assays 
 
There are various methods of anticancer assays which are known to be effective. However, 
these methods are not without drawbacks. The two most widely used assay methods will be 
discussed below namely: the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and sulforhodamine B (SRB) assay methods. The MTT assay determines the cell 
viability by measuring the reduced activity of enzymes inside the cell. These enzymes 
convert colourless tetrazolium compound into the water insoluble purple formazan crystals 
by dehydrogenase.34,35 In contrast, the SRB assay method determine the cell viability by 
measuring cellular protein content. The sulforhodamine B dye interacts electrostatically with 
the basic amino acids of cellular proteins depending on the pH of the environment (see figure 
5.1).36 
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Figure 5.1: Illustration of electrostatic interaction between sulforhodamine B and the amino 
acids from the primary protein structure. 
 
The MTT assay method suffers drawbacks because several enzymatic activities are involved 
within the cells. The MTT assay method entirely depends on the mitochondrial succinic 
118 
 
dehydrogenases to convert tetrazolium dye to formazan.34 Also the MTT assay method was 
found to suffer from sensitivity and interferences because few cells are used to minimize the 
non-linearity of the assay method.34,37 The SRB assay methods was found to have higher 
sensitivity and better linearity with the cell number and free of cell metabolic activity.34,38,39 
In addition, the staining of plates for SRB assays were found to be stable for use in several 
weeks to months as compared to the less stable stained plates for MTT assay. 
Therefore, in this study the SRB assay method was used to determine the cytotoxicity of the 
fourteen osmium cymene complexes against four cancer cell lines.  
 
5.3 Results and Discussion 
 
Osmium cymene complexes chelated with α-diketones, diphosphines and monodentate N- 
and P-donor ligands exhibit interesting potency against renal (TK-10), melanoma (UACC-
62), breast (MCF-7) and HeLa cancer cells. The complexes reported here have some 
similarity in structure however show some differences in anticancer activities. Table 5.1 
contains the IC50 values of the fourteen complexes against the TK-10, UACC-62, MCF-7 and 
HeLa cancer cell lines. 
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Chart 5.2: Complexes screened against TK-10, UACC-62, MCF-7 and HeLa cancer cells. 
 
5.3.1 Renal (TK-10) cell line 
 
Complexes 1(b), 3 and 4 were evaluated against the TK-10 cancer cells. The chelated-O,Oʹ 
osmium complexes 1(b), 3 and 4 exhibited a wide range of activities. Complex 1(b) was 
found to exhibit moderate activity against the renal cell line. Complex 3 also showed 
moderate activity against the renal cancer cells with IC50 value of 33.46 μM. Complex 4 was 
found to exhibit low activity against the renal cancer cell line (see chart 5.3). The low activity 
of 4 may be attributed to the bulkiness of the binuclear complex, which limits the cellular 
uptake.  
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The P,P′-chelated complexes 7(a)-(d) and the monodentate bis(phosphine) osmium complex 
6 were screened against the TK-10 cancer cells. Complex 6 was found to exhibit an IC50 
value of 1.53 μM (see table 5.1 p130). Complex 7(a) was found to be slightly more potent 
than 6 against the renal cancer cells. The slight potency may be due to chelate effect of the 
dppm ligand, which contributes to the stability of 7(a) relative to 6. Structure modification of 
7(a) with addition of a methylene (−CH2) group to afford 7(b) slightly increased the potency 
(see chart 5.4).  
The addition of a second −CH2 group which afforded 7(c) increased the potency by 2-fold 
relative to 7(a) and 7(b). The increase in potency may be attributed to the positioning of 
phenyl groups in suitable angles that allows increased exposure of interaction with the DNA 
bases as the alkyl chain was increased. In addition, the spreading of the phenyl rings may also 
contribute to exposure of the phenyl protons resulting hydrogen bonding.40 Complex 7(d) 
showed activity 3-times less than that of 7(c) (see chart 5.4). This observation can be 
attributed to longer alkyl chain length which brings more flexibility at the phenyl groups 
resulting in floating of the phenyl groups in solution and hence deviation from the special 
angles required for intercalation. The spacers created by 7(b) and 7(c) upon coordination to 
the osmium centre may also be attributed to the high activity against the renal cancer cell 
line. The order of potency of the chelated-diphosphine complexes against the renal cell line 
was found to be: 7(d)  7(a)  7(b)  7(c). 
The bridging diphosphine osmium cymene complexes were also screened against the TK-10 
cancer cells. Complex 8(a) was found to exhibit similar potency compared to 8(b) and was 3 
times more potent than 8(c). The activity was assumed to be because of the dppm ligand 
locks the two osmium centres closely together, reducing the movement of atoms and the size 
of the complex, which can easily get between DNA strands to allow intercalation or hydrogen 
bonding. The results showed that 8(b) was potent but slightly less than 8(a). Complex 8(d) 
was found to be inactive against the renal cancer cell line. This observation was attributed to 
the larger size of the 8(d) hence less space to be accommodated on the DNA strand. The 
order of potency of bridged-diphosphine complexes against the renal cancer cell line was 
found to be: 8(d)  8(c)  8(b)  8(a). 
The anticancer activities of N- and P-donor ligands in complexes 6, 9 and 10 are discussed 
below. Complex 9 was found to exhibit low activity against the renal cancer cell line. This 
may be due to the lability of CH3CN ligands which result in the formation of non-active 
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adducts in the aqueous environment. Similar observations were reported by Aird and co-
workers for the isostructural ruthenium complex against the human ovarian (A2780) cancer 
cells.41  Structural modification of 9 by replacing one labile CH3CN ligand with one PPh3 
ligand to afford 10, consequently, increases the potency by 2-3 fold (see figure 5.4). The 
increase in potency may be attributed to the presence of PPh3 ligand, which brought stability 
to complex 10. Addition of the second PPh3 ligand to afford 6 further increased the potency 
by 33-fold. The increased potency was due to the increased stability of the complex 
combined with increased hydrophobicity.  
 
5.3.2 Melanoma (UACC-62) cell line 
 
For complexes with O,O′-chelating ligands 1(b), 3 and 4 were screened against the UACC-62 
cancer cells. Complex 1(b) was found to be 11-fold active than 3 while the binuclear complex 
4 was less active against the melanoma cancer cells (see chart 5.3). Complex 1(b) consists of 
two oppositely charged ions, which may be held strongly by electrostatic interactions. Hence, 
hydrogen bonding between the protons on the phenyl rings with the nitrogen of the adenine 
and oxygen of the thymine is possible.40  Also, electrostatic charges may have played a role 
in the activity of 1(b) through interaction of the positively charged complex with the 
negatively charged phosphate backbone of DNA. Complex 3 exhibited moderate activity 
against the melanoma cancer cell line. The inactivity of the binuclear complex 4 may be 
attributed to the size of the complex as well as the lability of the ligands. 
The chelated-diphosphine osmium complexes and the monodentate bis(phosphine) complex 6 
were found to exhibit diverse anticancer activities. Complex 6 exhibited high activity against 
the melanoma cells, which may be attributed to the stability and large surface area (see chart 
5.6). Large surface area offers possible interactions, hence six phenyl rings of the two PPh3 
ligands offers large spectrum of reactivity with DNA nucleotides. Furthermore, the phenyl 
rings and the cymene ligand increase the hydrophobicity of the complex ion. There is also an 
increased probability of intercalation and hydrogen bonding of the phenyl and cymene 
protons to the nitrogen (adenine) and oxygen (thymine) atoms of the DNA bases.40 
Complexes 7(b) and 7(d) exhibited similar activities against the melanoma cancer cells (see 
chart 5.4). On the other hand, 7(a) and 7(c) exhibited lower activities against the melanoma 
cell line relative to 7(b) and 7(d). The high potency of 7(b) and 7(d) may be attributed to the 
delocalization of the charge on the dppe and dppb ligands upon coordination. From the 
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molecular structures of 7(b) and 7(d), the two complexes shows similar Oscentroidcymene 
distances. Also, the BF4 anion is located alongside the dppe and dppb ligands whereas in 7(a) 
and 7(c) the BF4 anion is located alongside the cymene ligand.  This indicated that the formal 
charge in 7(b) and 7(d) may be delocalised on the dppe and dppb ligands. Hence, the two 
complexes exhibited similar reactivity against the melanoma cell line. Complex 7(a) and 7(c) 
may have the positive charge delocalised on the cymene ligand. Hence, low activity was 
observed because of small surface area for reactivity compared to two phenyl rings on each P 
atom. The increase in potency of the chelated diphosphine complexes against the melanoma 
cell was found to be: 7(a)  7(c)  7(b)  7(d). 
For the complexes with bridging-diphosphine ligands 8(a)-(d), a wide range of anticancer 
activities with melanoma cells was observed. Complex 8(a) showed higher potency against 
the melanoma cell line compared to 8(b), 8(c) and 8(d) (see chart 5.5). The addition of 
methylene group (CH2) on the diphosphine backbone 8(b) was found to decrease the 
activity by 3-fold relative to 8(a). The high activity of 8(a) may be attributed to the shorter 
carbon chain length of the dppm hence possible intercalation of the DNA strand. Complex 
8(c) shows a slight decrease in activity when compared to 8(b), and both complexes were 
found to be potent against the melanoma cell line. Complex 8(d) was found to be inactive 
against the melanoma cell line. The inactivity of 8(d) may be due to the increased stability, 
flexibility and bulkiness, which may cause difficulty in penetrating the cell membranes. The 
trend of increased potency against the melanoma cell line was found to be: 8(d)  8(c)  8(b) 
 8(a). 
For complexes 6, 9 and 10 with monodentate N- and P-donor ligands, various activities were 
observed. Complex 9 was found to be inactive against the melanoma while complex 10 was 
found to exhibit moderate activity against the melanoma cell line. The non-labile PPh3 may 
be responsible for the moderate activity of 10, because of increased stability and 
hydrophobicity as well as increased surface reactivity with DNA’s helical structure. Addition 
of the second non-labile ligand PPh3 to afford 6 was found to increase potency by 27-fold 
relative to 10 (see chart 5.6). The high activity may be attributed to enhanced stability and 
increased surface area for reactivity. 
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5.3.3 Breast (MCF-7) cell line 
 
Complexes with O,Oʹ-chelating ligands 1(b), 2 and 4 were screened against the breast cancer 
cell line. Complex 1(b) was found to exhibit high potency against the breast cancer cell line. 
This activity may be due to electrostatic interaction of 1(b) and the DNA nucleotides. 
Complex 3 exhibited moderate activity against the breast cancer cell line (see chart 5.3). 
Complex 4 also showed some weak activity against the breast cancer cell line, which may be 
due to the lability of the ligands around the central metal.  
The chelating diphosphine osmium complexes 7(a)-(d) and the bis(phosphine) osmium 
complex 6 exhibited a wide range of activities against breast cancer cell line. Complex 6 
exhibited high activity with IC50 value below 1μM against the breast cancer cell line. The 
activity of 7(a) was found to be below 0.5 μM, which is twice as active as 6 but a similar 
activity to 7(d). Complex 7(b) was found to be twice active than 7(a) and 7(d) as well as 4-
fold active relative to 6. The activity of 7(b) may be due to the special bite angle of 
coordinated dppe which increases the exposure of the four phenyl rings towards the DNA 
nucleotides for interaction. Complex 7(c) exhibited high activity, which is slightly more than 
that of 7(a), and 7(d) (see chart 5.4). The free dppm and dppb ligands are found to be only 
moderately active against the breast (MCF7) cancer cell line with IC50 values of 0.7 ± 0.1 μM 
and 0.8 ± 0.5 μM respectfully.42 Therefore 7(a) and 7(d) has been found to exhibit increased 
anticancer activity relative to their respective free ligands. The increased activity may be 
attributed to the bite angles as well as the length of spacer upon coordination of the free 
ligands. The electronic properties of this coordinated dppe and dppp ligands may allow 
locking of P atoms by limiting movement of phenyl groups, hence increasing reactivity 
surface exposure. The trend of increased potency of the chelated complexes against the breast 
cancer cell line was found to be: 7(d)  7(a)  7(c)  7(b). 
The bridging-diphosphine osmium complexes 8(a)-(d) exhibited a wide range of activities 
against the breast cancer cells. Complex 8(a) showed an activity below 2 μM which was 
found to be 4-fold higher than that of 8(b) and 5-fold higher than that of 8(c) (see chart 5.5). 
Complex 8(b) was found to be slightly higher in activity against breast cancer cell line 
compared to 8(c). Surprisingly 8(d) was found to be inactive against the breast cancer cell 
line. The diphosphine-bridged binuclear complexes 8(a) and 8(d) were also found to exhibit 
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reduced activity against the breast cancer cell line relative to the respective free ligands. The 
reduced activity of 8(a) may be due to the size of the complex whereas the inactive character 
of 8(d) may be attributed to the larger size of the binuclear complex. The increased potency 
of the complexes with bridging-diphosphine ligands against the breast cancer cell line was 
found to be: 8(d)  8(c)  8(b)  8(a). 
Complexes with monodentate N- and P-donor ligands 6, 9 and 10 were also screened against 
the breast cancer cell line. Complex 9 was found to be inactive against the breast cancer cell 
lines. On replacement of one of the labile ligands with PPh3, 10 were found to increase 
activity against the breast cancer cell line. The introduction of a non-labile ligand was found 
to increase the cytotoxicity towards cancer cells. This may be due to increased stability and 
cell uptake of 10 because of the hydrophobicity of the phenyl groups.20 Replacement of the 
second labile ligand by another PPh3 ligand to afford complex 6 increased the activity by 29-
fold (see chart 5.6). The two PPh3 ligands in 6 offer an increased surface reactivity and 
increased stability as well as increased cellular uptake. 
 
 
 
125 
 
 
Chart 5.3: The plot of log concentration versus percentage cell viability of 1(b), 3 and 4 
against TK-10, UACC-62 and MCF-7. 
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Chart 5.4: The plot of log concentration versus percentage cell viability of complexes 7(a)-
(d) against TK-10, UACC-62 and MCF-7. 
 
127 
 
 
Chart 5.5: The plot of log concentration versus percentage cell viability of complexes 8(a)-
(d) against TK-10, UACC-62 and MCF-7. 
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Chart 5.6: The plot of log concentration versus percentage cell viability of 6, 9 and 10 
against TK-10, UACC-62 and MCF-7. 
 
5.3.4 HeLa cell line 
 
The HeLa cell line was used to determine the general cytotoxicity of the fourteen complexes 
(see chart 5.2). The general cytotoxicity has been classified according to CSIR criteria as 
follows: low hazard (IC50 value > 100 μM), weak hazard (100 μM > IC50 value > 50 μM), 
moderate hazard (50 μM > IC50 value > 10 μM) and high hazard (IC50 value  10 μM).43 
Complexes with O,Oʹ-chelating ligands 1(b), 3 and 4 showed a wide range of cytotoxicity 
against the HeLa cell line. Complex 1(b) exhibited a moderate activity and 3 showed low 
activities which were considered a weak hazard against the HeLa cell. Complex 4 was 
inactive against the HeLa cell line, which was considered a low hazard complex. 
For chelated-P,Pʹ osmium complexes and the monodentate bis(phosphine) osmium complex 6 
a wide range of anticancer activities against the HeLa cancer cells was observed. Complex 6 
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was found to exhibit potency below 1 μM against the HeLa cell line. This may be due to the 
stability of the complex combined with the hydrophobicity provided by six phenyl groups of 
the two PPh3 ligands, which in turn increases cellular uptake of the complex. The may be 
possible intercalation as well as hydrogen bonding between the nucleotides with the phenyl 
protons. Also the cationic character of the osmium cymene complex may contribute to the 
potency of the complex because of electrostatic interactions with the electronegative sugar 
phosphate ions of the DNA.40 Therefore, complex 6 was considered a high hazard according 
to the CSIR criteria. 
The chelated-diphosphine mononuclear complexes 7(a)-(d) were found to be potent against 
the HeLa cell lines. The potency of 7(a) was found to be below 4 μM against the HeLa cell 
line. This may be due to the decreased spacer of 7(a) relative to 7(b)-(d). Complex 7(b) was 
found to be more active against the HeLa cell line relative to 7(a). Complex 7(c) shows 
slightly higher potency against 7(a) but slightly lower than 7(b). Complex 7(d) shows activity 
slightly lower than that of 7(b) and 7(c) but slightly higher than that of 7(a). Since all the IC50 
values of the complexes 7(a)-(d) series were all below 10 μM. All the chelated-diphosphine 
complexes were considered hazardous towards the HeLa cell line (see table 5.1). 
The bridged-diphosphine binuclear complexes 8(a)-(d) exhibited different anticancer 
activities against the HeLa cells. Complex 8(a) showed high potency against the HeLa cancer 
cell line whereas structural modification of 8(a) by addition of CH2 group to afford 
complex 8(b) reduces the potency. The reduction in activity may be due to the larger size of 
8(b) as the carbon chain length was increased. The higher the carbon chain length of the 
diphosphine the more flexible the whole binuclear complex becomes, therefore the loss of 
fixed positions of the atoms. Complex 8(c) exhibited weak activity against the HeLa cell line. 
The loss of activity may be due to the increased carbon chain length, which increases the 
flexibility of the whole complex. Complex 8(d) was also found to be inactive against the 
HeLa cell line.  
The bridged-diphosphine binuclear complexes exhibited interesting behaviour against the 
HeLa cell line. The trend of increased potency against the HeLa cell line was found to be: 
8(d)  8(c)  8(b)  8(a). The trend of increased hazardousness against the HeLa cell line 
was found to be: 8(d)  8(c)  8(b)  8(a). Therefore, 8(c) and 8(d) exhibited weak hazard 
relative 8(b) and 8(a) against the HeLa cell line. 
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For complexes with monodentate N- and P-donor ligands, screening against the HeLa cell 
line exhibited a wide range of activities. Complex 9 exhibited low potency against the HeLa 
cell line while 10 exhibit a moderate potency against the HeLa cell line. The labile CH3CN 
ligands of 9 may be the reason lower potency was observed against the HeLa cell line. The 
introduction of PPh3 in 10 enhances stability, hence an increased potency was observed. 
Complex 6 exhibited higher potency relative to 9 and 10 because of increased stability, 
increased hydrophobicity and increased surface reactivity. Therefore 9 were found to exhibit 
lower hazard and 10 exhibit moderate hazards and 6 exhibit high hazards.  
 
Table 5.1: The IC50 (μM) results against TK-10, UACC-62, MCF-7 and HeLa cell lines. 
Complexes TK-10 (renal) UACC-62 
(melanoma) 
MCF-7 (breast) HeLa 
1(b) 16.02 2.56 2.76 21.3 
3 33.46 28.71 44.76 96.1 
4 ˃100 99.07 98.56 ˃100 
6  1.53 0.77 0.95 0.78 
7(a)  1.28 0.64 0.48 3.66 
7(b)  1.12 0.31 0.22 1.93 
7(c)  0.67 0.42 0.34 2.36 
7(d)  1.83 0.31 0.48 3.02 
8(a) 9.07 1.52 1.79 7.71 
8(b)  9.22 4.58 7.07 29.5 
8(c)  23.75 5.8 9.67 66 
8(d)  ˃100 ˃100 ˃100 ˃100 
9 ˃100 ˃100 ˃100 ˃100 
10  49.77 20.7 27.98 45.9 
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5.4 Conclusions 
 
Osmium cymene complexes have demonstrated a range of anticancer activity against three 
cancer cell lines (TK-10, UACC-62 and MCF-7) depending on the ligand system and the 
general cytotoxicity against the HeLa cells. However, a challenge remains the poor selectivity 
of these osmium cymene complexes between the three cancer cell lines and the HeLa cell 
line.  
The phosphine containing complexes 6, 7(a)-(d), 8(a) and 8(b) were found to be very active 
against the renal cancer cell line whereas 1(b), 3, 4, 8(c), 8(d), 9 and 10 were found to be less 
active. The melanoma cancer cell line showed some susceptibility against 1(b), 6, 7(a)-(d) 
and 8(a)-(c) in this study; however, some resistance was observed against 3, 4, 8(d), 9 and 
10. The breast cancer cell line also showed similar susceptibility to the same complexes and 
similar resistance to the same complexes as the melanoma cell line with more or less IC50 
values. Complexes 6, 7(a)-(d) and 8(a) showed to be the only active complexes against the 
HeLa cancer cells while 1(b), 3, 4, 8(b)-(d), 9 and 10 were found to be less active. The renal 
and HeLa cancer cell lines were observed to be resistance to all the O,Oʹ chelated complexes 
suggesting a similar mode of action of these O,Oʹ complexes.  
It has been found that the most potent complexes 6 and 7(a)-(d) have strongly bound 
phosphine ligands. Hence, the metal centre was assumed not to have covalent interaction with 
the DNA bases as Cisplatin does. The high potency of 6 and 7(a)-(d) may be attributed to the 
intercalation of phenyl groups on the diphosphine backbone, electrostatic interaction of the 
cationic osmium complex and/or the hydrogen bonding of phenyl protons to the thymine and 
adenine DNA bases. The presence of the phenyl groups had a positive influence on the 
anticancer activity of these complexes, in a sense that, they enhance the hydrophobicity on 
the metal complex moiety. Also the chelated-diphosphine complexes 7(a)-(d) have shown 
high anticancer activity against the four cancer cells relative to the monodentate 
bis(phosphine) complex 6.  
The carbon chain length on the diphosphine complexes plays a key role in the activity of the 
bridged-diphosphine osmium complexes. The shorter chain length of the bridged-diphosphine 
binuclear complexes exhibit enhanced anticancer activity against cancer cell lines compared 
to the longer carbon chain length of the bridged-diphosphine binuclear complexes.  
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5.5 Future work 
 
The mechanisms of action of the most potent complexes need further investigation. 
Complexes with activity lower than 1μM may be subjected to DNA binding studies in order 
to understand the selectivity of the complexes. 
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CHAPTER 6  
 
EXPERIMENTAL 
 
6.1 Standard procedures and materials 
All synthetic procedures were carried under an argon atmosphere using standard Schlenk 
techniques unless otherwise stated in the relevant synthetic method. All solvents, phosphine 
(ddpm, dppe, dppp, dppb and PPh3) and tropolone ligands used were obtained from Sigma-
Aldrich. Potassium osmate salt was kindly donated by Anglo-Platinum research laboratory. 
Phellandrene was purchased from Fluka and used as received. The (NH4)2C2O4∙H2O used was 
purchased from Kanto Chemical Co. Inc. and used as received. The Ag2C2O4 used was 
prepared in our laboratory from AgNO3 and (NH4)2C2O4∙H2O according to literature 
methods.1  Solvents were dried and purified by standard methods. Methanol was dried by 
distilling over Mg/I2, acetonitrile (CH3CN) over calcium hydride (CaH2), dichloromethane 
(CH2Cl2) stored over calcium chloride (CaCl2) for 24 hours followed by distillation over 
calcium hydride and nitrobenzene (C6H5NO2) was dried over phosphorus pentaoxide (P2O5) 
followed by distillation prior to use. 
 
6.2 Instrumentation 
 
Agilent technologies 500 MHz premium Compact NMR was used to collect data 1H (500 
MHz), 13C (125 MHz), 19F (470 MHz) and 31P (202 MHz). IR data was collected from Bruker 
vertex 70 FTIR instrument employing ATR with diamond crystal. The data was collected 
within the spectral range of 400 - 4000 cm-1, resolution of 4 and 32 numbers of scans.  Raman 
data was also collected from the Bruker Raman II instrument within the spectral range 0 – 
5000 cm-1, resolution 4 and 128 numbers of scans employing laser with pellets.  
Elemental Analysis data were obtained from Carlo Erba NA 1500 Nitrogen Carbon Sulphur 
Analyser. The instrument uses Gas Chromatography (GC) to separate the gases, i.e. N (in the 
form of N2), C (in the form of CO2) and S (in the form of SO2), using a He carrier gas and a 
thermal conductivity detector. The instrument is from Agricultural Research Council-Institute 
for Soil, Climate and Water analysed by Mr. M. Philport. Thermogravimetric Analysis of the 
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all complexes in this study was carried out with Thermogravimetric analyser (TGA/DSC) 
SQ600 between 50 and 800 ºC at a heating rate 20 ºC/min and gas flow rate of 10 mL/min 
under nitrogen atmosphere in our laboratories. Conductance data was collected from the 
Metrohm 644 conductometer in our laboratory. 
Single crystal XRD data were obtained from the diffractometer Bruker Venture D8 Photon 
CMOS with graphite-monochromated MoKα1 (λ = 0.71073 Å) radiation at 173 K using an 
Oxford Cryostream 600 cooler at Wits University collected by Professor A. Lemmerer. 
Ms. N. Kolesnikova at the CSIR Boiscience laboratories carried out anticancer testing. 
 
6.3 Methods for cancer testing against four cancerous cell lines 
 
The human cell lines TK10, UACC62 and MCF7 and were obtained from the National 
Cancer Institute (NCI) in the framework of collaborative research program between CSIR 
and NCI. The TK10, UACC62 and MCF-7 cell lines were routinely maintained as monolayer 
cell culture at 37 ºC, 5% CO2, 95% air and 100% relative humidity in RPMI containing 5% 
fetal bovine serum, 2 mM L-glutamine and 50 μg/ml gentamicin.   
For screening experiment of TK10, UACC62 and MCF-7, the cells (3-19 passages) were 
inoculated in a 96-well microtiter plates at plating densities of 7-10 000 cells/well and were 
incubated for 24 h. After 24 h the cells were treated with the experimental osmium complexes 
which were previously dissolved in DMSO and diluted in medium to produce 5 
concentrations. Cells without osmium complex addition served as control. The blank contains 
complete medium without cells. Parthenolide was used as a standard. 
The HeLa cell line (Human Negroid cervix epitheloid adenocarcinoma, ECACC) was 
routinely maintained as a monolayer cell culture at 37 oC, 5% CO2, 95% air and 100% 
relative humidity in EMEM containing 5% fetal bovine serum, 2 mM L-glutamine and 50 
μg/ml gentamicin.   
For screening experiment of HeLa, the cells (3-16 passages) were inoculated in a 96-well 
microtiter plates at plating densities of 7 000 cells/well and were incubated for 24 h. After 24 
h the cells were treated with the experimental osmium complexes which were previously 
dissolved in DMSO and diluted in medium to produce 5 concentrations. Cells without the 
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osmium complex addition served as control. The blank contains complete medium without 
cells. Emetine was used as a standard. 
All the plates were incubated for 48 h after addition of osmium complexes. Viable cells were 
fixed to the bottom of each well with cold 50% trichloroacetic acid, washed, dried and dyed 
by Sulforhodamine B (SRB). Unbound dye was removed and protein-bound dye was 
extracted with 10mM Tris base for optical density determination at the wavelength 540 nm 
using a multiwell spectrophotometer.  
Data analysis was performed using GraphPad Prism software. The 50% of cell growth 
inhibition (IC50) was determined by non-linear regression. 
6.3.1 Assay conditions 
 
The samples (14) were screened with the following assay conditions: samples were tested at 
concentrations of 100 – 0.01 μM (5 × 10-fold serial dilutions), reference standards of 
Parthenolide (100 – 0.01 μM) and Emetine (100 – 0.01 μM, 5 × 10-fold serial dilutions), the 
absorbance reading was recorded at 540 nm and the assay prerequisites of *Z’ factor > 0.5. 
 
6.4 Preparation of complexes 
 
6.4.1 Synthesis of starting material [Os(η6-p-cymene)Br2]2 
 
The osmium dimer [Os(η6-p-cymene)Br2]2 was used as starting material for the synthesis of 
the osmium cymene complexes studied in this work. The preparation of the starting material 
was followed as reported in the literature.2 
6.4.2 Preparation of 1(a) Ag[Os(η6-p-cymene)Br(2-O,Oʹ-C2O4)] 
 
The starting material [Os(η6-p-cymene)Br2]2 (2.130 g, 2.20 mmol) and excess Ag2C2O4 
(2.757 g, 9.08 mmol) were stirred in CH2Cl2/CH3OH solution (100 mL 1:1 v/v) at room 
temperature overnight. The Schlenk tube was covered with aluminium foil to prevent 
decomposition of silver oxalate to AgO by UV radiation.  The milky yellow solution was 
filtered to remove AgBr formed and unreacted Ag2C2O4 salt. The yellow filtrate developed 
yellow and grey suspensions on standing. The solvent was removed in vacuo and the yellow 
precipitate was dissolved in CH2Cl2 (10 mL) and the grey precipitate was filtered off. The 
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solvent was removed again in vacuo under reduced pressure resulting in a yellow product. 
The product was dried in vacuo. Yield 55% (1.437 g, 2.40 mmol). 1H NMR (500 MHz, dmso-
d6) δ: 1.24 (d, 6H, CH(CH3)2, J(HH) = 6.9 Hz); 2.17 (s, 3H, CH3C6H4); 2.67 (sept, 1H, 
CH(CH3)2, J(HH) = 6.8 Hz); 6.09 (d, 2H, η6-C6H4, J(HH) = 6.4 Hz); 6.22 (d, 2H, η6-C6H4, J(HH) = 
5.9 Hz). 13C{1H} NMR δ: 17.25 CH3C6H4; 22.34 CH(CH3)2; 30.65 CH(CH3)2; {95.41, 90.77, 
78.80, 77.46} η6-C6H4; 163.78 (CO). IR (cm-1): νasym(OCO) 1688vs/1671sh/1640sh, 
1595vs/1574sh; νsym(OCO) + ν(CC) 1457vw/1422m; νsym(OCO) 1265m; ν(CC) 911vw/876w; ν(CC) + 
δ(OCO) 794s.  
6.4.3 Preparation of 1(b) PPh4[Os(η6-p-cymene)Br(2-O,Oʹ-C2O4)] 
Complex 1(a) (0.507 g, 0.84 mmol) was dissolved in CH2Cl2 (50 mL). To this was added a 
solution of tetraphenylphosphonium bromide (PPh4Br) (0.426 g, 1.02 mmol) in CH2Cl2 (20 
mL) mixed dropwise with stirring for 30 minutes at room temperature. The yellow solution 
was reduced to ca. 20mL. Hexane (40mL) was added dropwise, the solution shaken to give 
bright yellow suspension, which was washed with hexane for 2 h. The bright yellow product 
was isolated by filtration and dried in vacuo. Yield 74% (0.522 g, 0.63 mmol). 1H NMR (500 
MHz, CDCl3): 1.27 (d, 6H, CH(CH3)2, J(HH) = 6.8 Hz); 2.23 (s, 3H, CH3C6H4); 2.80 (sept, 1H, 
CH(CH3)2, J(HH) = 6.9 Hz); 5.64 (d, 2H, η6-C6H4, J(HH) = 5.9); 5.91 (d, 2H, η6-C6H4, J(HH) = 5.4 
Hz); 7.57 ˗ 7.91 (m, 20H, PPh4). 13C{1H} NMR δ: 18.91 CH3C6H4; 23.01 CH(CH3)2; 31.66 
CH(CH3)2; {117.82, 117.15, 71.76, 68.86} η6-C6H4; 130.79 – 135.75 CAromatic; 166.90 (CO). 
31P{1H}: 24.06 (s, PPh4). IR (cm
-1): νasym(OCO) 1695s/1674s/1653s; νsym(OCO) + ν(CC) 
1483w/1436m; νsym(OCO) 1378s/1317w; ν(CC) 910vw/886vw; ν(CC) + δ(OCO) 787s. Elemental 
analysis (%) for C36H34BrO4OsP ∙ 0.1 mol CH3(CH2)4CH3: Calculated – C 51.98, H 4.12; 
found – C 52.26, H 4.46.  
 
6.4.4 Preparation of 2 [Os(η6-p-cymene)Br(2-O,Oʹ-C2O4)PPh3] 
 
The method for preparation of complexes 2 was adopted from Yan and co-workers with some 
modifications.3 Complex 1(a) (0.354 g, 0.59 mmol) and an excess PPh3 (0.570 g, 2.17 mmol) 
were placed into the Schlenk tube. The solids were dissolved in CH2Cl2/CH3OH (1:1 20 mL) 
solution. The orange yellow solution was stirred with reflux at 44 ºC overnight. The yellow 
solution was cooled to room temperature and filtered. The solvent was removed in vacuo to 
yield yellow oil. The yellow oil was washed in hexane over 24 h. The yellow precipitate was 
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obtained by filtration and dried in vacuo. Yield 79% (0.316 g, 0.47 mmol) 1H NMR (500 
MHz, CDCl3) δ: 1.16 (d, 6H, CH(CH3)2, J(HH) = 6.9 Hz); 2.01 (s, 3H, CH3C6H4); 2.47 (sept, 
1H, CH(CH3)2, J(HH) = 6.8 Hz); 5.29 (d, 2H, η6-C6H4, J(HH) = 5.4 Hz); 5.51 (d, 2H, η6-C6H4, 
J(HH) = 5.9 Hz); 7.41 ˗ 7.50 (m, 15H, Ph). 13C{1H} NMR δ: 18.04 CH3C6H4; 22.70 CH(CH3)2; 
31.00 CH(CH3)2; {98.82 (J = 3 Hz), 88.39, 79.35 (J = 5 Hz), 79.10 (J = 4 Hz)} η6-C6H4; 
128.91 ˗ 134.40 CAromatic; 164.22 CO. 31P{1H}: 1.78 (s, PPh3). IR (cm-1): νasym(OCO) 
1706sh/1693s/1669s; νsym(OCO) + ν(CC) 1482vw/1433w; νsym(OCO) 1371sh/1363sh/1356s; ν(CC) 
904vw/875w; ν(CC) + δ(OCO) 786s. Elemental analysis (%) for C30H29O4OsP: Calculated – C 
53.40, H 4.33; found – C 53.40, H 4.24.  
6.4.5 Preparation of 3 [Os(η6-p-cymene)Br(2-O,Oʹ-C7H5O2)] 
 
The procedure for preparation of complex 3 was adopted from Melchart and co-workers.4 
The starting material [Os(η6-p-cymene)Br2]2 (1.037 g, 1.07 mmol) and sodium tropolonate 
(0.448 g, 3.11 mmol) were weighed into a Schlenk tube. Methanol (100 mL) was added to the 
Schlenk tube and the reddish-orange solution was stirred overnight at room temperature. A 
dark brown solution was obtained. The solution was filtered and the solvent was removed in 
vacuo. The product was extracted with CH2Cl2 (80 mL). The resulting solution was reduced 
to ca. 20mL and hexane (40 mL) was added into the brown solution and shaken to give an 
opaque solution. Then the solution was filtered again to give a reddish solution. The solvent 
was removed to give a dark brown precipitate and dried in vacuo. Yield 72% (0.807 g, 1.54 
mmol). 1H NMR (500 MHz, CDCl3) δ: 1.29 (d, 6H, CH(CH3)2, J(HH) = 6.9 Hz); 2.38 (s, 3H, 
CH3C6H4); 2.76 (sept, 1H, CH(CH3)2, J(HH) = 6.9 Hz); 5.78 (d, 2H, η6-C6H4, J(HH) = 5.5 Hz); 
6.00 (d, 2H, η6-C6H4, J(HH) = 5.8 Hz); 6.80 – 6.87 (tt, 1H, trop-O,Oʹ, J(HH) = 8.8 Hz); 7.20 – 
7.31 (m, 4H, trop-O,Oʹ). 13C{1H} NMR δ: 19.56 CH3C6H4; 23.00 CH(CH3)2; 32.02 
CH(CH3)2; {91.00, 87.26, 71.76, 69.63} η6-C6H4; 185.85 (CO); 127.42 – 138.07 (trop-C). IR 
(cm-1): ν(CC) 1588s; ν(CO) + ν(CC) 1512s; ν(CC) 1424vs; δ(CH) 1407vs; ν(CO) 1353/1341. Elemental 
analysis (%) for C17H19BrO2Os: Calculated – C 38.86, H 3.64; found – C 38.73, H 3.72.  
6.4.6 Preparation of 4 [{Os(η6-p-cymene)Br}2 (μ-C2O4)] 
 
The method for the preparation of 4 was adopted from Yan and co-workers with some 
modifications.3 The starting material [Os(η6-p-cymene)Br2]2 (2.348 g, 2.43 mmol) and excess 
(NH4)2C2O4∙H2O (4.180 g, 29.53 mmol) were stirred in CH2Cl2/CH3OH solution (40 mL 1:1 
v/v) at room temperature overnight. The NH4Br salt formed was filtered off. The yellow 
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filtrate was concentrated to ca. 5 mL under reduced pressure to produce yellow oil. The oil 
was redissolved in CH2Cl2 (10 mL) and diethyl ether (20 mL) was added dropwise. The 
yellow product was obtained by filtration then washed with ethanol (30 mL) and diethyl ether 
(20 mL). The precipitate was dried in vacuo. Yield 82% (1.785 g, 1.99 mmol).1H NMR (500 
MHz, CDCl3) δ: 1.32 (d, 6H, CH(CH3)2, J(HH) = 6.8 Hz); 2.28 (s, 3H, CH3C6H4); 2.77 (sept, 
1H, CH(CH3)2, J(HH) = 6.8 Hz); 5.97 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 6.21 (d, 2H, η6-C6H4, 
J(HH) = 5.9 Hz). 
13C{1H} NMR δ: 19.51 CH3C6H4; 22.94 CH(CH3)2; 32.07 CH(CH3)2; {90.68, 
86.64, 71.97, 69.75} η6-C6H4; 175.39 (CO). IR (cm-1): νasym(C-O) 1611vs; νsym(OCO) 
1387/1341vs; νsym(OCO) + ν(CC) 1468w; ν(CC) 891sh/881w; ν(CC) + δ(OCO) 803sh/796w. 
Elemental analysis (%) for C22H28Br2Os2: Anal. Found – C 29.44, H 3.19. C22H28Br2Os2 
Calculated – C 29.47, H 3.15.  
6.4.7 Preparation of 5 [Os(η6-p-cymene)Br2(PPh3)] 
 
The method for the preparation of 5 was adopted with modifications from Clayton and co-
workers.2 The starting material [Os(η6-p-cymene)Br2]2 (0.202 g, 0.21 mmol) and PPh3 (0.130 
g, 0.50 mmol) were dissolved in dichloromethane (20 mL). The reddish-orange solution was 
stirred overnight at room temperature. A reddish-orange solution was obtained and the 
solvent was removed in vacuo. The orange precipitate obtained was washed with hexane (30 
mL) overnight. The orange precipitates were obtained by filtration then dried in vacuo. Yield 
70% (0.218 g, 0.29 mmol) 1H NMR (300 MHz, CDCl3) δ: 1.17 (d, 6H, CH(CH3)2, J(HH) = 7.0 
Hz); 1.96 (s, 3H, CH3C6H4); 2.98 (sept, 1H, CH(CH3)2, J(HH) = 7.0 Hz); 5.11 (d, 2H, η6-C6H4, 
J(HH) = 5.3 Hz); 5.46 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 7.31 ˗ 7.75 (m, 15H, Ph). 13C{1H} 
NMR δ: 18.38 CH3C6H4; 22.54 CH(CH3)2; 30.72 CH(CH3)2; {104.70, 89.40, 81.21 (J = 5 
Hz), 80.13 (J = 2 Hz)} η6-C6H4; 128.91 ˗ 134.40 CAromatic; 164.22 CO. 31P{1H}: 17.55 (s, 
PPh3). 
6.4.8 Attempted preparation of [{Os(η6-p-cymene)(PPh3)}2 μ-C2O4](BF4)2 
 
The procedure for the attempted preparation of [{Os(η6-p-cymene)(PPh3)}2 μ-C2O4](BF4)2 
was adopted from Yan and co-workers.3 Complex 4 (0.516 g, 0.58 mmol) and excess PPh3 
(1.500 g, 5.72 mmol) were placed in a Schlenk tube. To this was added NH4BF4 (0.157 g, 
1.50 mmol) and dissolved in CH2Cl2 (20 mL). A yellow solution was stirred at room 
temperature overnight. The reddish-orange solution was filtered and the solvent was removed 
in vacuo to give reddish-orange oil. The oil was washed with (60 mL) hexane for 72 h with 
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decanting the hexane solution. The orange product was obtained by filtration and dried in 
vacuo. Yield 76% (0.625 g, 0.44 mmol). 1H NMR (500 MHz, CDCl3) δ: 1.17 (d, 6H, 
CH(CH3)2, J(HH) = 6.9 Hz); 1.18 (d, 6H, CH(CH3)2, J(HH) = 6.9 Hz); 1.94 (s, 3H, CH3C6H4); 
2.01 (s, 3H, CH3C6H4); 2.47 (sept, 1H, CH(CH3)2, J(HH) = 6.8 Hz); 2.96 (sept, 1H, CH(CH3)2, 
J(HH) = 7.0 Hz); 5.10 (d, 2H, η6-C6H4, J(HH) = 5.4 Hz); 5.30 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 
4.45 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 5.52 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 7.31 ˗ 7.73 (m, 
30H, Ph). 13C{1H} NMR δ: 18.02, 18.33 CH3C6H4; 22.49, 22.71 CH(CH3)2; 30.65, 30.98 
CH(CH3)2; {104.61 (J = 6 Hz), 98.75 (J = 3 Hz), 89.37, 88.41, 81.15 (J = 5 Hz), 80.10 (J = 2 
Hz), 79.36 (J = 5 Hz), 79.10 (J = 4 Hz)} η6-C6H4; 127.82-134.97 CAromatic; 164.23 CO. 
31P{1H}: 1.77, 17.54 (s, 2PPh3). IR (cm-1): νasym(OCO) 1705s, 1694s; ν(OCO) 1670s. Elemental 
analysis (%) for C58H58Br2O4Os2P2: Calculated – C 48.54, H 4.07; found – C 46.96, H 3.95.   
6.4.9 Preparation of 6 [Os(η6-p-cymene)Br(PPh3)2]BF4 
 
The complex [Os(η6-p-cymene)Br(NCCH3)2]BF4 (2.068 g, 3.61 mmol) was reacted with 
excess PPh3 (3.632 g, 13.85 mmol) in CH2Cl2 (50 mL). The orange solution was stirred at 
room temperature overnight. The reddish-orange solution was filtered and the solvent was 
removed in vacuo. Reddish-orange oil was obtained and washed with hexane (80 mL) over 
48 hours. The reddish-orange precipitate was obtained by filtration and dried in vacuo. Yield 
77% (2.803 g, 2.76 mmol). 1H NMR (500 MHz, CDCl3) δ: 1.20 (d, 6H, CH(CH3)2, J(HH) = 6.9 
Hz); 2.15 (s, 3H, CH3C6H4); 2.75 (sept, 1H, CH(CH3)2, J(HH) = 7.0 Hz); 5.23 (d, 2H, η6-C6H4, 
J(HH) = 5.9 Hz); 5.80 (d, 2H, η6-C6H4, J(HH) = 2.9 Hz); 7.23 ˗ 7.37 (m, 30H, Ph). 13C{1H} 
NMR δ: 15.30 CH3C6H4; 21.79 CH(CH3)2; 31.63 CH(CH3)2; {96.42, 89.37, 81.30, 73.13} η6-
C6H4; 128.31 ˗ 134.71 CAromatic. 19F{1H} NMR δ: 157.67, 157.72. 31P{1H}: 28.94 (s, 
2PPh3). IR (cm
-1): ν(B-F) 1052s.  
 
6.4.10 Preparation of 7(a)-(d) [Os(η6-p-cymene)(2-PPh2(CH2)nPPh2)Br]BF4 (n = 1 - 4) 
 
Complexes 7(a)-(d) were synthesized by the general method below adopted from literature 
by Jensen et al. with modifications.5 
The complex [Os(η6-p-cymene)(NCCH3)2Br]BF4 was weighed into the Schlenk tube. To this 
was added PPh2(CH2)nPPh2 (where n = 1 – 4). Dichloromethane (50 mL) was then added and 
the resulting solution was stirred at room temperature overnight. A yellow-brown solution 
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was filtered and the solvent was reduced to ca. 10 mL in vacuo. Diethyl ether (20mL) was 
added and solution cooled to 15 ºC for 24 h. The yellow product was washed with hexane 
for 72 h. The yellow product was obtained by filtration and dried in vacuo. The quantities of 
starting materials used for the four complexes are given below.  
For preparation of complex 7(a): [Os(η6-p-cymene)(NCCH3)2Br]BF4 (1.202 g, 2.10 mmol) 
and dppm (1.105 g, 2.87 mmol). The product was obtained as a bright yellow solid. Yield 
91% (1.673 g, 1.91 mmol). 1H NMR (500 MHz, dmso-d6) δ: 0.91 (d, 6H, CH(CH3)2, J(HH) = 
6.9 Hz); 1.45 (s, 3H, CH3C6H4); 2.20 (sept, 1H, CH(CH3)2, J(HH) = 6.8 Hz); 4.77, 4.68 (dd, 
2H, PCH2P); 6.31 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 6.45 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 7.26 
˗ 7.67 (m, 20H, Ph). 13C{1H} NMR δ: 16.37 CH3C6H4; 21.64 CH(CH3)2; 29.86 CH(CH3)2; 
43.69 PCH2P; {112.98, 95.79, 84.37, 81.07} η6-C6H4; 128.44 ˗ 131.70 CAromatic. 19F{1H} 
NMR δ: 143.46, 143.52. 31P{1H} NMR δ: 43.52 (s, dppm). IR (cm-1): ν(B-F) 1046s.  
For preparation of complex 7(b): [Os(η6-p-cymene)(NCCH3)2Br]BF4 (1.203 g, 2.10 mmol) 
and dppe (0.879 g, 2.21 mmol). The product was obtained as a yellow solid. Yield 70% 
(1.308 g, 1.47 mmol). 1H NMR (500 MHz, CDCl3) δ: 0.89 (d, 6H, CH(CH3)2, J(HH) = 7.0 Hz); 
1.26 (s, 3H, CH3C6H4); 2.38 (sept, 1H, CH(CH3)2, J(HH) = 6.7 Hz); 2.65, 2.99 (m, 2H, PCH2); 
5.87 (d, 2H, η6-C6H4, J(HH) = 4.1 Hz); 6.01 (d, 2H, η6-C6H4, J(HH) = 6.4 Hz); 7.21-7.77 (m, 
20H, Ph). 13C{1H} NMR δ:1 5.52 CH3C6H4; 21.44 CH(CH3)2; 30.50 CH(CH3)2; 27.80, J(P-C) 
= 24 Hz, PCH2; 29.72 PCH2CH2; {117.56, 95.40, 85.96 (J = 3 Hz), 83.41 (J = 8 Hz)} η6-
C6H4; 128.70 – 135.97 CAromatic. 19F{1H} NMR δ: 152.86, 152.92. 31P{1H} NMR δ: 30.92 
(s, dppe). IR (cm-1): ν(B-F) 1061s. Elemental analysis (%) for C36H38BBrF4OsP2: Calculated – 
C 48.61, H 4.31; found – C 48.37, H 4.51. 
For preparation of complex 7(c): [Os(η6-p-cymene)(NCCH3)2Br]BF4 (2.053 g, 3.58 mmol) 
and dppp (1.513 g, 3.67 mmol). The product was obtained as a yellow solid. Yield 73% 
(2.374 g, 2.63 mmol). 1H NMR (500 MHz, CDCl3) δ: 0.75 (d, 6H, CH(CH3)2, J(HH) = 6.8 Hz); 
1.37 (s, 3H, CH3C6H4); 1.77 ˗ 2.54 (m, 2H, PCH2CH2CH2P); 2.46 (sept, 1H, CH(CH3)2, J(HH) 
= 6.8 Hz); 3.21 (m, 2H,PCH2); 5.58 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 5.97 (d, 2H, η6-C6H4, 
J(HH) = 5.4 Hz); 7.25 ˗ 7.55 (m, 20H, Ph). 13C{1H} NMR δ: 15.60 CH3C6H4; 21.12 CH(CH3)2; 
21.47 PCH2CH2; 23.79, J = 20 Hz, PCH2; 30.54 CH(CH3)2; {94.00, 86.32, 85.15, 70.60} η6-
C6H4; 128.73 ˗ 136.02 CAromatic. 19F{1H} NMR δ: 152.51, 152.56. 31P{1H} NMR δ: 25.00 
(s, dppp). IR (cm-1): ν(B-F) 1061s.  
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For preparation of complex 7(d): [Os(η6-p-cymene)(NCCH3)2Br]BF4 (2.032 g, 3.55 mmol) 
and dppb (1.593 g, 3.74 mmol). The product was obtained as a yellow solid. Yield 72% 
(2.339 g, 2.55 mmol). 1H NMR (500 MHz, CDCl3) δ: 0.97 (d, 6H, CH(CH3)2, J(HH) = 6.9 Hz); 
1.17 (s, 3H, CH3C6H4); 1.58 ˗ 2.27 (m, 4H, PCH2CH2CH2CH2P); 2.65 (sept, 1H, CH(CH3)2, 
J(HH) = 7.1 Hz); 3.90 (m, 2H,PCH2); 5.05 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 5.80 (d, 2H, η6-
C6H4, J(HH) = 5.4 Hz); 7.31 ˗ 7.58 (m, 20H, Ph). 13C{1H} NMR δ: 14.99 CH3C6H4; 21.57 
CH(CH3)2; 22.66 PCH2CH2; 28.83 PCH2; 30.70 CH(CH3)2; {126.25, 92.45, 87.53, 83.32} η6-
C6H4; 128.88 ˗ 133.35 CAromatic. 19F{1H} NMR δ: 152.85, 152.91. 31P{1H} NMR δ: 17.10 
(s, dppb). IR (cm-1): ν(B-F) 1061s. Elemental analysis (%) for C38H42BBrF4OsP2 ∙ 0.3(CH2Cl2): 
Calculated – C 49.74, H 4.61; found – C 48.85, H 4.64. 
6.4.11 Preparation of 8(a)-(d) [{Os(η6-p-cymene)Br2}2 μ-PPh2(CH2)nPPh2] (n = 1 - 4) 
 
Complexes 8(a)-(d) were prepared by the general method below. 
The starting material [Os(η6-p-cymene)Br2]2 was weighed in a Schlenk tube and dissolved in 
CH2Cl2 (20 mL). To this was added a solution of PPh2(CH2)nPPh2 (where n = 1 − 4) in 
CH2Cl2 (20 mL) dropwise over 4 h. The resulting reddish-orange solution was stirred at room 
temperature overnight. The reddish-orange solution was filtered and then the filtrate was 
reduced to ca. 10 mL in vacuo. Diethyl ether (20 mL) was added to give an orange 
precipitate. The orange precipitate was washed with hexane (40 mL) over 72 h to remove 
excess diphosphine. The product was obtained by filtration and dried in vacuo. The quantities 
of starting materials used for preparation of the four complexes are found below. 
For preparation of 8(a): [Os(η6-p-cymene)Br2]2 (1.194 g, 1.23 mmol) and  dppm (0.509g, 
1.32mmol). Yield 82% (1.374 g, 1.02 mmol). 1H NMR (500 MHz, CDCl3) δ: 0.94 (d, 6H, 
CH(CH3)2, J(HH) = 6.4 Hz); 1.90 (b, 2H,PCH2); 2.09 (s, 3H, CH3C6H4); 2.52 (sept, 1H, 
CH(CH3)2, J(HH) = 6.9 Hz); 4.88 (virtual triplet, 1H,CH2, J(HH) = 7.3 Hz); 5.07 (d, 2H, η6-
C6H4, J(HH) = 4.7 Hz); 5.31 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 7.04 ˗ 7.59 (m, 20H, Ph). 
13C{1H} NMR δ: 18.71 CH3C6H4; 22.49 CH(CH3)2; 30.45 CH(CH3)2; 53.65 PCH2P; {101.66, 
87.52, 82.95, 78.28} η6-C6H4; 127.04-134.54 CAromatic. 31P{1H} δ: 28.73 (s, dppm). 
Elemental analysis (%) for C45H50Br4Os2P2: Calculated – C 39.95, H 3.73; found – C 39.94, 
H 3.72.  
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For preparation of 8(b): [Os(η6-p-cymene)Br2]2 (2.093 g, 2.16 mmol) and dppe (0.862 g, 2.16 
mmol). Yield 84% (2.471 g, 1.81 mmol). 1H NMR (500 MHz, CDCl3) δ: 0.79 (d, 6H, 
CH(CH3)2, J(HH) = 6.9 Hz); 0.95 (b, 4H,PCH2CH2); 1.95 (s, 3H, CH3C6H4); 2.48 (sept, 1H, 
CH(CH3)2, J(HH) = 6.9 Hz); 2.64 (b, 4H,PCH2); 5.15 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 5.29 (d, 
2H, η6-C6H4, J(HH) = 5.9 Hz); 7.24 ˗ 7.52 (m, 20H, Ph). 13C{1H} NMR δ: 17.80 CH3C6H4; 
19.30 PCH2CH2; 21.87 CH(CH3)2; 26.72 (J = 23 Hz) PCH2; 30.22 CH(CH3)2; {100.59, 
86.19, 82.72 (J = 3 Hz), 78.09 (J = 6 Hz)} η6-C6H4; 128.05 – 133.48 CAromatic. 31P{1H} δ: 
25.22 (s, dppe). Elemental analysis (%) for C46H52Br4Os2P2: Calculated – C 40.42, H 3.83; 
found – C 40.47, H 3.92.  
For preparation of 8(c): [Os(η6-p-cymene)Br2]2 (0.502 g, 0.52 mmol) and dppp (0.300 g, 0.73 
mmol). Yield 84% (0.597 g, 0.43 mmol). 1H NMR (500 MHz, CDCl3) δ: 0.82 (d, 6H, 
CH(CH3)2, J(HH) = 7.0 Hz); 0.99 (b, 4H,PCH2CH2); 1.97 (s, 3H, CH3C6H4); 2.51 (sept, 1H, 
CH(CH3)2, J(HH) = 6.9 Hz); 2.66 (b, 4H,PCH2); 5.17 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 5.31 (d, 
2H, η6-C6H4, J(HH) = 5.3 Hz); 7.24 ˗ 7.56 (m, 20H, Ph). 13C{1H} NMR δ: 17.61 CH3C6H4; 
19.14 PCH2CH2; 21.91 CH(CH3)2; 26.52 (J = 15 Hz) PCH2; 30.04 CH(CH3)2; {100.43, 
85.98, 82.50, 77.90 (J = 6 Hz)} η6-C6H4; 127.85-133.33 CAromatic. 31P{1H} δ: 25.35 (s, 
dppp). Elemental analysis (%) for C47H54Br4Os2P2: Calculated – C 40.88, H 3.94; found – C 
39.55, H 3.94. 
For preparation of 8(d): [Os(η6-p-cymene)Br2]2 (0.514 g, 0.53 mmol) and dppb (0.295 g, 0.69 
mmol). Yield 82% (0.606 g, 0.43 mmol). 1H NMR (500 MHz, CDCl3) δ: 0.75 (d, 6H, 
CH(CH3)2, J(HH) = 7.0 Hz); 0.91 (b, 4H, PCH2CH2); 1.98 (s, 3H, CH3C6H4); 2.49 (sept, 1H, 
CH(CH3)2, J(HH) = 7.0 Hz); 2.51 (b, 4H,PCH2); 5.20 (d, 2H, η6-C6H4, J(HH) = 5.9); 5.36 (d, 
2H, η6-C6H4, J(HH) = 5.3); 7.27 ˗ 7.68 (m, 20H, Ph). 13C{1H} NMR δ: 17.49 CH3C6H4; 21.48 
CH(CH3)2; 22.65 PCH2CH2; 29.69 PCH2; 30.03 CH(CH3)2; {99.86, 85.45, 82.81, 77.92} η6-
C6H4; 128.11-133.39 CAromatic. 
31P{1H}: 23.77 (s, dppb). Elemental analysis (%) for 
C48H56Br4Os2P2 ∙ 0.5(CH2Cl2): Calculated – C 41.33, H 4.05; found – C 40.41, H 4.17.  
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6.4.12 Preparation of 9 [Os(η6-p-cymene)(NCCH3)2Br]BF4  
 
The starting material [Os(η6-p-cymene)Br2]2 (5.226 g, 5.39 mmol) was weighed into the 
Schlenk tube. To this was added a solution of NH4BF4 (1.14 g, 10.89 mmol) in CH3CN (100 
mL) to give an orange solution which was stirred at room temperature overnight. The yellow-
orange solution was filtered to remove NH4Br. The solvent was reduced in vacuo to give an 
orange oil. Dichloromethane (30 mL) was added to redissolve the oily product and diethyl 
ether (50 mL) was also added to make a two layer solution which was left to precipitate over 
24 h at room temperature. A yellow precipitate was obtained by filtration then dried in vacuo. 
Yield 75% (4.629 g, 8.08 mmol). 1H NMR (500 MHz, CDCl3) δ: 1.26 (d, 6H, CH(CH3)2 J(HH) 
= 6.8 Hz); 2.34 (s, 3H, CH3C6H4); 2.74 (s, 6H, NCCH3); 2.80 (sept, 1H, CH(CH3)2 J(HH) = 6.8 
Hz); 5.86 (d, 2H, η6-C6H4 J(HH) = 5.9 Hz); 6.05 (d, 2H, η6-C6H4 J(HH) = 5.9 Hz). 13C{1H} 
NMR δ: 4.19 NCCH3; 18.97 CH3C6H4; 22.63 CH(CH3)2; 31.40 CH(CH3)2; {97.67, 94.41, 
78.69, 75.74} η6-C6H4; 122.09 NC. 19F{1H} NMR δ: 151.84, 151.89. IR (cm-1): ν(NC) 
2331w, 2303w; ν(B-F) 1052s.  
6.4.13 Preparation of 10 [Os(η6-p-cymene)(NCCH3)Br(PPh3)]BF4 
 
Complex 9 (2.073 g, 3.62 mmol) and one mole equivalent of PPh3 (0.961 g, 3.66 mmol) were 
placed in a Schlenk tube. Dichloromethane (30mL) was added to give a brownish solution 
which was stirred at room temperature overnight. The brownish-orange solution was filtered 
and the solvent was removed in vacuo to give yellow oil.  The yellow oil was washed in 
hexane for 24 h to remove unreacted PPh3. The yellow precipitate was obtained by filtration 
and dried in vacuo. Yield 86% (2.413g, 3.10mmol). 1H NMR (500 MHz, CDCl3) δ: 1.24 (d, 
6H, CH(CH3)2, J(HH) = 6.9 Hz), 1.32 (d, 6H, CH(CH3)2, J(HH) = 6.8 Hz); 1.88 (s, 6H, 
CH3C6H4); 2.18 (s, 3H, NCCH3); 3.00 (sept, 1H, CH(CH3)2, J(HH) = 6.8 Hz); 4.75 (d, 2H, η6-
C6H4, J(HH) = 5.9); 5.66 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 5.89 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 
6.46 (d, 2H, η6-C6H4, J(HH) = 5.4 Hz); 7.23 – 7.57 (m, 15H, Ph). 13C{1H} NMR δ: 3.32 
(NCCH3); 18.36 CH3C6H4; 20.92 CH(CH3)2; 31.06 CH(CH3)2; {121.92, 109.88 (J=7 Hz), 
96.99, 89.14 (J = 6 Hz), 83.43, 80.61} η6-C6H4; 130.05 (NC); 128.72 – 135.07 CAromatic. 
19F{1H} NMR δ: 152.31, 152.37. 31P{1H} δ: 24.06 (s, PPh3). IR (cm-1): ν(NC) 2322w; ν(B-
F) 1054s. 
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6.4.14 Preparation of 11 [Os(η6-p-cymene)(C7H8N2O)Br2] 
 
The starting material [Os(η6-p-cymene)Br2]2 (1.118 g, 1.15 mmol) and an excess of 2-
aminobenzamide (C7H8N2O) (0.698 g, 5.13 mmol) were placed in a Schlenk tube. To this 
was added NH4BF4 (0.328 g, 3.13 mmol) and CH2Cl2 (40 mL). The reddish-orange solution 
was stirred at room temperature overnight. The reaction mixture was filtered to remove a 
white suspension of unreacted NH4BF4. The solvent was then removed under reduced 
pressure to give a yellow-brownish solid. The yellow-brownish solid was washed with 
CH2Cl2 (30 mL) to remove impurities. The yellow solid was isolated by filtration and dried in 
vacuo. Yield 81% (1.172 g, 1.87 mmol). 1H NMR (500 MHz, CDCl3) δ: 1.20 (d, 6H, 
CH(CH3)2, J(HH) = 7.0 Hz); 2.22 (s, 3H, CH3C6H4); 2.83 (sept, 1H, CH(CH3)2, J(HH) = 7.0 Hz); 
3.34 (b, 2H, NH2); 6.03 (d, 2H, η6-C6H4, J(HH) = 5.9 Hz); 6.09 (d, 2H, η6-C6H4, J(HH) = 5.9 
Hz); 6.42 – 7.51 (m, 4H, Ph); 7.70 (b, 2H, NH2C(=O)). 13C{1H} NMR δ: 18.45 CH3C6H4; 
21.74 CH(CH3)2; 30.16 CH(CH3)2; {116.38, 114.37, 78.75, 78.21} η6-C6H4; 93.16 ˗ 131.85 
CAromatic; 150.13 N-(C)Ph; 171.26 NC(=O). 
19F{1H} NMR δ: 148.19, 148.24. IR (cm-1): 
ν(C=O) 1660s; ν(N-H) 3332m, 3263m, 3177m, 3112m.  
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APPENDICES  
APPENDIX A: ADDITIONAL IR AND RAMAN SPECTRA OF COMPLEXES IN 
CHAPTER 2 
 
 
Figure A-1: The combined infra-red and raman spectra of 1(b). 
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Figure A-2: The combined infra-red and raman spectra of 2. 
 
 
 
 
Figure A-3: The combined infra-red and raman spectra of 4. 
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APPENDIX B: TGA THERMOGRAMS WITH DTG CURVES 
 
 
 
Figure B-1: TGA thermogram of 1(b) with DTG curve. 
 
 
Figure B-2: TGA thermogram of 2 with DTG curve. 
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Figure B-3: TGA thermogram of 7(a) with DTG curve. 
 
 
Figure B-4: TGA thermogram of 7(c) with DTG curve. 
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Figure B-5: TGA thermogram of 8(a) with DTG curve. 
 
 
Figure B-6: TGA thermogram of 8(c) with DTG curve. 
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Figure B-7: TGA thermogram of 10 with DTG curve. 
 
 
 
